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Abstract 
Patients with chronic kidney disease (CKD) are a group with a markedly increased risk of 
adverse events following cardiac surgery. A particular problem for these patients is the 
development of post-operative acute kidney injury (AKI), which is associated with a 
significant increase in morbidity and mortality. Currently, there are no effective therapies 
proven to modify AKI in patients undergoing cardiac surgery. 
 
This thesis has three parts. The first describes an analysis of the Barts Health NHS Trust 
cardiac surgical dataset. Specifically, outcomes of patients with CKD and AKI were 
examined. The second describes a randomized control trial that examined the effect of remote 
ischaemic preconditioning (RIPC) upon AKI and myocardial injury in patients with CKD 
undergoing coronary artery bypass graft surgery (CABG). The final part describes the 
development of a panel of AKI biomarkers to allow the accurate prediction of AKI in patients 
with CKD undergoing CABG. 
 
The aims of this thesis were: 
1. In our local cardiac surgical cohort,  
a. To assess the effects of CKD upon outcomes after CABG. 
b. To asses the prognostic importance of AKI after CABG.  
2. To assess the potential for RIPC to reduce AKI and myocardial injury in patients with 
CKD undergoing CABG. 
3. To investigate the diagnostic performance of serum and urine AKI biomarkers in a 
population of patients with CKD undergoing CABG.  
 
Analysis of the Barts Health NHS Trust cardiac surgical dataset confirmed that patients with 
CKD account for almost one-third of patients undergoing CABG. However, these patients 
account for a disproportionate two-thirds of all early mortality. CKD was also independently 
associated with late mortality after CABG. AKI was common in these patients. AKI was 
associated with late mortality even after accounting for pre-operative comorbidity and 
surgical complexity.  
 
In the randomized control trial, RIPC showed no effect upon the incidence of AKI or 
myocardial injury in the. 86 patients with CKD recruited.  Secondary analysis of serum and 
urine biomarkers collected found change in serum cystatin C and NGAL as impressive 
predictors of AKI in patients with CKD. They allowed accurate early prediction of AKI more 
than 24 hours before diagnosis was possible using serum creatinine.  
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Chapter 1 
 
1 Introduction 
Each year in the United Kingdom approximately 40,000 cardiac surgical operations are 
performed [1]. The majority of these are isolated first time coronary artery bypass graft 
(CABG) operations which by cardiac surgical standards is a low-risk procedure; associated 
with an expected in-hospital mortality in most patients of less than 2%[2]. In recent years 
there has been an increase in the risk profile of patients undergoing cardiac surgery [1]. One 
patient group at particularly high risk of adverse events during cardiac operations are 
patients with pre-existing chronic kidney disease (CKD) [3]. A particular problem for these 
patients is the development of perioperative acute kidney injury (AKI). The development of 
AKI in patients undergoing cardiac surgical procedures is associated with a significant 
increased in both perioperative and long-term morbidity and mortality [4-6]. To date, 
attempts to modify outcomes after cardiac surgery in patients with CKD, in particular 
therapies to reduce the development of perioperative AKI, have been largely unsuccessful. 
 
This thesis describes my research methodology and results obtained during my MD (Res) 
studies. It begins with a review of the cardiovascular complications of CKD. This naturally 
leads to a discussion of the management of cardiovascular disease in patients with CKD. I 
will also review the importance of AKI in cardiac surgery and highlight the current lack of 
effective strategies to prevent this important surgical complication. 
 
 
1.1 Chronic Kidney Disease 
Chronic kidney disease (CKD) is the general term given to a heterogeneous group of 
disorders affecting the structure and/or function of the kidney.  It is defined by the presence 
of albuminuria or reduced glomerular filtration rate [GFR] for 3 months or more. CKD is 
classified into five stages on the basis of GFR (Table 1) [7]. 
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Table 1 Stages of chronic kidney disease (adapted from[7]) 
Stage Description eGFR ml/min 
1* Kidney damage with normal or increased GFR !90 
2 Kidney damage with mildly decreased GFR 60-89 
3 Moderately decreased GFR 30-59 
4 Severely decreased GFR 15-29 
5 Kidney Failure <15 or RRT 
End-stage renal disease (ESRD) is defined as the need for renal replacement therapy RRT (dialysis or 
renal transplantation). 
*Stage 1 CKD is mostly recognized by either albuminuria or structural renal abnormality. 
 
Further refinement of this classification system has been suggested by subdividing stage 3 
CKD by GFR into stages 3A (45-59 mL/min) and 3B (30-44 mL/min) [8]. The wide range of 
GRF that defines CKD stage 3 means that patients with differing clinical patterns and risks 
are classified within the same stage. As many of the complications associated with CKD 
increase exponentially as GFR falls subdivision of CKD stage 3 allows differentiation of 
relatively low risk patients with CKD 3A from higher risk patients with CKD 3B. 
  
In developed countries CKD is usually associated with ageing, diabetes, hypertension or 
vascular disease, with diabetic glomerulosclerosis and hypertensive nephrosclerosis the most 
frequently observed pathologies [9]. In developing countries CKD may result from 
glomerular or tubulointerstitial disease due to infection, drugs or toxins [9]. 
 
CKD is a current public health problem due largely to the increased risk of cardiovascular 
(CV) disease faced by these patients. CKD is estimated to affect 10% of adults in the 
western world [10, 11], with the worldwide prevalence of CKD increasing rapidly due to the 
‘diabetes epidemic’, increased rates of hypertension and an ageing population [12].  
 
1.1.1 CKD and Cardiovascular Risk 
Patients with CKD are at particularly high risk of developing CV disease. This risk is highest 
in patients with end stage renal disease (ESRD), of whom approximately 50% will die of a 
CV cause [13]. It is now appreciated that the risk of developing CV disease is also 
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significant in patients with lesser degrees of renal dysfunction. For example, Go et al [14] 
recently described the relationship between GFR and CV disease in 1.1 million American 
adults that they followed for an average of 2.8 years. These investigators found that CV 
events (a composite of myocardial infarction, stroke, heart failure, and complications of 
peripheral vascular disease) increased markedly once GFR fell below 60 mL/min. Even after 
adjusting for potential confounders, GFR remained an independent predictor of CV events 
(Figure 1).  
 
Figure 1 Age-adjusted rates of CV events by levels of eGFR(Adapted from [14]) 
 
This graded, inverse correlation between GFR and CV events is consistent in the literature, 
and appears to hold across populations with varying baseline CV risk. In the Hypertension 
Optimal Treatment (HOT) study, that enrolled more than 15000 hypertensive adult patients, 
the adjusted relative risks for all-cause mortality and for major CV events were 1.65 and 
1.58, respectively, in subjects with an estimated glomerular filtration rate (eGFR) <60 
mL/min when compared with those with an eGFR >60 mL/min [15]. In the Heart Outcomes 
Prevention Evaluation (HOPE) trial that involved more than 9000 patients with high baseline 
CV risk, an entry serum creatinine (sCr) of 124 mmol/L or higher was associated with a 40% 
increase in the risk of CV events during follow up {[16]. In a recent meta-analysis of the 
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relationship between GFR and CV risk, it was estimated that lowering GFR by 30% was 
associated with a 20%–30% higher risk of major CV events and all-cause mortality [17]. 
1.1.2 Albuminuria and Cardiovascular risk 
Pathological albuminuria often precedes functional renal deterioration. Albuminuria is also 
recognized an important marker of CV risk. The association between albuminuria and CV 
events was first recognized in patients with overt macroalbuminuria (urine 
albumin:creatinine ratio [ACR] >300 mg/g) [18, 19], but this relationship has now been 
extended to more modest elevations of urinary albumin (ACR 30 to 300 mg/g) [20]. 
Recently it has been recognized that CV risk may rise within currently defined normal levels 
of albuminuria (ACR<30 mg/g). Thus, urinary albumin is a continuous CV risk factor, 
whereas microalbuminuria is a designated threshold for functional renal disease [21]. 
 
1.1.3 Arterial disease in patients with CKD 
Arterial disease, particularly coronary artery disease (CAD) is especially common in patients 
with CKD. It results from two distinct arterial pathologies, namely atherosclerosis and 
arteriosclerosis [22]. Atherosclerosis is primarily an intimal disease, characterized by 
intima–media thickening and the formation of fibroatheromatous plaques. In patients with 
CKD there is marked plaque calcification and increased intima-media thickening. 
Arteriosclerosis is the thickening and calcification of the arterial media. It results in a 
reduction in arterial dampening (responsible for transforming pulsatile central arterial flow 
into steady peripheral flow) and an increase in systolic and pulse pressure. Arteriosclerosis 
causes an increase in left ventricular afterload and eventually the development of left 
ventricular hypertrophy (LVH), with a resultant increase in microvascular perfusion demand. 
Due to a reduction in myocardial capillary density and endothelial dysfunction which also 
occur in patients with CKD, the ability to match microvascular perfusion to increased 
myocardial oxygen demand is impaired, thus creating a state of chronic myocardial 
ischaemia that will result in myocardial fibrosis [23]. 
 
1.1.4 Causes of arterial disease in CKD 
There is a clustering of traditional CV risk factors such as hypertension and diabetes mellitus 
in patients with CKD. However, these factors perform very poorly in the prediction of CV 
risk in this population, particularly in later stage CKD and these factors alone do not fully 
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explain the excess in arterial disease observed [24].  Novel ‘uraemia’ related factors are 
increasingly suggested as an explanation of the excess of arterial disease observed in these 
patients [24]. 
 
An understanding of the mechanisms underlying arterial disease in CKD is essential for 
devising strategies to prevent this pathophysiology. Below I will review the potential 
mechanisms that explain the increase in arterial disease observed in patients with CKD. 
 
1.1.4.1 Hypertension  
Hypertension is almost invariably present in patients with CKD. Sodium retention together 
with the aberrant hyperactivation of the renin-angiotensin-axis (RAA) and sympathetic 
nervous system are important mechanisms that contribute to hypertension in patients with 
CKD [25]. Also production of renalase in the glomeruli and proximal tubules of the kidney 
(an enzyme that breaks down catecholamines and is a potent hypotensive agent) is reduced 
in CKD [26]. Hypertension has direct deleterious CV effects such as LVH induction [23]. 
Indirectly, hyperactivation of the RAA causes oxidative stress, endothelial dysfunction and 
increased uptake of oxidised low-density lipoproteins by endothelial cells, accelerating 
atherosclerosis [27].  
1.1.4.2 Dyslipidaemia 
Dyslipidaemia affects approximately two-thirds of patients with CKD [28]. In CKD, hepatic 
synthesis of apolipoprotein-A1 (the major component of plasma HDL) is reduced, and 
plasma HDL levels fall. HDL is an important antioxidant protecting the endothelium from 
the effects of proinflammatory cytokines. Also in CKD, levels of apolipoprotein-CIII, a 
competitive inhibitor of lipoprotein lipase, are increased, leading to reduced hepatic uptake 
of triglycerides and a resultant increase in serum triglycerides. Reduced lipoprotein lipase 
activity also results in the accumulation of intermediate-density lipoproteins (which 
comprise very low-density lipoprotein and chylomicron remnants). Both serum triglyceride 
and intermediate density lipoproteins impair endothelial function and are associated with the 
development of CAD [29]. 
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1.1.4.3 Inflammation 
Atherosclerosis is thought to be an inflammatory condition. Atherosclerotic lesions represent 
a protective, inflammatory-fibroproliferative response to endothelial injury. In CKD there is 
chronic low-grade inflammation of the vascular wall that results in excessive inflammation 
and fibrous connective tissue proliferation that result in accelerated atherosclerosis [30]. 
Furthermore, in CKD chronic inflammation is linked to excessive vascular calcification [31]. 
Inflammation and atherosclerosis in CKD is complex, driven in part by traditional CV risk 
factors such as diabetes (due to the accumulation of advanced glycation end products in the 
vascular wall), hypertension (due to aberrant activation of RAA) and the modified 
lipoproteins associated with CKD dyslipidaemia, but also by an increase in oxidative stress, 
concurrent or chronic infection, or haemodialysis-related factors such as dialysis membrane 
biocompatibility [29].  
 
1.1.4.4 Endothelial dysfunction and oxidative stress  
Endothelial dysfunction is a central pathophysiological mechanism in the development of 
atherosclerosis. It is thought to result from a reduction in nitric oxide (NO) bioavailability 
and an increase in oxygen free radical formation [32].  
 
In patients with renal disease, endothelial dysfunction is ubiquitous. This is because uraemia 
is characterized by a reduction in the bioavailability of NO, predominantly due to an increase 
in vascular wall oxidative stress, but also in part due to a reduction in NO production as NO 
synthase is inhibited by asymmetric dimethyl arginine. In uraemia enhanced oxidative stress 
results from an increase in the generation of reactive oxygen species (ROS) by endothelial 
cells under the influence of nicotinamide adenine dinucleotide NAD(P)H oxidase (itself 
stimulated by the aberrant production of angiotensin-II) [33], myeloperioxidase (MPO), 
uncoupled endothelial NO synthase [34] and there is also reduced inactivation of ROS by 
antioxidant systems such as superoxide dismutase [35].  
 
Asymmetric dimethyl arginine (ADMA) is a potent endogenous competitive inhibitor of NO 
synthase that contributes to the reduced availability of endothelial NO, and thus endotheilal 
dysfunction. In CKD, ADMA levels are increased; potential explanations for the increased 
levels of AMDA include accelerated ADMA production, decreased breakdown or reduced 
renal clearance [29]. Elevated plasma levels of ADMA have been associated with 
progression of renal disease and CV mortality in CKD populations [36]. 
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1.1.4.5 Vascular calcification in renal disease 
In CKD hyperphosphataemia develops as the kidneys fail to excrete excess dietary 
phosphate. Hyperphosphataemia suppresses the renal hydroxylation of inactive 25-
hydroxyvitamin D to calcitriol eventually leading to hypocalcaemia. Thereafter, parathyroid 
hormone (stimulated by both hyperphosphataemia and hypocalcaemia) causes the 
mobilization of calcium from bone. Uraemia along with excessively elevated extracellular 
phosphate levels and possibly calcium levels are sufficient stimulus to cause the 
transformation of vascular smooth muscle cells into osteoblast-like cells that allow 
subsequent vascular calcification. Progressive mineralization then depends upon the balance 
of pro-calcific factors such as the calcium-phosphorus product, parathyroid hormone, and 
bone morphogenetic protein-2 and inhibitory factors such as the protein fetuin-A, 
pyrophosphate, osteopontin, osteoprotegerin, and !-carboxyglutamic acid protein [29].  
 
Patients with CKD have calcified atherosclerotic plaque disease in the intima, along with 
calcification of the media and premature calcific valvular heart disease [37]. Coronary artery 
calcification can be demonstrated in approximately 40% of patients with stage 4 CKD [38]. 
Coronary artery calcification, quantified by electron-beam computed tomography is 
associated with subsequent myocardial infacrtion (MI) [39].  
 
1.1.4.6 Anaemia 
Anaemia is common in the CKD population, and its prevalence increases as GFR falls [40]. 
It is a marker of increased CV risk independent of GFR [41].  
 
In CKD anaemia may be due to the combination of chronic disease, iron deficiency but 
mostly it is a result of a relative deficiency of erythropoietin (EPO) [42]. Anaemia causes 
and/or exacerbates LVH in patients with CKD, and EPO deficiency may result in a reduction 
in the production of bone marrow-derived endothelial progenitor cells, which may be 
associated with impaired endothelial repair mechanisms [43].  
 
1.1.4.7 Hyperhomocysteinaemia 
Homocysteine, a product of methionine metabolism, is predominantly excreted by the 
kidneys. Thus in renal failure homocysteine levels are raised [27]. Elevated homocysteine 
levels predict CV events in the general population and in patients with CKD [44]. In one 
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study, elevated homocysteine and fibrinogen levels were associated with an almost 40% 
increase in CV mortality in patients with CKD [45]. Trials of lowering homocysteine with 
folic acid and/or B vitamins have been largely unsuccessful at reducing CV events in the 
general population and in patients with CKD [44]. 
 
1.1.5 Diabetes and CKD 
Currently in the UK, diabetes mellitus (DM) affects 2.8 million people (4.3% of UK 
population) [46]. Approximately 40% of adults with DM also have CKD characterized by 
either albuminuria or decreased GFR [47]. With population ageing and increasing obesity 
the prevalence of DM is predicted to rise by 20% by 2030 [48]. Consequently there will be a 
vast increase in patients affected by both DM and CKD in coming years. 
  
DM is also associated with the premature development of CAD. When both CKD and 
diabetes are concurrent, the prevalence of CAD increases dramatically and risks of cardiac 
morbidity and mortality are particularly elevated. In an analysis of more than 1 million US 
patients both DM (RR 1.2) and non-diabetic CKD (RR 2.4) were found to be associated with 
an increase in CV mortality. Patients with the combination of DM and CKD had the highest 
risk of subsequent CV mortality (RR 2.6). In addition, in this analysis atherosclerotic 
vascular disease was evident in 35.7% of patients with non-diabetic CKD but evident in 
49.1% patients with both DM and CKD [49]. 
 
The particularly high prevalence of CAD, and subsequent CV risk found in patients with 
both DM and CKD may be explained by atherogenic mechanisms common to both 
conditions such as dyslipidaemia, endothelial dysfunction, oxidative stress, systemic 
inflammation and homocysteinaemia [50]. It is probable that these mechanisms are 
augmented in patients with both DM and CKD.  
 
In addition to these ‘shared’ atherogenic mechanisms, hyperglycaemia and insulin resistance 
that define DM can further disrupt normal endothelial function and enhance atherosclerosis.  
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1.1.5.1 Hyperglycaemia and insulin resistance 
Hyperglycaemia inhibits the NO production by blocking eNOS synthase activity [51]. It also 
activates the intracellular second messenger protein kinase-C (PKC) [51], producing ROS 
which react with NO to produce peroxinitrate [52]; a cause of direct endothelial damage.  
 
Insulin-resistance is associated with less NO production and more vasoconstrictor 
production, most notably endothelin-1 (ET-1) [53]. Also insulin-resistance causes liberation 
of free fatty acids from adipose tissues, activating PKC, inhibiting phosphatidylinositol-3 
(PI-3) kinase (an eNOS agonist pathway) and thus increasing ROS production [53]. Hence 
the combination of hyperglycaemia and insulin-resistance is associated with reduced 
bioavailability of NO and increased vasoconstrictor production, which are central 
mechanisms in endothelial dysfunction. 
 
1.1.5.2 Advanced Glycation Endproducts (AGEs) 
Both hyperglycaemia and oxidative stress cause the generation of AGEs by non-enzymatic 
glycation of proteins and lipids in the arterial wall [54]. In both DM and CKD AGEs 
concentration in plasma and AGE formation in vascular tissues is increased [55]. The kidney 
usually excretes AGEs and so they accumulate in renal failure [55]. Thus in patients with 
DM and CKD the generation of AGEs are enhanced, but excretion reduced. 
 
AGEs affect the vasculature both directly and indirectly via cell surface receptors for AGEs 
(RAGE) [54]. AGEs are found in accelerated atherosclerotic lesions, where they may induce 
collagen crosslinking, resulting in thickening and stiffening of arterial walls [55]. AGEs also 
inhibit the bioavailability and activity of endothelium-derived NO and so directly contribute 
to endothelial dysfunction. Binding of AGEs to cell surface RAGE induces intracellular 
ROS production along with expression of proinflammatory cytokines and adhesion 
molecules associated with inflammation. Thus AGEs potentiate the development of 
atherosclerosis [54].  
 
1.1.5.3 Impaired platelet function  
Hyperglycaemia affects platelets in the same fashion that it affects the endothelium; reducing 
NO production, activating PKC and increasing oxidative stress [53]. DM also affects platelet 
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calcium homeostasis, which is vital for regulating platelet shape change, platelet aggregation 
and thromboxane production [53]. Finally, hyperglycaemia increases platelet surface 
expression of glycoprotein 1b (Gp1b). Gp1b mediates the platelet fibrin interaction in 
thrombus formation [53]. Platelets are modulators of vascular function, thus these 
abnormalities of platelet function may potentiate atherosclerosis progression.   
 
1.1.5.4 Abnormal Coagulation  
DM can be considered a procoagulant state. Coagulation factors such as plasminogen 
activator inhibitor-1 (PAI-1), von willebrand Factor (vWF), fibrinogen, factor VII and 
thrombin–antithrombin complexes are increased resulting in a propensity for coagulation 
[56]. Fibrinolytic pathways are also suppressed in patients with DM in association with 
insulin resistance [53]. The procoagulant state of DM may predispose the thrombotic 
complications of CAD. 
 
1.1.6 Management of coronary artery disease in CKD 
Managing CAD is particularly challenging in patients with CKD. Firstly clinical diagnosis is 
difficult as patient symptoms are often atypical or absent. Furthermore many investigations 
for CAD are less useful in patients with CKD than in the general population. For example, 
due to the high prevalence of resting ECG abnormalities and a reduced exercise capacity in 
many patients with CKD the exercise ECG is of limited diagnostic value with a reported 
sensitivity as low as 30% [57]. As such most patients with CKD require pharmacological 
stress imaging with either adenosine or dobutamine for diagnosis. Nuclear myocardial 
perfusion imaging (MPI), although more sensitive than the exercise ECG, is limited by LVH 
and endothelial dysfunction, which may cause false positive perfusion defects [58] and thus 
the specificity of nuclear MPI is approximately 70% in this population [57]. Dobutamine 
stress echocardiography (DSE) can be both sensitive and specific, but is highly operator 
dependent. The recent association between gadolinium based contrast agents and the 
development of nephrogenic systemic fibrosis (NSF) in patients with low GFR has limited 
the application of adenosine stress cardiovascular magnetic resonance (CMR) in patients 
with CKD. Computed tomographic coronary angiography (CTCA) is a non-invasive 
anatomical imaging alternative to invasive coronary angiography. Unfortunately, calcific 
plaque disease limits the diagnostic accuracy of CTCA in patients with CKD. Furthermore, 
the risk of contrast induced nephropathy (CIN) means CTCA is rarely used in this patient 
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population. Thus, invasive coronary angiography remains the gold standard for the diagnosis 
of CAD and is a prerequisite for any revascularisation strategy.  
 
1.1.6.1 Treatment of CAD in CKD 
1.1.6.1.1 Pharmacological Therapy 
Pharmacological therapy is the mainstay of treatment for CAD, and is underused in patients 
with CKD compared with the general population. This is most probably due to concerns 
about limited efficacy, potential toxic effects and ignorance of the potential benefits of 
pharmacological therapy in this population (a concept termed ‘therapeutic nihilism’) [59].  
 
Pharmacology for the primary prevention of CAD in CKD: In view of the high prevalence 
of CAD in patients with CKD, a strategy of primary prevention with aggressive targeting of 
both traditional and uraemia related risk factors is advocated in guidelines published by the 
UK based Renal Association and the US National Kidney Foundation (Table 2).  
 
Pharmacology for the secondary prevention of CAD in CKD: Anti-platelets, beta-blockers, 
angiotensin converting-enzyme (ACE) inhibitors and statins are established effective 
treatments proven to reduce CV morbidity and mortality in patients with arterial disease.  
However, most major clinical trials evaluating these therapies have systematically excluded 
patients with renal insufficiency, and therefore the treatment of CAD in patients with CKD is 
often not evidence-based. 
 
Antiplatelet therapy: Aspirin is underused following acute myocardial infarction (AMI) in 
patients with CKD. In the US National Cardiovascular Data ACTION (Acute Coronary 
Treatment and Intervention Outcomes Network) registry, including nearly 50,000 patients 
with AMI, aspirin prescription decreased as severity of renal disease increased [61]. The 
efficacy of aspirin for secondary prevention after an AMI is undiminished in CKD. Aspirin 
is most likely underused due to safety concerns, in particular bleeding risk. Uraemia is 
associated with platelet dysfunction and prolonged bleeding times. However, in the UK 
HARP (Heart and Renal Protection)-1 trial chronic low-dose aspirin (100 mg/day) use was 
not associated with an increase in major bleeding or worsening of renal function in patients 
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with CKD [62].  There are no controlled data on the efficacy of long-term aspirin use in 
CKD patients diagnosed with stable coronary artery disease.  
 
International guidelines recommend combining aspirin and clopidogrel post-AMI. There are 
no specific recommendations for adjustment of clopidogrel dosing in patients with renal 
disease. Clopidogrel appears to be clinically efficacious in patients with lower GFR, 
although there is more minor bleeding (but not major bleeding) in patients with impaired 
renal function who are prescribed clopidogrel post AMI [63, 64].  
 
Table 2 Treatment recommendations for cardiovascular risk factors in patients 
with CKD (Adapted from [57]) 
 Recommendation 
Smoking Stop 
Obesity Lose weight to improve insulin resistance, hypertension, dyslipidaemia 
Hypertension <140/<90 mmHg for all patients with CKD. For patients with a urinary 
protein/creatinine ratio > 100 mg/mmol and diabetics with microalbuminuria 
BP shpuld ideally be <130/<80. Initial treatment should be an ACE inhibitor or 
ARB [60]. If creatinine rises >20% or GFR falls >15%, repeat tests and 
consider referral for exclusion of renal artery stenosis. Do not stop treatment 
for a lesser rise in creatinine or GFR change. 
Dyslipidaemia Total cholesterol < 4mmol/L (or 25% reduction from baseline); LDL <2.0 
mmol/L (or 30% reduction from baseline). Statins should be initial therapy. 
Diabetes HbA1c <7.5% 
Albuminuria Reduce as much as possible: Angiotensin II inhibition treatment of choice.  
Antiplatelets Indicated for secondary prevention as no evidence for beneficial effect in 
primary prevention of CVD 
Calcium/phosphate  
product 
Maintain calcium and phosphate levels in normal range; PTH in patients on 
RRT 2–9 x upper limit of normal 
  
 
Lipid lowering therapy: Statins are used for the primary and secondary prevention of 
atherosclerosis in the general population. Their role in the primary prevention of 
atherosclerosis in CKD patients remains to be clarified. Despite reductions in low-density 
lipoprotein and a significant decrease in CV events, no significant reduction in mortality has 
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been shown with statin therapy in patients with CKD [65]. This may be because most deaths 
in patients with CKD are due to cardiac failure or arrhythmia rather than acute coronary 
events [47]. For secondary prevention statins are safe and effective in patients with mild 
CKD [66, 67], although evidence of benefit of statin therapy in patients with more advanced 
renal disease is limited. There is evidence that statin use may slow the rate of decline of renal 
function in patients with CKD through anti-inflammatory effects on the glomerulus and 
tubules meaning that statins may be beneficial in CKD in a manner independent of lipid 
lowering [57]. 
 
Hypertension management: Target blood pressure in patients with CKD is <130/80 mm Hg, 
or <125/75 mm Hg for patients with significant proteinuria > 1 g/day [60]. In CKD, 
hypertension is volume-dependent. Hence maintenance of fluid balance with careful oral 
restriction of fluid intake and judicious diuretic use is paramount.  
 
ACE inhibitors form the mainstay of antihypertensive therapy in most patients with CKD 
and slow the decline in renal function. Their ‘renoprotective’ effect is due in part to their 
antihypertensive effect, but also a specific antiproteinuric effect [57]. As CV mortality is 
intimately related to renal function, it seems logical that the renoprotective effects of ACE 
inhibition would lead to improved CV outcomes.  In the HOPE trial, ACE inhibitors reduced 
CV mortality more so in patients with CKD than in those with normal renal function [16]. 
Angiotensin receptor blockers (ARBs) are also renoprotective. However, ARBs have not 
been shown to reduce CV events in patients with CKD. Due to the lack of proven 
cardioprotective effect of ARBs in CKD, ACE inhibitors are preferred when possible. 
 
"-blockers can be particularly useful in CKD, both as an antihypertensive agent and an anti-
anginals. However, due to the high prevalence of sudden cardiac death in patients with 
ESRD perhaps the most important role of "-blockers is as an anti-arrhythmic agent. In a 
study of haemodialysis patients with LV dysfunction, those treated with "-blockers showed 
an improvement in LVEF of almost 10% over 12 months and a 49% reduction in all cause 
mortality at 2 years, compared with similar patients not receiving "-blockers [68]. This 
beneficial effect of "-blockade is not restricted to patients with severe renal dysfunction; in 
an analysis of over 200,000 patients with mild CKD, "-blocker therapy was associated with 
a 35% reduction in mortality [69].  
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Management of anaemia: Anaemia is a strong CV risk factor in CKD. It may cause angina, 
decreased exercise tolerance and induce LVH. It can be treated with erythropoietin-
stimulating agents (ESA) although, two large studies investigating the effect of haemoglobin 
correction with ESA (to levels >13 g/dL) in patients with advanced renal disease did not 
show any improvement in CV outcomes compared to lower haemoglobin levels [70, 71]. 
Also the risk of stroke may be increased with overzealous haemoglobin correction with ESA 
[72]. As a result target haemoglobin level of between 10–11.5 g/dL would be considered 
optimal for most patients with CKD [73], however any therapy for anaemia (ESA or blood 
transfusions) should only be administered after carefully weighing the risks of the therapy 
(ie. stroke or vascular complication), against the benefits of relieving symptoms secondary to 
anaemia.  
 
Calcium/phosphate product: Elevated calcium/phosphate product and parathyroid hormone 
(PTH) are associated with an increased incidence of CV disease and increased mortality in 
patients with CKD [74]. No randomised trials have proven that treating secondary 
hyperparathyroidism and hyperphosphataemia alters CV outcome. Guidelines suggest that 
calcium and phosphate levels are maintained within normal range for patients with advanced 
CKD [75].  
 
Hyperglycaemia: The relationship between glycaemic control and the microvascular 
complications of DM is well established. Tight glycaemic control has consistently been 
shown to prevent the onset of microalbuminuria [76]. Once CKD is established it is 
unknown whether tight glycaemic control retards the progression of renal disease.  
 
The effect of tight glycaemic control upon CV complications in patients with T2DM is 
questionable. For patients with T1DM targeting an HbA1C level of 6%, reduced CV 
outcome by 42% over 17 years of follow up when compared with conventional DM therapy 
[77]. In T2DM, trials targeting HbA1C levels of < 6–6.5%, despite confirming a reduction in 
microvascular complications, have not shown a reduction in the incidence of CV events [78, 
79]. In fact in the ACCORD trial the overall and CV mortality was higher in patients with 
T2DM treated with intensive glycaemic therapy [79].  
 
Published guidelines recommend HbA1c levels <7.0% for all stages of renal function, but 
that lower HbA1C levels may be appropriate in young patients with little comorbidity, 
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whereas higher HbA1C levels may be accepted in patients at high risk hypoglycaemic events 
[75]. 
 
1.1.6.1.2 Coronary revascularization  
Coronary revascularization, either with percutaneous coronary intervention (PCI) or CABG 
is indicated for the relief of angina, improvement of prognosis, or both. It may be performed 
in patients with stable coronary disease or following an acute coronary syndrome. 
Stable coronary disease: In patients with stable CAD, PCI is a symptomatic treatment. It 
provides superior angina relief to optimal medical therapy (OMT) but does not reduce risk of 
subsequent myocardial infarction (MI) or death [80]. Whether PCI of a coronary stenosis 
causing a large amount of ischaemic myocardium has a beneficial prognostic effect is 
unknown. Whether PCI of a coronary stenosis causing a large amount of ischaemic 
myocardium has a beneficial prognostic effect is currently unknown. However, there is 
limited data to suggest that PCI of a coronary stenosis causing ischaemic myocardium may 
be associated with improved prognosis [81, 82]. 
 
CABG is a highly successful surgical treatment indicated for the relief of angina not 
controlled by OMT. It has also been associated with improved survival in selected patients 
with a greater than 50% stenosis of the left main coronary artery [83], or three-vessel 
coronary artery disease with left ventricular dysfunction [84]. 
 
When extrapolating these indications for revascularisation to the CKD population it is 
important to consider,  
1. the application rate of OMT in patients with CKD  
2. the efficacy of revascularization in CKD 
3. the risks of revascularization in CKD  
 
Percutaneous coronary intervention: Prior to the advent of intracoronary stents, balloon 
only angioplasty was associated with unacceptably high rates of procedural complications 
(~10%) and restenosis (~80%) in patients with CKD [85]. However since the advent of 
coronary stents early success rates of PCI are now similar among patients with CKD and 
those without. Restenosis following PCI remains a problem in patients with CKD, although 
drug-eluting stents (DES) have been shown to reduce in-stent restenosis (ISR) compared 
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with bare metal stents (BMS) in both the general population and in patients with CKD; for 
example an analysis of the TAXUS-IV database showed that the implantation of paclitaxel-
eluting stents was associated with lower 9-month re-stenosis rates (2.1% vs. 20.5%, p < 
0.01) and one-year target vessel revascularisation (TVR) rates (3.3% vs. 12.2%, p < 0.001) 
than BMS in patients with CKD [86].  
 
Table 3 Studies examining morbidity and mortality in patients with renal 
disease following PCI 
Year 
(Ref) 
N Study Groups 
eGFR cutoff: number of 
patients 
Early 
Mortality 
Time point: 
(%) 
Late 
Mortality 
Time point: 
(%) 
Early 
MACE 
Time point: 
(%) 
Late 
MACE  
Time 
point: 
(%) 
2002 
[87] 
5327  
 
 
GFR !70: BMS 2687 
GFR  50-69: BMS 1537   
GFR 30-49: BMS 899  
GFR <30: BMS 154   
ESRD: BMS 50   
In-hosp 
0.5 
0.7 
2.3 
7.1 
6.0 
1-yr 
1.5 
3.6 
7.8 
18.3 
19.9 
 1 yr 
23.2 
26.2 
30.4 
38.1 
38.5 
2004 
[88] 
11187 
 
 
GFR >89: BMS 5384 
GFR 60-89: BMS 4054 
GFR <60: BMS 1749 
30-day 
0.07 
0.27 
0.17 
9-mon 
0.8 
1.16 
2.16 
30-day 
1.17 
1.23 
1.66 
9-mon 
15.4 
14.5 
16.6 
2006 
[89] 
6840 
 
 
GFR >80: BMS 3474  
GFR 61-80: BMS1670  
GFR 41-60: BMS1111   
GFR # 40: BMS 585   
In-hos 
0.3 
0.7 
1.5 
6.0 
 In-hos 
2.4 
3.0 
4.8 
9.7 
 
2006 
[90] 
371 
 
 
GFR!60: BMS 269 
GFR<60, no HD: BMS 102 
30-day 
0.75 
9.8 
9-yrs 
7.1 
35.4 
 9 yr 
39 
57 
2007 
[91] 
2758 
 
 
GFR ! 60 DES: 2093 
GFR <60 DES: 665 
In-hosp 
0.5 
5.3 
2-yrs 
4.7 
17.7 
 2-yrs 
15.3 
25.6 
2005 
[92] 
1314 
 
 
GFR >90 BMS: 346  
GFR >90 SES: 312  
GFR 60-89 BMS: 200  
GFR 60-89 SES: 219  
GFR <60 BMS: 100  
GFR <60 SES: 123  
 1-yr 
1.2 
1.3 
0.6 
0.9 
3.0 
1.6 
 1-yr 
22.3 
9.7 
17.1 
10.7 
19.1 
13.1 
2006 
[93] 
1012 
 
CKD=GFR<60 
No CKD: 602  
CKD: 410 
CKD+ DES: 264 
CKD+ BMS: 146  
In-hosp 
1 
3.4 
3 
4.3 
  17-mon 
13.8 
18.3 
15.2 
24.7 
2007 
[94] 
304 
 
 
GFR ! 60 SES: 204 
GFR <60  SES: 69 
HD SES: 31 
 8-mon 
0 
2.9 
3.2 
 8-mon 
10.8 
18.8 
38.7 
2009 
[95] 
4791 
 
 
GFR > 75: 2827 
GFR 50-75: 1253 
GFR 30-49: 571 
GFR <30: 140 
In-Hosp 
0.1 
0.2 
0.9 
0.0 
1-yr 
1.5 
3.5 
5.8 
13.6 
 1 yr 
18.0 
22.3 
21.5 
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Both early and late morbidity and mortality are consistently higher in patients with CKD 
than the general population following PCI (Table 3). In summary, despite encouraging 
procedural success rates, and reduced restenosis rates with DES, CKD remains a strong 
independent predictor of adverse outcomes following PCI.  
 
Coronary artery bypass graft surgery: There are an abundance of studies reporting outcome 
after coronary surgery in patients with non-dialysis dependent CKD, but most have 
categorised patients using arbitrary serum creatinine (sCr) values to define renal dysfunction 
rather than the more discriminating eGFR. This causes problems in comparing outcomes 
between surgical series, but also using these creatinine cutoffs to define CKD may 
underestimate its prevalence within a given population.  
 
In general CABG surgery is associated with higher levels of early post-operative 
complications and early mortality in patients with CKD than the general population. For 
example, in an analysis of the US National Adult Cardiac Database including approximately 
half a million patients stratified by eGFR (mild CKD, eGFR 60–90 mL/min; moderate CKD, 
eGFR 30–60 mL/min; severe CKD, eGFR <30 mL/min and those requiring dialysis), CKD 
was prevalent (mild CKD 51%, moderate CKD 24%, severe CKD 2% and ESRD 1.5%) and 
a powerful independent predictor of operative mortality and early complication including 
stroke, prolonged ventilation, deep sternal wound infection, prolonged hospital stay and new 
dialysis requirement. Operative mortality was 1.3% in those with normal renal function but 
as high as 9% in those with severe CKD or ESRD [3]. Long-term mortality is also higher in 
patients with CKD after CABG than in patients with normal renal function. In a cohort study 
of 2,067 consecutive CABG operations, patients with moderate CKD (eGFR <60 mL/min) 
were twice as likely to have died at median follow-up of 2.3-years than patients with an 
eGFR >60mL/min. Although patients with CKD had an excess of co-morbidity, after 
adjusting for this, CKD remained a strong independent predictor of long-term mortality [96]. 
 
However despite the increase in early and late mortality following CABG observed in 
patients with CKD it is important to remember that the prognostic advantage of CABG 
compared to medical therapy in selected patients with multivessel CAD is unabated despite 
the coexistence of CKD [97]. Thus the increased risks associated with coronary surgery 
should not act as a deterrent to surgical coronary revascularization in patients with CKD. 
The challenge for cardiac surgeons, cardiologists and nephrologists is to develop new 
therapies and techniques to make coronary surgery safer within this high-risk population. As 
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such this thesis focuses upon developing novel strategies to make cardiac surgery safer for 
patients with CKD. 
 
Summary 
CKD is an increasing world health problem, associated with increased CV morbidity and 
mortality. The mechanisms underlying this increased CV risk are diverse and far more 
complicated than in the general population. CAD in patients with CKD is uniquely different 
from CAD in patients with normal renal function, with increased vascular stiffness, more 
calcification and a particularly aggressive disease course. Consequently, treatment of CAD 
in patients with CKD is challenging, especially coronary revascularization. Both PCI and 
CABG are associated with higher rates of adverse events than are seen in patients with 
normal renal function. Novel strategies to make coronary revascularization safer for patients 
with CKD are now urgently needed.  
 
 
1.2 Acute kidney injury following cardiac surgery 
Acute kidney injury (AKI) is a significant problem following cardiac surgery and is 
especially common in patients with CKD. As AKI after cardiac surgery is a central concept 
within this thesis it is therefore reviewed in detail below; 
 
The incidence of AKI following cardiac surgery varies from 1% to 30% depending upon 
how it is defined and population that is studied [5, 6, 98-107]. The reported frequency of 
AKI requiring post-operative renal replacement therapy (RRT) is generally lower ranging 
from 1% to 6%[5, 6, 98-107]. AKI following cardiac surgery is a serious event, associated 
with an increase in post-operative infectious complications, increased length of hospital stay 
and an increase in post-operative mortality [4-6] which can exceed 60% among patients 
requiring post operative RRT [100]. Despite advances in our understanding of the aetiology 
and pathophysiology of AKI after cardiac surgery there has not been a significant reduction 
its incidence [108] nor the mortality associated with this complication [109].  
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1.2.1 Defining Cardiac Surgery Associated Acute Kidney Injury 
Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) is an impairment of renal 
function, either of new onset or an exacerbation of pre-existing renal dysfunction that 
follows cardiac surgery. Until recently a standardized definition for CSA-AKI was lacking. 
This absence of consistency in the diagnosis of CSA-AKI made the comparison of results 
between studies into CSA-AKI extremely challenging. For example, CSA-AKI has been 
diagnosed by absolute or percentage changes in sCr value, or eGFR, by reduction in urine 
output post-operatively or the need for post-operative RRT [5, 6, 98-107]. In order to 
standardize the definition of CSA-AKI, the Second International Consensus Conference of 
the Acute Dialysis Quality Initiative (ADQI) proposed a graded classification system for the 
diagnosis of CSA-AKI [110]. This classification system defined 3 grades of increasing 
severity of AKI (risk, injury, and failure) on the basis of changes of sCr or glomerular 
filtration from baseline as well as reductions in urine output, and has 2 final stages that are 
outcome variables (loss and end-stage kidney disease), thus the acronym of the RIFLE 
classification [110]. To further refine this grading system for CSA-AKI, the Acute Kidney 
Injury Network (AKIN) proposed a modification of the RIFLE classification, known as the 
AKIN classification [111]. The differences between RIFLE and AKIN staging criteria are 
subtle (Table 4).  
 
Despite the advantages of using these standardized, graded definitions for CSA-AKI, both 
classification systems have limitations. sCr and urine output perform poorly as surrogates of 
AKI. sCr is influenced by many factors independent of the kidney, including hydration and 
nutritional status, gender, age, race, and muscle mass, and can vary by as much as 20% each 
day [108]. Furthermore, due to extensive intrinsic renal reserve, the glomerular filtration rate 
must decrease by approximately 50% before sCr changes significantly from baseline [108], 
and as such changes in sCr may lag by upto 48 to 72 hours behind the initial renal insult 
[112]. 
 
1.2.2 Prognostic Implications of CSA-AKI 
The development of CSA-AKI is clearly associated with an adverse prognosis. Early 
mortality is highest in patients with CSA-AKI requiring post-operative hemodialysis, and 
may exceed 60% [100]. However, these patients often have multiple-organ failure, and so 
the direct contribution of AKI to mortality is difficult to discern. Importantly, smaller 
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reductions in renal function following surgery without obvious immediate clinical sequelae 
are also associated with increased early mortality [106, 113].  
 
The prognostic implications of CSA-AKI are not confined to the short term. Hobson et al 
detailed the association between long-term mortality and CSA-AKI defined by the RIFLE 
criteria. These authors found that CSA-AKI was an important independent predictor of 10-
year mortality. At this time point the mortality rate was 56% in the patients who had 
previously developed CSA-AKI compared with 37% in patients without CSA-AKI [6]. 
Further to this, recent studies have reported that both the duration of CSA-AKI [99] and 
recovery of renal function after CSA-AKI also predict long-term survival following cardiac 
surgery[114]. 
 
The crucial question as to whether CSA-AKI has a causal relationship with subsequent 
mortality, or whether the development of CSA-AKI is simply a reflection of comorbidity and 
procedural complexity within a high-risk population remains unresolved. Despite attempting 
to account for confounding factors, it remains a distinct possibility that CSA-AKI is 
associated with mortality as it occurs in patients with a worse profile of pre-operative 
comorbidity who would have a poor post-surgical prognosis independent of the development 
of CSA-AKI.  
 
1.2.3 Financial Implications of CSA-AKI 
Inevitably, hospital costs and length of stay for patients affected by CSA-AKI are higher 
than unaffected patients [5]. Patients with CSA-AKI have been shown to incur higher 
intensive care unit (ICU) costs (1.7-fold), pharmacy costs (2.3-fold), and laboratory costs 
(1.6-fold). Patients requiring postoperative RRT had a doubling of post-operative costs and a 
tripling of ICU costs [115]. 
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Table 4 Classification systems for acute kidney 
RIFLE criteria*[110] AKIN criteria+[111]  
Stage GFR or sCr Urine output Stage sCr Urine output 
Risk sCr increase x 1.5  
or GFR decrease >25% 
<0.5 
mL/kg/h for 
> 6 hours 
1 sCr increase x 1.5  
or sCr increase 
>26.5 $mol/L from 
baseline 
<0.5 mL/kg/h for 
> 6 hours 
Injury sCr increase x 2.0  
or GFR decrease >50% 
<0.5 
mL/kg/h for 
> 12 hours 
2 sCr increase x 2 
from baseline 
<0.5 mL/kg/h for 
> 12 hours 
Failure sCr increase x 3.0  
or GFR decrease >75% 
or sCr >353.6 $mol/L 
with an acute rise >44.2 
$mol/L 
<0.3 
mL/kg/h for 
> 24 hours; 
 or anuria > 
12 hours 
3 sCr increase x 3  
or sCr increase 
>353.6 $mol/L with 
an acute increase 
>44.2 $mol/L 
<0.5 mL/kg/h for 
>24 hours; or 
anuria > 12 
hours 
Loss Persistent acute renal 
failure (complete loss of 
kidney function) >4 
weeks 
    
ESRF End-stage renal failure 
>3 months 
    
* Renal assessment time window upto 7 days. + Renal assessment time window upto 48 hours. 
 
1.2.4 Risk factors for CSA-AKI and pre-operative risk prediction models 
The pre-operative estimation of risk of developing CSA-AKI is vital to individualize and 
optimize peri-operative care. At least six validated CSA-AKI risk-prediction models 
currently exist (Table 5). Most of these models predict the need for RRT after cardiac 
surgery. Only one model predicts less severe CSA-AKI, defined as an eGFR < 30mL/min 
post-operatively in patients with ‘normal’ pre-operative renal function (eGFR > 60mL/min) 
[98]. 
 
Most risk models use broadly similar categories of variables; including patient related 
factors, surgery specific factors, and peri-operative physiologic insults. Common risk factors 
to all these models include advanced age, diabetes mellitus, congestive heart failure, and pre-
operative CKD. Of these, pre-operative CKD is by far the most important risk factor for 
CSA-AKI. The risk of requiring post-operative RRT approaches 20% in patients with a 
 33 
baseline sCr of 176.8 to 353.6 mmol/L and is approximately 25% when the baseline sCr c is 
greater than 353.6 mmol/L [109]. Other established patient related CSA-AKI risk factors 
include female gender, and left ventricular ejection fraction lower than 40%. Surgery 
specific CSA-AKI risk factors include the need for emergency surgery, peri-operative use of 
inotropic/device support and increasing procedural complexity; valve procedures are 
associated with a higher risk compared with CABG alone; with the highest risk for CSA-
AKI found after combined CABG-valve procedures [109].  
 
To date no risk model exists that predicts CSA-AKI defined by either RIFLE or AKIN 
criteria in an all-comer population. The development and validation of a risk model of this 
type would not only be of benefit to patients undergoing cardiac surgery, but would also be a 
powerful research tool providing a means for pre-operative selection of patients for trials of 
reno-protective therapies. 
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Table 5 Risk prediction models for CSA-AKI 
                                                 First author reference 
   Mehta [104]  Chertow [100] Thakar [106] Wijeysundera 
[107] 
Brown[98] Palomba 
[105] 
Risk prediction 
model for  
 
Post-
operative 
RRT 
Post-
operative 
RRT 
Post-
operative 
RRT 
Post-
operative 
RRT 
CSA-AKI a Post-
operative 
RRT 
Number of 
patients, n 
 
 
449,524 
 
43,642 
 
33,217 
 
20,131 
 
8,363 
 
603 
Operation type, 
% 
CABG only 
Valve ± CABG 
 
 
 
78.6 
20.4 
 
 
81.5 
18.5 
 
 
na 
na 
 
 
65 
35 
 
 
100 
0 
 
 
53 
47 
Elective surgery, 
% 
 
54 
 
74.0 
 
na 
 
59 
 
28 
 
na 
Post-operative 
RRT, n 
Overall, % 
CABG only, % 
 
 
6451 
1.4 
1.1 
 
 
460 
1.1 
0.9 
 
 
269 
1.7 
na 
 
 
139 
1.3 
na 
 
 
31 
0.4 
0.4 
 
 
11 
1.8 
na 
 
Independent 
predictors for 
AKI 
 
Age  
Pre-op sCr 
Diabetes 
Surgery type  
Shock 
Prior MI 
NYHA class 
Reoperation  
COPD Etnicity 
 
EF<35%  
Pre-op sCr 
SBP  
Surgery type  
Preop IABP  
NYHA class 
Reoperation  
COPD  
PVD 
 
EF<35%  
Pre-op sCr 
Diabetes 
Surgery type 
Preop IABP 
Emergency 
NYHA class 
Reoperation 
COPD Female 
 
EF<40%  
eGFR 
Diabetes 
Surgery type 
Preop IABP 
Emergency 
NYHA class 
CVP >14 cm  
 
Age  
Female 
Diabetes 
PVD 
Preop IABP 
Hypertension 
NYHA class 
Reoperation 
WCC>12,000 
 
Age >65 
Preop sCr 
Diabetes 
Surgery type 
CPB >120m  
LCO 
AUROC 0.83 0.76 0.81 0.81 0.72 0.84 
a CSA-AKI defined as post operative eGFR<30mls/min. LCO: low cardiac output 
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1.2.5 Pathology of CSA-AKI 
The pathophysiological processes thought to explain the development of CSA-AKI are 
depicted in Figure 2. The proposed first phase of CSA-AKI is a vasomotor nephropathy, in 
which there is an absolute or relative reduction in renal perfusion (either global or regional), 
effecting a reduction in GFR and an increase in both sCr and blood urea; this is usually but 
not always accompanied by oliguria. Subsequent consequences of renal hypoperfusion are 
cellular adenosine triphosphate depletion, and oxidative injury. This leads to an activation of 
inflammatory cells, renal epithelial cells and endothelial cells (initiation phase) [116, 117]. 
Inflammatory cells adhere to an activated endothelium in the peritubular capillaries of the 
outer medulla, with medullary congestion and hypoxic proximal tubular injury (extension 
phase) [116, 117]. Tubular cells will then proliferate and redifferentiate (maintenance phase), 
followed ultimately by the reconstitution of polarity and function (repair phase) [116, 117].  
 
 
 
Figure 2 Conceptual model of CSA-AKI [117] 
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1.2.6 Pathogenesis of CSA-AKI 
Aetiological factors central to the pathogenesis of CSA-AKI can be divided into 
preoperative, intraoperative, and postoperative events.  
 
1.2.6.1 Preoperative events 
Many patients undergoing cardiac surgery are pre-disposed to the development of CSA-AKI. 
Recent myocardial infarction, valvular heart disease and reduced left ventricular function 
may all cause a pre-operative reduction in renal perfusion. Furthermore, treatments for 
cardiac disease (such as diuretics) may impair the autoregulation of renal blood flow, and 
iodinated contrast used during coronary angiography may cause direct nephrotoxicity. 
Finally, a significant proportion of patients undergoing cardiac surgery have pre-existing 
CKD and thus lack ‘renal-reserve’, compounding the risk of CSA-AKI.  
 
1.2.6.2 Intra-operative events 
The intraoperative period is a crucial time when patients are exposed to anesthesia and 
cardiopulmonary bypass (CPB).  Reduced renal perfusion pressure, activation of a systemic 
inflammatory response, and direct effects of the CPB circuit may all contribute to the 
development of CSA-AKI. 
 
The goal of CPB is to maintain tissue perfusion at a level that supports optimal cellular 
function. Any reduction in tissue perfusion during CPB can lead to ischaemic cellular injury. 
The kidneys are particularly prone to ischemic injury as the renal medulla is normally 
perfused at a low oxygen tension with a limited reserve [118]. Maintenance of stable tissue 
perfusion during CPB requires interplay between blood flow generated by the CPB pump, 
systemic vascular resistance, and the autoregulatory capacity of end vascular beds. Standard 
haemodynamic goals of CPB are a mean perfusion pressure of 50 to 70 mmHg and CPB 
blood flow rates of 1.8 to 2.4 L/min per m2.  These haemodynamic parameters maintain 
cerebral blood flow autoregulation during CPB [119]; however the effect of these parameters 
upon regional renal blood flow is largely unknown. It is likely that renal perfusion and 
autoregulation are maintained as long as these parameters are met [120], but these values 
likely represent the minimum blood flows that support normal cellular function, and any 
further perturbation may lead to an oxygen supply/demand imbalance, with resultant renal 
ischaemia/reperfusion injury. Furthermore, these ‘standard parameters’ may be inadequate to 
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achieve adequate tissue perfusion in some patients undergoing CPB.  Hypertensive patients 
and patients with diabetes are thought to have a ‘right-shifted’ tissue autoregulation curve 
[121], and so may require higher perfusion pressures to achieve optimal tissue perfusion. In 
addition, preexisting ATN or CKD may also impair the autoregulatory capacity of the kidney 
[122] and so renal blood flow becomes linearly dependent on pressure, increasing the 
likelihood of an already ‘vulnerable’ kidney sustaining a further ischaemic insult.  
 
Other CPB related factors that may be implicated in CSA-AKI include haemodilution, 
hypothermia and the absence of pulsatile blood flow during CPB [118]. Haemodilution is 
necessary during CPB to reduce blood viscosity during hypothermia, but results in reduced 
tissue oxygen delivery. Hypothermia during CPB reduces metabolic demand [118], but 
nephron damage may occur due to hypoperfusion of the superficial cortex during rewarming 
[123]. 
 
The CPB circuit is a potent pro-inflammatory stimulus that can provoke a systemic 
inflammatory response syndrome (SIRS) [109, 118]. Contact of blood components with the 
artificial surface of the CPB circuit, ischemia-reperfusion injury, operative trauma, non-
pulsatile blood flow during CPB, and pre-existing left ventricular dysfunction have all been 
associated with the development SIRS following cardiac surgery [109, 118]. Interleukins 
(IL-6 and IL-8) and tumor necrosis factor (TNF)-% are thought to be central to the SIRS 
response [124]. The effect of SIRS upon the kidney is unknown, but in animal models 
systemic inflammation can result in renal injury [125, 126]. Thus, it is a distinct possibility 
that CPB- induced SIRS may have a significant deleterious effect upon the kidney.  
 
Microemboli generated by the CPB circuit can also cause directly renal injury. The 
microemboli are composed of fibrin, platelet aggregates, cellular debris, fat, and air [109]. 
Although the CPB system can filter larger emboli (greater than 40 $m) smaller emboli are 
not effectively filtered and can cause direct damage to renal capillaries [118]. Studies using 
transcranial doppler ultrasound to record emboli counts during CPB found that the number 
of emboli during CPB was independently associated with CSA-AKI [127]. 
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1.2.6.3 Post-operative events 
Postoperative haemodynamic instability, inotrope or pressor use and/or nephrotoxins (such 
as non-steroidal anti-inflammatory drugs), volume depletion and sepsis/SIRS are all events 
that may cause or exacerbate AKI [120].  
 
1.2.7 Strategies to Reduce Incidence of CSA-AKI 
1.2.7.1 General measures 
Pre-operative recognition of CSA-AKI risk is key to improving outcomes. As previously 
discussed several scoring systems exist to identify patients at risk of CSA-AKI. In at risk 
patients the pre-operative correction of intravascular volume depletion and optimization of 
cardiac failure will increase cardiac output and renal perfusion and may reduce the potential 
for CSA-AKI. Moreover, the discontinuation of nephrotoxins, and potentially delaying 
surgery for 24 hours after exposure to iodinated contrast media may also help reduce the 
incidence of CSA-AKI [118].  
 
1.2.7.2 Optimising Cardiopulmonary Bypass 
Conceptually, many of the pathophysiologic mechanisms that result in CSA-AKI stem from 
CPB. The duration of CPB is independently associated with the development of CSA-AKI 
[128]. Tissue perfusion during CPB is a function of pump flow and arterial resistance. 
Haemodilution is undertaken during CPB to decrease blood viscosity and improve end organ 
microcirculatory flow, but haemodilution to a haematocrit of less than 21% is associated 
with a significant increase in the incidence of CSA-AKI [109]. Blood conservation 
guidelines published by the Society of Thoracic Surgeons and the Society of Cardiovascular 
Anaesthesiologists suggest maintaining a hematocrit of at least 21% (haemoglobin 
concentration, 7 g/dL) during CPB to reduce the incidence of CSA-AKI [129]. Pulsatile flow 
during CPB may also improve end-organ perfusion and has been shown to preserve renal 
function better than standard non-pulsatile CPB [118]. 
 
The development of ‘off-pump’ surgical techniques that allow the elimination of CPB and 
maintenance of pulsatile intra-operative blood flow could theoretically reduce the incidence 
of CSA-AKI. However, these techniques may be associated with more hemodynamic 
instability as the left ventricle is compressed when manipulating the heart to access the 
 39 
coronary arteries [130]. Published studies comparing ‘off-pump’ and ‘on-pump’ CABG 
upon renal outcomes have yielded conflicting results. Most of these studies were single 
centre, and observational in design, including heterogeneous patient populations with vastly 
different baseline risk of developing CSA-AKI. Furthermore, they used a variety of 
definitions of CSA-AKI. A recent meta-analysis of 22 studies (6 RCTs and 16 observational 
studies) including approximately 28,000 patients, demonstrated a statistically significant 
reduction in CSA-AKI (OR 0.57; 95% CI 0.43 to 0.76) with ‘off-pump’ compared to 
conventional ‘on-pump’ surgery [131]. Also, Hix and coworkers [132] reported a large 
cohort of 1365 patients undergoing ‘off-pump’ CABG matched by propensity score with 
1365 patients undergoing conventional ‘on-pump’ CABG. These investigators found that 
‘off-pump’ surgery was associated with a significant 2-fold reduction in the risk of CSA-
AKI and a 2-fold decrease in the need for RRT. Prospective, randomized studies to assess 
the effect of ‘off-pump’ surgery upon CSA-AKI are currently underway.  
 
1.2.7.3 Pharmacological interventions to modify the incidence of CSA-AKI 
A multitude of clinical studies have investigated the effects of pharmacological 
renoprotective agents aimed at improving renal perfusion, reducing renal oxygen 
consumption, or attenuating inflammation to reduce the incidence of CSA-AKI. To date 
these interventions have been largely unsuccessful. Potential explanations for the failure of 
these measures to prevent CSA-AKI include:  
1. The pathophysiology of CSA-AKI is complex, and most interventions have targeted 
a single pathophysiological pathway.  
2. CSA-AKI is defined by an increase in sCr, or decrease in urine output. These are 
late events occurring up to 24-48 hours after the renal insult. Therapies to ameliorate 
CSA-AKI instituted at this late stage are unlikely to be successful.  
3. Most clinical trials have enrolled small numbers of low risk patients and are as such 
underpowered to detect small benefits of trial therapies. 
 
Renal vasodilators: Dopamine, which causes dilatation of both afferent and efferent 
glomerular arterioles and results in increased renal blood flow, has failed to demonstrate any 
renoprotective benefit after cardiac surgery [133]. Fenoldopam, a selective dopamine 
receptor agonist may also be used to increase renal perfusion and has been shown in some 
studies to reduce CSA-AKI [134-136]. Trials assessing the effect of fenoldapam upon CSA-
AKI are limited by small sample size, variation in trial inclusion criteria and fenoldapam 
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treatment regimes. Furthermore, concerns have been raised that the beneficial renal 
vasodilation afforded by fenoldopam may be offset by systemic hypotension that results in 
an overall net reduction in renal blood flow [120]. Currently further evaluation of 
fenoldopam to prevent CSA-AKI is needed.  
 
Drugs that induce natriuresis: Forced diuresis theoretically may reduce AKI by preventing 
tubular obstruction and decreasing oxygen consumption through the inhibition of the Na-K-
2Cl co-transporter in the loop of Henle. Randomised trials of both frusemide and mannitol 
have failed to demonstrate any renoprotective effects of forced diuresis [137, 138]. In fact, 
when combining the results of these trials there is a non-significant trend towards an increase 
in the need for RRT and incidence of AKI attributable to the use of diuretic agents [133].  
 
Cardiac natriuretic peptides induce natriuresis by increasing glomerular filtration rate and 
inhibiting sodium reabsorption in the collecting ducts. Following cardiac surgery the 
administration of recombinant cardiac natriuretic peptides increases urine output and reduces 
post-operative creatinine levels. Individual RCTs have not detected a consistent reduction in 
the need for RRT or post-operative mortality with the peri-operative administration of 
recombinant natriuretic peptides, but as with so many trials in this arena, these studies were 
small and underpowered [139, 140]. A meta-analysis evaluating the efficacy of natriuretic 
peptides in patients undergoing cardiac as well as non-cardiac surgery has demonstrated a 
reduced need for post-operative RRT [133]. An adequately powered study examining 
natriuretic peptides in cardiac surgery is now needed. 
 
Drugs that block inflammation: Drugs targeting post CPB SIRS to reduce CSA-AKI have 
been intensively investigated and in majority have yielded disappointing results. For 
example, statins attenuate inflammation and oxidative stress but do not reduce CSA-AKI 
[141]. N-acetylcysteine, which has been proven to prevent AKI in animal models, has failed 
to show the same promise in clinical studies [131]. 
 
Other strategies: Calcium channel antagonists: A systematic review of the perioperative 
administration of calcium channel antagonists (CCAs) in non-cardiac surgery reported that 
post-operative eGFR was 8.54 mL/min (95% CI 0.82, 16.25, p = 0.03) higher in patients that 
received CCA compared with patients receiving placebo [142]. Unfortunately, trials in 
patients undergoing cardiac surgery have not found a significant benefit of CCAs upon post-
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operative renal function [133]. The renoprotection of CCAs seen in non-cardiac surgical 
patients may be offset by CCA induced hypotension in patients with compromised cardiac 
function undergoing cardiac surgery. 
 
Urinary alkalinization: Hydration plus urinary alkalinization with sodium bicarbonate has 
been used extensively to prevent contrast-induced nephropathy where it has been associated 
with inconsistent results. Sodium bicarbonate to prevent CSA-AKI is less well studied. A 
small randomized trial of 100 patients (receiving normal saline or sodium bicarbonate during 
cardiac surgery) found that patients receiving sodium bicarbonate peri-operatively were less 
likely to develop a postoperative increase in sCr >25% from baseline within the first five 
postoperative days compared with the patients that received normal saline (OR 0.43 [95% CI 
0.19-0.98])(p = 0.043) [143]. The role of sodium bicarbonate in the protection of CSA-AKI 
is currently the focus of a number of larger RCTs. 
 
Remote ischaemic pre-conditioning (RIPC): RIPC is the phenomenon by which the 
application of brief intervals of non-lethal ischemia to a distant organ provides protection of 
another organ to a subsequent injurious ischaemic insult. RIPC is reported to reduce renal 
injury following abdominal aortic aneurysm (AAA) surgery [144]. As the mechanisms of 
renal ischemia–reperfusion injury following AAA surgery are broadly similar to those 
proposed for CSA-AKI, and that RIPC may modulate CPB related inflammatory response, 
RIPC represents an attractive non-invasive therapy to ameliorate CSA-AKI.  
 
In cardiac surgery a retrospective secondary analysis of renal outcomes drawn from 2 
randomized trials of RIPC for myocardial protection found that RIPC resulted in a reduction 
in CSA-AKI [145]. Three small prospective studies in cardiac surgery have prospectively 
investigated the renoprotective effects of RIPC. Rahman et al failed to show a beneficial 
effect of RIPC upon renal injury following CABG, although renal function was not the 
primary outcome of this study, and was assessed only upon the fourth post-operative day. 
Conceivably sCr may have risen and returned to baseline within this time frame [146]. Choi 
et al, also failed to show any renoprotective effect of RIPC within a small heterogeneous 
population undergoing a variety of complex cardiac surgical procedures [147]. Finally, 
Zimmerman et al found that RIPC significantly reduced the incidence of CSA-AKI in their 
cohort of 118 patients undergoing cardiac surgery [148]. RIPC needs to undergo further 
investigation as a renoprotective procedure; larger RCTs are needed, and RIPC must be 
tested in patients with pre-existing renal disease before it becomes a mainstream therapy. 
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Prophylactic renal replacement therapy: Prophylactic RRT has been studied in high-risk 
patients with pre-operative renal dysfunction. In a single study, 44 patients with sCr greater 
than 221 $mol/L were randomized to either prophylactic RRT or control [149]. In the group 
receiving RRT, mortality was 4.8% versus 30.4% in the control group, and postoperative 
AKI requiring RRT was 4.8% versus 34.8% in the control group. Prophylactic RRT may 
become a viable option in the future, but before this these results will have to be repeated in 
larger RCTs.  
 
1.2.8 Renal Biomarkers for the early diagnosis of AKI 
CSA-AKI is diagnosed by peri-operative changes in sCr level and urine output [111]. 
Creatinine is the product of creatine breakdown and is filtered by the glomerulus, with blood 
creatinine levels rising, if glomerular filtration of creatinine is deficient.  sCr has several 
limitations as a biomarker of AKI; firstly creatinine release is affected by age, gender, diet, 
muscle mass, drugs, and exercise [108]. Secondly, up to 40% of creatinine clearance is due 
to the renal secretion of creatinine into urine, which could potentially mask important 
changes in GFR [108]. Finally, sCr levels only become abnormal when greater than 50% of 
glomerular filtering capacity is lost, and it may require up to 24 hours following AKI for 
increases in sCr concentration to become detectable [103]. Urine output is also a crude gauge 
of renal function but may be a more sensitive indicator of changes in renal hemodynamics 
than a measure of solute clearance. Importantly, many drugs used post-operatively (eg: 
diuretics, inotropes and vasopressors) will confound the use of urine output as an accurate 
measure of renal function [103]. 
 
Given the limitations of sCr and urine output for the detection of CSA-AKI there is a 
growing interest in novel biomarkers that allow rapid and reliable diagnosis of kidney injury. 
Early diagnosis of CSA-AKI may facilitate better peri-operative risk stratification, and allow 
the institution of renoprotective therapies during a ‘time-window’ when they will have the 
best chance of being effective. They may also offer a novel surrogate end-point for trials of 
renoprotection in cardiac surgery. 
 
The most promising AKI biomarkers to emerge include neutrophil gelatinase-associated 
lipocalin (NGAL), cystatin C (CyC), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-
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18) and liver-type fatty acid binding protein (L-FABP). These biomarkers have been 
evaluated in several AKI populations, but CSA-AKI has attracted most interest as it is the 
second most common cause of AKI in critically ill patients and patients undergoing cardiac 
surgery are a relatively homogenous, well-characterized population, and most importantly 
the timing of renal injury is known. 
 
1.2.9 Summary 
AKI is common complication after cardiac surgery and is associated with an increased risk 
of both morbidity and mortality. Despite recent advances in the understanding of the 
predisposing risk factors and the pathophysiological processes central to the development of 
CSA-AKI, neither the incidence nor the mortality associated with the condition have 
changed. Currently there are no established prophylaxes or therapies for CSA-AKI and novel 
strategies to prevent and manage this complication are now urgently needed. 
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1.3 Aims of this thesis 
The remainder of this thesis is structured into three parts. The first section describes outcomes 
of patients undergoing cardiac surgery within Barts Health NHS Trust. I have developed a 
cardiac surgical dataset that has allowed analysis of our cardiothoracic unit’s outcomes. 
Analysis of this dataset has allowed me to investigate the effect of CKD upon outcome after 
CABG surgery, and also to study the effect of CSA-AKI following CABG surgery upon 
patients at our institution. 
 
The second section of this thesis describes a randomized control trial in patients with CKD 
undergoing CABG surgery. The specific aims of this trial were to assess the potential for 
remote ischaemic preconditioning to reduce CSA-AKI and myocardial injury in patients with 
CKD undergoing CABG surgery. 
 
Finally the third section of this thesis describes the development of a panel of renal AKI 
biomarkers that we hoped would allow the accurate prediction of CSA-AKI in patients with 
CKD undergoing CABG surgery. 
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Chapter 2 
 
2. Outcomes of patients with chronic kidney disease undergoing 
coronary artery bypass graft surgery at Barts Health NHS Trust: 
2003 to 2007 
 
Background 
Patients with ESRD represent a group at particularly high risk for mortality following 
CABG. Patients with lesser degrees of CKD undergoing CABG are less well studied. The 
aim of this study was to evaluate the impact of CKD stage upon mortality in patients 
undergoing CABG at Barts Health NHS Trust. 
 
Methods  
This was an observational cohort study of 4769 patients undergoing CABG at Barts Health 
NHS Trust between 2003 and 2008. eGFR was calculated from the MDRD equation. The 
cohort was divided into four groups according to pre-operative eGFR: Reference group 
(eGFR >90 mL/min), stage 2 CKD (eGFR 89.9-60 mL/min), stage 3 CKD (eGFR 59.9-30 
mL/min) and stage 4 CKD (eGFR <30 mL/min). Clinical outcomes were compared between 
the groups. The primary outcome measure was five-year all cause mortality.  
 
Results 
779 deaths occurred during median 5.5 (CI 4.2 to 6.8) years follow-up. Pre-operative eGFR 
was significantly lower for the patients that died compared with survivors (60.8 vs 72.9 
mL/min; p<0.0001). Five-year mortality adjusted for potentially confounding factors 
following CABG was significantly worse for patients with stage 3 CKD (HR 1.29, 95% CI 
1.02 to 1.64) and for patients with stage 4 CKD (HR 3.12, 95% CI 2.08 to 4.67) when 
compared with the reference group. 
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Conclusions 
Patients with stage 3 and 4 CKD represent a group at particularly high risk of adverse 
outcome following CABG.  
 
2.1 Introduction 
In recent years the number of patients with CKD undergoing cardiac surgery has increased 
dramatically [3, 150, 151]. Current data suggests that CKD may now affect more than one-
quarter of all cardiac surgical patients [150, 152]. Although severe CKD and ESRD are 
understood to be risk factors for adverse outcomes following cardiac surgery, there is limited 
information upon the risk associated with lesser degrees of CKD. Furthermore, many 
previous observational studies that have investigated the association between CKD and 
outcome following cardiac surgery have used arbitrary sCr measurements to define CKD 
[153-156]. This is inappropriate as sCr measurements can vary by as much as 20% each day 
due to factors independent of kidney function. In contrast eGFR is a more accurate and 
robust measure of kidney function that may identify patients with mild CKD despite normal 
or near normal sCr levels.  
 
This chapter represents an analysis of Barts Health NHS Trust cardiac surgical dataset. The 
aim of the study was to evaluate the impact of CKD stage defined according to National 
Kidney Foundation guidelines using eGFR cut-offs upon mortality in patients undergoing 
CABG at Barts Health NHS Trust. 
 
2.2 Methods  
2.2.1 Patients and Setting 
Between January 1 2003 and December 31 2007, 4,891 patients underwent isolated first time 
CABG at Barts Health NHS Trust. The 87 patients who had incomplete surgical datasets and 
the 35 patients who required renal replacement therapy pre-operatively were excluded, 
leaving 4,769 patients in the study cohort (Figure 3). 
 
2.2.2 Data Collection  
Detailed clinical information was recorded prospectively and stored electronically. Baseline 
clinical data included age, sex, body mass index (BMI), history of MI, PCI, insulin 
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dependent diabetes mellitus (IDDM), hypertension, peripheral vascular disease (PVD), 
stroke, and pre-operative left ventricular function, severity of CAD, and the logistic 
EuroSCORE [157]. 
 
Operative data recorded included procedural urgency, use of CPB, internal mammary arterial 
(IMA) grafts, intra-aortic balloon pump (IABP), cross clamp time, and perfusion time. 
Procedural urgency was defined as urgent, or elective. Urgent surgery was defined by the 
requirement for the patient to remain in hospital for CABG following coronary angiography. 
Elective surgery was defined as CABG in patients who were discharged from the hospital 
following coronary angiography and readmitted in a planned way for surgery at a later date. 
 
2.2.3 Renal function 
sCr concentration was measured pre-operatively in all patients undergoing cardiac surgery. 
For patients undergoing elective surgery, the sCr concentration was measured in a 
preadmission clinic approximately 4 weeks before surgery. For patients undergoing urgent 
surgery, sCr concentration was measured on admission to hospital. eGFR was calculated 
from the Modification of Diet in Renal Disease equation [158].  
 
sCr was measured daily for the first post-operative week unless patients were discharged 
within this period. Post-operative AKI was defined as a 50% increase in sCr concentration 
within seven days of surgery compared with the pre-procedure level. 
 
2.2.4 Outcome Measures  
The primary study end point was mid-term all-cause mortality. The secondary end-point was 
30-day post-operative mortality. Mortality data were obtained from the United Kingdom 
Office of National Statistics which periodically links live/death status of treated patients to 
our unit’s surgical database as part of the national Central Cardiac Audit Database. Study 
patients were followed up until August 2011. The median follow-up period was 5.5 
(interquartile range (IQR) 4.2 - 6.9) years. 
 
2.2.5 Ethics  
Data were collected routinely as part of a national cardiac surgical audit and patient 
identifiers were removed prior to analysis. The local ethics committee advised us that formal 
ethical approval was not required for this study.  
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2.2.6 Statistical Analysis 
Using pre-operative eGFR, and guidelines defined by the National Kidney Foundation [7], 
the cohort was divided into four groups for analysis; patients with an eGFR > 90 mL/min 
(Reference group), patients with stage 2 CKD (eGFR 60–89.9 mL/min), patients with stage 3 
CKD (eGFR 30-59.9 mL/min) and patients with stage 4 CKD (eGFR < 30 mL/min).  
 
Baseline clinical characteristics and procedural data were compared between the groups. 
Categorical data are summarised using absolute values (percentage). Continuous data with a 
normal distribution are presented as mean ± standard deviation or, where skewed, as median 
(IQR). Normally distributed data were compared with a one-way analysis of variance 
(ANOVA) and non-normally distributed variables were compared with the Kruskal-Wallis 
test. Categorical data were compared using the Pearson chi square test. Procedural outcomes, 
30-day mortality, and mid-term mortality were compared between the four groups. Potential 
independent associations with 30-day mortality were assessed using multivariate logistic 
regression. Mid-term survival was described using the Kaplan-Meier method, and 
comparisons between groups were made using the log-rank statistic. Variables associated 
with mid-term mortality were analysed using multivariable Cox proportional regression in 
order to account for confounding factors. Statistical analyses were performed using SPSS 
(Version 18.0, IBM SPSS statistics UK). 
  
Figure 3 Flow diagram of patients treated by CABG between January 2003 and 
December 2007 describing patient exclusions and pre-operative stage of chronic 
kidney disease. 
4891 patients underwent 
first time CABG surgery 
during study period
Exclusions:
87 patients with incomplete  data  
35 patients established on dialysis
Study cohort 
4769 patients
Reference Group 
(eGFR > 90 mL/min) 
1685 patients 
(35.5%)
Stage 2 CKD 
(eGFR 60-89.9 mL/min) 
1609 patients 
(33.7%)
Stage 3 CKD
(eGFR 30-59.9 mL/min) 
1403 patients 
(29.4%)
Stage 4 CKD 
(eGFR < 30 mL/min) 
72 patients 
(1.5%)
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2.3 Results 
2.3.1 Patient clinical and procedural characteristics  
The baseline clinical characteristics of the study groups are shown in Table 6. Among 4769 
patients who underwent CABG, 1609 (33.7%) patients had CKD stage 2, 1403 (29.4%) 
patients had CKD stage 3 and 72 (1.5%) patients had CKD stage 4. Patients with more 
advanced CKD were older, more likely to be female and had a lower BMI. When compared 
with patients with an eGFR > 60 mL/min (reference group and stage 2 CKD group 
combined), patients with stage 3 or 4 CKD were significantly more likely to have had a prior 
MI, PCI, stroke, PVD, left ventricular impairment, three vessel or left main stem CAD and 
had higher median logistic EuroSCORE. Also these patients were more likely to undergo 
urgent surgery and less likely to receive an IMA graft. Patients with CKD stage 4 were most 
likely to have IDDM. 
 
2.3.2 Post-operative complications and 30-day mortality 
The in-hospital complications and 30-day mortality data are also shown in Table 6. AKI 
developed in 613 (12.9%) patients. The rate of post-operative AKI and dialysis were highest 
in patients with stage 4 CKD. Length of hospital stay was also significantly longer in this 
group. The 30-day mortality rates were 0.8% (reference group), 0.9% (stage 2 CKD), 3.1% 
(stage 3 CKD), and 11.1% (stage 4 CKD) (p<0.0001). Logistic regression confirmed both 
stage 3 and stage 4, but not stage 2 CKD as univariate predictors of 30-day mortality post 
CABG, when compared to reference group (Table 7). After multivariable adjustment for all 
factors with a significant (p<0.15) univariate relationship with 30-day mortality after CABG 
(see Table 7) only stage 4 CKD independently predicted 30-day mortality (when compared 
to reference group). In a multivariate model that included just CKD stage and logistic 
EuroScore both stage 3 and stage 4 CKD were significant predictors of 30-day mortality. 
Other independent predictors of 30-day mortality included increasing age, hypertension and 
need for pre-operative IABP.  
 
2.3.3 Mid-term all-cause mortality 
Kaplan-Meier analysis (Figure 4) showed significant differences between the study groups 
in mortality rates during follow-up after CABG. The one-year mortality rates in the reference 
group, stage 2 CKD group, stage 3 CKD group and stage 4 CKD group were 2.0% (95% CI 
0.4 – 6.2), 3.1% (95% CI 1.0 – 7.2), 8.6% (95% CI 5.3 – 12.8) and 22.3% (95% CI 8.6 – 
39.9), respectively. The five-year mortality rates were 7.3% (95% CI 4.3 – 11.3), 11.9% 
(95% CI 8.5 – 15.9), 21.1% (95% CI 17.4 – 25.1) and 49.7% (95% CI 37.1 – 61.1) 
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respectively. Cox-regression analysis demonstrated a significant univariate relationship 
between CKD stages 2, 3 and 4 and mid-term mortality when compared to the reference 
group. The relationship between stage 3 and stage 4 CKD, but not stage 2 CKD, and mid-
term mortality following CABG persisted after multivariate analysis (Table 7). Other 
independent predictors of mid-term mortality included increasing age, presence of IDDM, 
PVD, left ventricular ejection fraction less than 50%, and the need for urgent CABG surgery. 
 
 
Figure 4 Kaplan-Meier curve describing mid-term mortality after CABG 
surgery in relation to CKD stage
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Table 6 Clinical and procedural characteristics of study cohort according to 
CKD stage  
 eGFR, mL/min  
 Reference  > 90 (n=1685) 
CKD stage2 60 – 89.9 (n=1609) 
CKD stage 3 30 – 59.9 (n=1403) 
CKD stage 4 < 30 (n=72) 
p value 
      
Patient Characteristics      
Age 59.7 ± 8.7 68.0 ± 7.4 73.7±6.6 73.8±9.3 <0.0001 
Gender, female 193 (11.5) 300 (18.6) 456 (32.5) 27 (37.5) <0.0001 
BMI 30.0 ± 5.7 27.4 ± 4.9 25.8±4.5 24.4±3.6 <0.0001 
Hypertension 1291 (76.6) 1277 (79.4) 1110 (79.1) 56 (77.8) 0.217 
IDDM 164 (9.7) 148 (9.2) 164 (11.7) 14 (19.4) 0.007 
Previous MI 749 (44.5) 707 (43.9) 687 (49.0) 36 (50.0) 0.022 
Previous PCI 217 (12.9) 165 (10.3) 82 (5.8) 6 (8.3) <0.0001 
Previous stroke 88 (5.2) 109 (6.8) 125 (8.9) 7 (9.7) 0.001 
PVD 160 (9.5) 193 (12.0) 242 (17.2) 21 (29.2) <0.0001 
LVEF < 50% 584 (34.7) 600 (37.3) 587 (41.7) 40 (55.6) <0.0001 
3 vessel coronary disease 1136 (67.4) 1067 (66.3) 997 (70.9) 52 (72.2) 0.030 
Left main stem disease 428 (25.4) 376 (23.4) 400 (28.5) 21 (29.2) 0.012 
      
Procedural Characteristics    
Procedural urgency 523 (31.0) 481 (29.9) 528 (37.6) 29 (40.3) <0.0001 
CPB 1560 (92.6) 1492 (92.7) 1291 (92.0) 67 (93.1) 0.889 
IMA usage 1579 (93.7) 1490 (92.6) 1232 (87.8) 62 (86.1) <0.0001 
Preoperative IABP 19 (1.1) 21 (1.3) 20 (1.4) 3 (4.2) 0.166 
Cross-clamp time 57.3±22.3 55.4±20.1 54.6±24.7 55.8±18.6 0.690 
Perfusion time 83.4±40.8 82.1±40.6 80.7±36.8 87.3±37.1 0.216 
EuroSCORE 1.6 (1.1 to 2.7) 2.7 (1.7 to 4.7) 4.3 (2.9 to 7.9) 8.6 (4.3 to 9.1) <0.0001 
      
Post operative outcomes    
AKI 157 (9.3) 176 (10.9) 254 (18.1) 26 (36.1) <0.0001 
Post-operative dialysis 7 (0.4) 9 (0.6) 18 (1.3) 6 (8.3) <0.0001 
Post-operative stroke 4 (0.2) 11 (0.7) 12 (0.9) 0 (0) 0.106 
      
Length of hospital stay 7 (6 to 11) 8 (6 to 13) 9 (6 to 16) 12 (7 to 26) <0.0001 
30-day mortality 13 (0.8) 15 (0.9) 43 (3.1) 8 (11.1) <0.0001 
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Table 7 Relation of 30-day and mid-term mortality to CKD stage 
 eGFR, mL/min  
Of  Reference group 
 > 90 
(n=1685) 
CKD stage 2 
60 – 89.9 
(n=1609) 
CKD stage 3 
30 – 59.9 
(n=1403) 
CKD stage 4 
< 30 
(n=72) 
     
30-day mortality 13 (0.8) 15 (0.9) 43 (3.1) 8 (11.1) 
Unadjusted OR (95% CI) 1 1.21 (0.57–2.55) 4.07 (2.18 – 7.59) 16.08 (6.44 – 40.16) 
OR adjusted for EuroScore (95% CI) 1 1.08 (0.51–2.29) 3.07  (1.62 – 5.82) 8.21 (3.03 – 22.24) 
Multivariate adjustment* (95% CI) 1 0.82 (0.37–1.79) 1.93  (0.92 – 4.05) 6.67 (2.36 – 18.86) 
     
     
Mid-term mortality 159 (9.4) 240 (14.9) 343 (24.4) 37 (51.4) 
Unadjusted HR (95% CI) 1 1.57 (1.28–1.92) 2.81 (2.33 – 3.39) 8.15 (5.69 – 11.65) 
Cox multivariate adjustment §(95% CI) 1 1.01 (0.81–1.26) 1.29 (1.02 – 1.64) 3.12 (2.08 – 4.67) 
eGFR indicates estimated glomerular filtration rate; OR odds ratio; HR hazard ratio. 
* Multivariate logistic regression analysis included the following variables: age, previous MI, hypertension, previous stroke, PVD, presence of three vessel CAD, presence of 
left main stem CAD, pre-operative left ventricular function, procedural urgency, use of IMA, use of peri-operative IABP, and CKD stage. 
§ Multivariate logistic regression analysis included the following variables: age, BMI, previous MI, hypertension, previous stroke, PVD, presence of three vessel CAD, 
presence of left main stem CAD, pre-operative left ventricular function, procedural urgency, use of CPB, use of IMA, use of peri-operative IABP, and CKD stage. 
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2.4 Discussion 
These data demonstrate the relationship between CKD stage and outcome after CABG. 
Consistent with previous research we have found that CKD is a harbinger of poor outcome 
following CABG. In this surgical cohort stage 3 CKD or worse (defined as an eGFR < 60 
mL/min) was common, affecting approximately one third of patients, with these patients 
accounting for a disproportionate two thirds of all deaths within the first 30-days of surgery. 
Within 5-years of surgery 22% of patients with CKD stage 3 or stage 4 were dead, in 
comparison with a 5-year mortality rate of only 12% of patients with a pre-operative eGFR > 
60mL/min.  
 
The association between renal dysfunction and adverse prognosis after cardiac surgery is well 
described. However, most previous observational studies have defined kidney disease on the 
basis of arbitrary measurements of sCr, which may underestimate the prevalence of 
significant kidney disease [153-156]. For example, one commonly used definition of kidney 
disease used was sCr greater than 1.5 mg/dL (133 !mol/L). If this definition was applied to 
our cohort only 7.4% of patients would be considered to have kidney disease. eGFR is a far 
more discriminatory measure of renal function, that allows the detection of patients with less 
severe kidney disease. GFR has now been confirmed as powerful independent predictor of 
cardiovascular events and mortality in a number of settings, including after coronary surgery, 
PCI and MI [150, 152, 159, 160]. This data adds to this rapidly growing evidence base, but 
most importantly it highlights the risk faced by patients with stage 3 and stage 4 CKD 
undergoing CABG. Novel strategies to reduce risk in this group of patients are now urgently 
needed. 
 
In keeping with previous research we found that the relationship between mortality risk after 
coronary surgery and kidney dysfunction is non-linear [150]. The risk of mortality for patients 
with mild kidney disease (stage 2 CKD) appears broadly similar to patients in our reference 
group. Once patients develop stage 3 CKD mortality risk following surgery seems to increase 
steeply.  
 
Although we have no data upon cause of death in our cohort, similar studies have reported 
that the majority of deaths following coronary surgery in patients with CKD are due to 
cardiovascular disease [152]. There are a number of potential explanations for the increase in 
cardiovascular mortality observed in patients with CKD. Firstly, as previously described, 
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traditional cardiovascular risk factors such as diabetes mellitus and hypertension, themselves 
independently associated with an increased mortality risk, are more prevalent in patients with 
CKD [161]. Secondly, the uraemic milieu that characterizes CKD is associated with novel 
cardiovascular risk factors such as inflammation, endothelial dysfunction and oxidative stress, 
hyperhomocysteinaemia and vascular calcification [161]. These novel risk factors may 
interact with traditional cardiovascular risk factors to accelerate arterial disease and result in 
the development of de novo cardiovascular events. An excess of MI and stroke has been 
observed in patients with CKD following cardiac surgery [151]. Thirdly, left ventricular 
hypertrophy, dilatation and dysfunction are more common in patients with significant CKD 
and are associated with increased mortality in both population studies and following coronary 
surgery [96]. Fourthly, patients with significant CKD are significantly more likely to sustain 
peri-operative AKI, which is also an independent predictor of cardiovascular risk and 
mortality after cardiac surgery [6]. Finally, patients with CKD are less likely to receive 
prognostically beneficial cardiovascular risk modification therapies such as ACE inhibitors, 
angiotensin II receptor blockers or aldosterone antagonists[162]. Although these therapies 
have never been proven within a specific cohort of patients with CKD, there is no reason to 
expect these therapies to be less efficacious in these patients. 
 
Renal function is often considered a ‘barometer’ of vascular health [163], and thus CKD is 
commonly associated with the development of premature arterial disease. In this cohort 
patients with more advanced CKD were older, had a higher burden of pre-operative 
comorbidity and thus had an elevated procedural risk, and less commonly received an IMA 
graft. These differences potentially confound the association between mortality and CKD 
stage that was identified in this study. After accounting for the differences between patient 
groups, the presence of CKD stage 3 was associated with an approximately 29% increase in 
the risk of five-year mortality, while the CKD stage 4 more than tripled the risk compared to 
patients in the reference group.  
 
In this surgical cohort the overall prevalence of diabetes mellitus (DM) was 31.1%. In 
patients with CKD the prevalence of DM was 31.7%, although there was a higher prevalence 
of insulin dependent DM within these patients when compared with patients without CKD. 
DM is associated with the development of accelerated diffuse CAD. The combination of 
CKD and DM serves to amplify vascular risk resulting in premature accelerated CAD [164]. 
Much of the increased morbidity and mortality associated with both DM and CKD is driven 
by complications of coronary artery disease (CAD) [165, 166]. 
 55 
2.4.1 Comparisons with previous studies 
An analysis of the Society of Thoracic Surgeons National Adult Cardiac Database that 
included approximately 500,000 patients undergoing isolated CABG stratified by eGFR 
reported 30-day mortality was 1.3% for patients with an eGFR > 90mL/min compared with 
1.8%, 4.3% and 9.3% for patients with CKD stage 2, stage 3 and stage 4 respectively. This is 
broadly similar to the early mortality observed in our CABG cohort. 
 
There is limited data upon long-term outcomes of patients with CKD (defined by eGFR) after 
CABG. A Swedish study of more than 6,000 patients [151] reported five-year mortality rates 
of 5.7% for patients with an eGFR > 90mL/min compared with 8.9%, 14.9% and 45.6% for 
patients with CKD stage 2, stage 3 and stage 4 respectively.  
 
Early outcomes of patients with CKD established upon dialysis have been extensively studied 
[3, 167]. These patients have a particularly poor prognosis with an operative mortality as high 
as 9.0% [3]. These patients were excluded form this study in order to maintain the 
consistency of this thesis which investigates outcomes after cardiac surgery in patients with 
non-dialysis dependent CKD. Furthermore only 35 patients with dialysis dependent CKD 
underwent CABG during the study period. Analysis of such a small patient group may yield 
inconsistent results.  
 
2.5 Strengths and Limitations 
This study assessed short- and mid-term outcomes in a large contemporary cohort of 
consecutive patients who underwent CABG. The only exclusion was pre-operative dialysis 
requirement and the primary study end-point was all-cause mortality tracked by the Office for 
National Statistics, a robust clinical outcome. The results are therefore likely to offer genuine 
insights into the relation between CKD stage and mortality after CABG.  
 
This study suffers from the same limitations as all observational studies. Also, it is an analysis 
of a single cardiac centers’ data, and so the results may not be generalizable to all. 
Furthermore the primary outcome is all-cause mortality rather than cardiac death, and I 
acknowledge that the development of new co-morbidities during follow-up might affect long-
term prognosis and that an analysis of these might yield interesting results. The hub and spoke 
model of care employed by cardiothoracic centres in the United Kingdom (and most other 
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countries) means that patients are typically discharged to their local hospitals and general 
practitioner after surgery which makes the comprehensive collection of new data during long-
term follow-up impossible. For these reasons, rarely are data upon the development of new 
comorbidities or cause of death available for presentation in cohort studies of this nature. 
 
I have already acknowledged that there were significant differences in baseline and operative 
characteristics between patient groups. Specifically, patients with more advanced CKD, were 
older and had a higher burden of comorbidities than other patients. This is the reality of these 
patients. However, it should be noted that the GFR was estimated with the MDRD equation. 
The equation uses sCr age and gender to calculate eGFR and so in elderly women eGFR may 
seem inappropriately low. In this study the elderly and women become more frequently as 
GFR decreases. Prospective data collection together with multivariate analyses allowed the 
mitigation of the effect of confounding on the relationship between CKD stage and mortality. 
However, there remains the possibility of residual confounding from unmeasured variables. 
For example, the type of medical therapy received by patients following hospital discharge. 
Patients with CKD are less likely to receive prognostically beneficial medical therapies which 
may in turn affect long-term outcomes [162]. 
 
In this analysis, CKD was defined by a single measurement of eGFR. We did not record 
whether or not proteinuria was present. Proteinuria is a well-established independent predictor 
of cardiovascular mortality [21] and has been shown to be an independent predictor of 
adverse prognosis in diabetic patients undergoing CABG [168]. Data upon proteinuria may 
have led to the reclassification of a number of patients in the reference group as having CKD. 
Furthermore, the definition of CKD in this way did not allow us to identify patients who 
might have had transient AKI following acute myocardial infarction complicated by left 
ventricular dysfunction or following recent coronary angiography, a clinical variable which is 
known to affect prognosis adversely following cardiac surgery. In our cohort, most of the 
patients were elective cases without any reason for AKI.  
 
Despite these limitations the current study highlights the important association between CKD 
and post-operative outcomes after cardiac surgery. Patients with significant CKD appear to be 
at particularly high-risk of premature mortality. Despite the high prevalence of CKD in 
patients undergoing cardiac surgery, and their consistently poor outcomes, these patients are 
rarely the included in studies of new cardiovascular therapies. As such many treatments 
routinely used in practice are untested in CKD. Novel therapies to improve outcomes for this 
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high-risk patient group are urgently needed. This thesis describes my investigations of novel 
strategies to improve outcomes for patients with CKD undergoing cardiac surgery.  
 
2.6 Conclusions 
These data highlights the important relationship between CKD stage, measured by eGFR, and 
outcome after coronary surgery. Patients with stage 3 and stage 4 CKD represent a group at 
particularly high risk of adverse outcome following CABG, and targeted research in this 
group is urgently needed. 
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Chapter 3  
 
3. Acute Kidney Injury and Mid-Term Outcomes Following CABG: 
A Matched Propensity Score Analysis 
 
Background 
The development of AKI following CABG is associated with increased short- and long-term 
mortality. Whether AKI has a causal relationship with subsequent mortality or whether the 
development of AKI simply occurs in patients with more comorbidity, undergoing more 
complex procedures remains unresolved.  
 
Methods  
This was an observational cohort study of 4694 patients who were discharged from hospital 
after first time CABG surgery at Barts Health NHS Trust between 2003 and 2008. The 
cohort was dived in those patients that sustained AKI and those that did not. AKI was 
defined using the RIFLE criteria, which requires at least a 50% increase in serum creatinine. 
The primary outcome measure was five-year all-cause mortality.  
 
Results 
562 (12.0%) patients developed AKI following CABG surgery. Patients that developed AKI 
were older, more likely to be female and had more associated comorbidity than patients that 
did not develop AKI. After Cox multivariable analysis the development of AKI was an 
independent predictor of long-term mortality HR 1.72, 95% CI 1.43-2.07). Subsequently a 
comparison of 562 patients that sustained AKI with 562 propensity-score matched patients 
that did not sustain AKI was undertaken. After propensity matching, baseline clinical and 
operative characteristics were similar between both groups. After Cox multivariable analysis 
of the propensity-matched cohort AKI remained an independent predictor of long-term 
mortality (HR 1.52, 95% CI 1.20–1.94). 
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Conclusions 
The development of AKI following CABG is a serious event associated with worse long-
term survival. This excess mortality cannot be explained simply by coexisting comorbidity 
and surgical complexity.  
 
3.1 Introduction 
AKI is a common problem following cardiac surgery. Depending upon definition, AKI may 
complicate more than 30% of cardiac operations [99], with 1-6 % of patients subsequently 
requiring post-operative dialysis [4, 100]. It is likely that the aetiology of AKI after cardiac 
surgery is multifactorial with advanced age, pre-existing kidney disease, left ventricular 
impairment, and procedural complexity with prolonged cardiopulmonary bypass (CPB) and 
aortic cross times being important predictors of its subsequent development [4, 100, 106, 
155]. 
 
The need for dialysis after cardiac surgery is a serious event associated with a marked 
increase in early morbidity and mortality [4, 100]. Recently evidence has emerged to suggest 
that AKI defined by smaller post-operative increases in sCr is also associated with a poor 
prognosis following cardiac surgery [113, 169]. This evidence is primarily derived form 
retrospective analyses of large cardiac surgical datasets or observational studies and may be 
confounded by the fact that patients with the highest burden of comorbidity before surgery or 
those undergoing the most complex operations are most likely to develop post-operative 
AKI. By virtue of comorbid disease or procedural complexity these patients are likely to 
have a worse post-surgical prognosis independent of the development of AKI. Whether AKI 
has a causal relationship with subsequent mortality or whether the development of AKI 
simply reflects comorbidity and/or procedural complexity within a high-risk patient 
population remains unresolved.  
 
This chapter represents an analysis of Barts Health NHS Trust cardiac surgical dataset with 
the aim of evaluating the impact of AKI upon survival of patients following CABG. Using 
propensity score matching I have minimized the impact of patient comorbidity and surgical 
complexity upon long-term mortality after cardiac surgery.  
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3.2 Methods  
3.2.1 Patients and Setting 
This study analyses consecutive patients undergoing isolated first time CABG surgery at 
Barts Health NHS Trust who survived to hospital discharge. During the study period of 
January 1 2003 to December 31 2007 4891 patients underwent first time CABG surgery, of 
whom we excluded 87 patients with incomplete surgical database records, 35 patients 
established upon pre-operative renal replacement therapy and 75 patients that died in 
hospital post-operatively. The final study cohort comprised 4694 patients who for 
subsequent analysis were divided into two groups; those that developed AKI (AKI group; 
n=562) and those that did not develop AKI (no AKI group; n=4132) (Figure 5). 
 
3.2.2 Data Collection 
Detailed clinical information was recorded prospectively and stored electronically. Baseline 
clinical data included age, sex, BMI, symptom status (NYHA class and CCS angina status), 
history of MI, PCI, pre-operative atrial fibrillation, hypertension, diabetes mellitus, PVD, 
stroke, chronic obstructive pulmonary disease (COPD), baseline renal function (sCr and 
eGFR) and pre-operative left ventricular function, and severity of CAD. 
 
Procedural information recorded included procedural urgency, use of CPB, internal IMA 
grafts, use of IABP, cross clamp time, and perfusion time. Procedural urgency was defined 
as urgent, or elective. Urgent surgery was defined by the requirement for the patient to 
remain in hospital for CABG following coronary angiography. Elective surgery was defined 
as CABG in patients who were discharged from the hospital following coronary angiography 
and readmitted in a planned way for surgery at a later date. 
 
3.2.3 Definition of AKI 
sCr concentration was measured pre-operatively in all patients undergoing cardiac surgery. 
For patients undergoing elective surgery, the sCr concentration was measured in a 
preadmission clinic approximately 4 weeks before surgery. For patients undergoing urgent 
surgery, sCr concentration was measured on admission to hospital. eGFR was calculated 
from the Modification of Diet in Renal Disease equation [158].  
 
sCr was measured daily for the first post-operative week unless patients were discharged 
within this period. AKI was defined according to the RIFLE classification by the change in 
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sCr post-operatively compared with baseline sCr. The RIFLE classification system requires 
sCr levels to increase by at least 50% from baseline to be classified as AKI [110]. Patients 
sustaining AKI were further stratified according to RIFLE class: RIFLE-R corresponds to a 
50% increase in sCr, RIFLE-I to a 100% increase in sCr, and RIFLE-F to a 200% increase in 
sCr.  
 
3.2.4 Outcome Measures 
The primary study end point was mid-term all-cause mortality. Mortality data were obtained 
from the United Kingdom Office of National Statistics which periodically links live/death 
status of treated patients to our unit’s surgical database as part of the national Central 
Cardiac Audit Database. Study patients were followed up until August 2011. The median 
follow-up period 5.6 years (IQR 4.2 to 6.9). In addition, early in-hospital outcomes including 
peri-operative stroke, need for resternotomy, 30-day mortality and length of hospital stay 
were also recorded.  
 
3.2.5 Ethics 
Data were collected routinely as part of a national cardiac surgical audit and patient 
identifiers were removed prior to analysis. The local ethics committee advised us that formal 
ethical approval was not required for this study.  
 
3.2.6 Statistical Analysis and Propensity Score Matching 
All Statistical analyses were performed using SPSS (Version 18.0, IBM SPSS statistics UK). 
Baseline clinical characteristics and procedural data were compared between the groups. 
Categorical data are summarised using absolute values (percentage). Continuous data with a 
normal distribution are presented as mean ± standard deviation or, where skewed, as median 
(IQR). Normally distributed continuous variables are compared using Student’s t-tests and 
the Mann-Whitney U test was used to compare non-normally distributed continuous 
variables. Categorical data were compared using the Pearson chi-square test. 
 
Baseline comorbidity was unbalanced between the AKI and no AKI groups. A non-
parsimonious logistic regression model with AKI as the dependent variable (c-statistic 
0.775) was constructed to adjust for the confounding of baseline comorbidity. Covariates in 
the model included (age, gender, body mass index, previous MI, hypertension, previous 
stroke, peripheral vascular disease, 3-vessel coronary disease, left main stem disease, LV 
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ejection fraction <35%, diabetes mellitus, chronic obstructive airways disease, IABP use, 
IMA use, new stroke, baseline SCr, pre-operative atrial fibrillation, and procedural urgency). 
To balance comorbidity between the study groups, a greedy matching SPSS macro was used 
to match the 562 patients that sustained AKI with 562 patients from the ‘no AKI’ group with 
similar comorbidity. This created a ‘propensity matched no AKI’ population.   
 
Mid-term survival was described using the Kaplan-Meier method, and comparisons made 
using the log-rank statistic. Estimations of risk were calculated using Cox regression 
analysis. Potential independent predictors of outcome were identified by univariate Cox 
regression analyses, and all significant univariate predictors (p!0.15) were then entered into 
multivariate Cox regression model.  
 
 
Figure 5 Flow diagram of patients treated by CABG between January 2003 and 
December 2007 describing patient exclusions and incidence of AKI. RRT 
indicates renal replacement therapy 
 
3.3 Results 
A total of 4694 patients underwent first time CABG surgery and survived to hospital 
discharge during the study period. A total of 562 patients (12.0%) developed an episode of 
4891 patients underwent 
first time isolated CABG 
surgery in study period
197 patients excluded: 
87 patients with incomplete surgical data records 
35 patients undergoing pre-operative RRT 
75 patients that died in hospital
Final study cohort 
4694 patients 
AKI Group 562 
patients
No AKI Group 
4132 patients
 63 
post-operative AKI: of these 342 (7.3%) had RIFLE-R, 145 (3.1%) had RIFLE-I, and 75 
(1.6%) had RIFLE-F. 
 
3.3.1 Patient and operative characteristics (Table 8) 
a) Full unmatched study population 
Patients that developed AKI were older (69.4 vs 66.3 years, p<0.0001), more likely to be 
female (23.7% vs 20.0%, p=0.041) and more likely to have associated comorbidity than 
patients that did not develop AKI.  Notably, patients that developed AKI had more severe 
pre-operative angina symptoms (CCS class 3-4) (41.5% vs 34.9%, p=0.002), and pre-
operative heart failure symptoms (NYHA class 3-4) (30.1% vs 18.8%, p<0.0001). Moreover, 
DM (46.8% vs 28.8%, p<0.0001), hypertension (86.8% vs 77.0%, p<0.0001), PVD (20.1% 
vs 11.8%, p<0.0001), previous MI (53.9% vs 44.3%, p<0.0001), LV dysfunction 
(LVEF<50%) (48.9% vs 36.0%, p<0.0001), pre-operative atrial fibrillation (4.6% vs 2.4%, 
p=0.003), COPD (11.9% vs 7.9%, p=0.001) and previous stroke (9.9% vs 6.5%, p=0.006) 
were significantly more common in the AKI group than the no AKI group. 
 
Patients in the AKI group were also more likely to have undergone urgent CABG (43.8% vs 
31.0%, p<0.0001), have had a pre-operative IABP (2.8% vs 1.0%, p<0.0001) and were less 
likely to have received an IMA graft at time of surgery (89.1% vs 91.9%, p=0.026) than 
patients in the no AKI group. 
 
b) Propensity matched population  
After propensity matching, all baseline patients characteristics were balanced between the 
two groups, except the presence of LMS disease, which was more common in the propensity 
matched no AKI group (30.6% vs 24.7%, p=0.028). Procedural characteristics were also 
balanced between the two groups after matching. 
 
3.3.2 Renal characteristics (Table 8) 
a) Full unmatched study population 
The mean baseline sCr and eGFR for all patients were 99.0 ± 30.1 mmol/L and 75.0 ± 26.4 
ml/min respectively. Patients that developed AKI had significantly higher baseline sCr 
(109.6 vs 97.2 mmol/L, p<0.0001) and lower baseline eGFR (68.9 vs 75.9 mL/min, 
p<0.0001) than patients that did not develop AKI. Peak post-operative sCr was higher in the 
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AKI group (228.1 vs 107.8 mmol/L, p<0.0001). Only 21 (3.7%) of the patients with AKI 
required post-operative dialysis.  
 
b) Propensity matched population  
Baseline SCr and eGFR were not different between AKI and no AKI groups after propensity 
matching. Obviously, peak post-operative SCr remained different between the groups. 
 
3.3.3 Early Postoperative Outcomes in full unmatched population (Table 8) 
a) Full unmatched study population 
Post-operative stroke (1.4% vs 0.3%, p<0.0001), need for re-sternotomy (5.5% vs 1.8%, 
p<0.0001) and 30-day mortality (1.1% vs 0.1%, p<0.0001) were significantly higher in the 
patients that developed AKI. Furthermore, length of hospital stay was longer for patients that 
developed AKI compared to patients that did not (14 vs 7 days, p<0.0001). 
 
b) Propensity matched population  
After propensity matching there was no difference in post-operative stroke, need for 
resternotomy or 30-day mortality. Length of hospital stay remained longer for patients that 
developed AKI compared with patients that did not (14 vs 8 days, p<0.0001). 
 
3.3.4 Long Term All Cause Mortality following CABG  
Patients that sustained AKI had higher mortality rates during follow-up [1 year 8.6% (95% 
CI 3.8 – 15.7) and 5 year 24.2% (95% CI 18.4 - 30.4)] than patients that did not sustain AKI 
[1 year 2.4% (95% CI 1.2 – 4.7) and 5 year 10.6% (95% CI 8.5 – 13.1))(Log rank p<0.0001] 
(Figure 6).  After propensity matching long-term mortality remained higher in the AKI 
group than the propensity matched no AKI group [1 year mortality 5.0% (95% CI 1.3 - 12.6) 
and 5 year mortality 17.3% (95% CI 11.6 - 24.0))(Log rank p=0.0008] (Figure 6).   
 
3.3.5 Predictors of mid-term all-cause mortality following CABG  
The development of AKI (HR 1.72, 95% CI 1.43–2.07), age (HR 1.06, 95% CI 1.05–1.07), 
urgent surgery (HR 1.37, 95% CI 1.16–1.62), baseline sCr (HR 1.54, 95% CI 1.34-1.79) and 
pre-operative co-morbidities (DM (HR 1.33, 95% CI (1.13–1.56)), COPD (HR 1.61, 95% CI 
1.30–1.99), LV ejection fraction < 35% (HR 2.04, 95% CI 1.63–2.54), 3 vessel coronary 
artery disease (HR 1.20, 95% CI 1.00-1.44) and pre-procedural atrial fibrillation (HR 1.47, 
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95% CI 1.06–2.06)) were all associated with a significantly increased risk of mid- term post-
operative all-cause mortality in the unmatched analysis (Table 9). After propensity score 
matching, development of AKI remained an independent predictor associated with increased 
mid-term mortality risk (HR 1.52, 95% CI 1.20–1.94) (Table 9).  
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Table 8 Clinical and procedural characteristics of both the unmatched and 
propensity matched cohorts according to the development of AKI 
 No AKI 
 
n=4132 
AKI 
 
n=562 
P value Propensity 
matched no 
AKI 
n=562 
P value† 
Patient Characteristics      
Age 66.34±9.59 69.36±9.17 <0.0001 69.32±8.92 0.937 
Gender, female 825 (20.0) 133 (23.7) 0.041 149 (26.5) 0.271 
BMI 27.72±5.31 28.50±5.85 0.001 28.62±6.20 0.740 
CCS 3-4 1142 (34.9) 233 (41.5) 0.002 250 (44.5) 0.306 
NYHA 3-4 778 (18.8) 169 (30.1)) <0.0001 150 (26.7) 0.209 
Hypertension 3182 (77.0) 48 (86.8) <0.0001 492 (87.5) 0.721 
Diabetes Mellitus 1188 (28.8) 263 (46.8) <0.0001 281 (50.0) 0.281 
Previous MI 1830 (44.3) 303 (53.9) <0.0001 293 (52.1) 0.550 
MI within 30 days 467 (11.3) 115 (20.5) <0.0001 117 (20.8) 0.677 
Previous PCI 419 (10.1) 45 (8.0) 0.102 61 (10.9) 0.112 
COPD 326 (7.9) 67 (11.9) 0.001 67 (11.9) 1.00 
Pre-operative atrial fibrillation 101 (2.4) 26 (4.6) 0.003 28 (5.0) 0.780 
Previous stroke 267 (6.5) 54 (9.6) 0.006 58 (10.3) 0.690 
Peripheral vascular disease 489 (11.8) 113 (20.1) <0.0001 111 (19.8) 0.881 
LV ejection fraction    <0.0001  0.411 
 35-50% 1225 (29.6) 213 (37.9)  198 (35.2)  
 <35% 264 (6.4) 62 (11.0)  55 (9.8)  
3 vessel coronary disease 2781 (67.3) 415 (73.8) 0.002 417 (74.2) 0.892 
Left main stem disease 1058 (25.6) 139 (24.7) 0.656 172 (30.6) 0.028 
      
Procedural Characteristics    
Procedural urgency 1281 (31.0) 246 (43.8) <0.0001 251 (44.7) 0.764 
CPB 3817 (92.4) 526 (93.6) 0.303 528 (93.6) 0.805 
Perfusion time 81.07±40.29 84.02±39.21 0.246 80.32±37.10 0.233 
Cross clamp time 55.83±22.54 55.77±22.15 0.963 56.55±20.60 0.602 
IMA usage 3798 (91.9) 501 (89.1) 0.026 489 (87.0) 0.269 
Preoperative IABP 40 (1.0) 16 (2.8) <0.0001 15 (2.7) 0.855 
      
Renal Characteristics      
Baseline sCr 98.1±27.4 109.6±51.3 <0.0001 107.0±51.3 0.388 
Baseline eGFR 75.90±26.00 68.60±28.52 <0.0001 68.46±24.69 0.931 
Peak sCr 107.8±36.2 228.1±109.6 <0.0001 122.0±67.2 <0.0001 
Post-op dialysis 0 (0) 21 (3.7) <0.0001 0 (0) <0.0001 
      
Post operative outcomes      
New stroke 12 (0.3) 8 (1.4) <0.0001 4 (0.7) 0.246 
Return to theatre 75 (1.8) 31 (5.5) <0.0001 29 (5.2) 0.791 
      
30-day mortality 6 (0.1) 6 (1.1) <0.0001 1 (0.2) 0.058 
Length of stay 7(6 to 11) 14 (8 to 27) <0.0001 8 (6 to 14) <0.0001 
BMI indicates body mass index; CCS Canadian Cardiovascular Society; NYHA New York Heart 
Association; MI myocardial infarction; PCI percutaneous coronary intervention; COPD chronic 
obstructive pulmonary disease; CPB cardiopulmonary bypass; IMA internal mammary artery; IABP 
intra-aortic balloon pump; sCr serum creatinine; eGFR estimated glomerular filtration rate. 
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Table 9 Independent predictors of long-term mortality in the unmatched and 
the matched study cohorts 
A) Unmatched population: Multivariate analysis 
 Hazard Ratio 95% CI P value 
Age (per year) 
 
1.06 1.05 - 1.07 <0.0001 
Development of AKI 1.72 1.43 - 2.07 <0.0001 
Diabetes Mellitus 1.33 1.13 - 1.56 <0.0001 
COPD 
 
1.61 1.30 - 1.99 <0.0001 
Preoperative atrial fibrillation 1.47 1.06 - 2.06 0.023 
LV ejection fraction <35% 2.04 1.63 - 2.54 <0.0001 
3 vessel coronary disease 1.2 1.00 – 1.44 0.046 
Baseline sCr 
 
1.54 1.34 – 1.79 <0.0001 
Procedural urgency 1.37 1.16 – 1.62 <0.0001 
 
B) Matched population: Multivariate analysis 
 Hazard Ratio 95% CI P value 
Age (per year) 1.05 1.04 – 1.07 <0.0001 
Preoperative atrial fibrillation 1.68 1.08 – 2.63 0.023 
Previous stroke 1.52 1.07 – 2.16 0.02 
Procedural urgency 1.33 1.03 – 1.71 0.028 
LV ejection fraction <35% 1.91 1.37 – 2.66 <0.0001 
Development of AKI 1.52 1.20 – 1.94 0.001 
Baseline sCr 1.40 1.18 – 1.68 <0.0001 
COPD indicates chronic obstructive pulmonary disease; LV left ventricle; sCr serum creatinine.
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Figure 6 Kaplan-Meier curves describing mid-term mortality after CABG in relation to the development of AKI 
A) Unmatched population      B) Matched population 
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3.4 Discussion 
In this large single centre cohort of patients undergoing first time CABG surgery who 
survived to hospital discharge the development of AKI was associated with an increase in 
all-cause mortality during mid-term follow-up. By 5 years after CABG surgery an absolute 
difference in mortality of 13.6% was evident between patients that sustained AKI and those 
that did not. Other than poor LV function, developing AKI was the most powerful 
independent predictor of death in this cohort. 
 
The aim of this study was to investigate the association between peri-operative AKI, patient 
comorbidity and/or surgical complexity upon mid-term mortality following cardiac surgery. 
I was interested in establishing if AKI was an independent predictor of adverse outcome in 
this cohort. Consistent with my findings, numerous studies have reported that the 
development of AKI following cardiac surgery is associated with an increase in long-term 
mortality [113, 170, 171]. Furthermore, it has been clearly shown that patients with the 
highest burden of pre-operative comorbidity and those undergoing the most complex cardiac 
surgeries more commonly develop post-surgical AKI [98, 106, 107]. Importantly pre-
surgical and surgical factors may confer a worse post surgical prognosis independent of the 
development of AKI and thus confound previous analyses.  
 
As expected, in this cohort patients that developed AKI were older, had more comorbid 
disease, worse pre-operative renal function, and were more likely to undergo urgent surgery. 
Potentially any or all of these factors may affect subsequent mortality. However, when the 
effect of comorbidity and surgical complexity were controlled in a multivariable model the 
development of AKI remained a powerful independent predictor of mortality (HR 1.72). To 
further assess the association between AKI and post-operative mortality a propensity-score 
matching algorithm was used to match comorbidity and surgical complexity between 
patients that developed AKI and those that did not. This matching approach achieved two 
well-balanced groups for both comorbidities and surgical factors. After matching for 
comorbidity, the development of AKI still remained associated with a significant increase in 
5-year mortality (24.2% vs 17.3%). Because no matching process can eliminate all 
differences between two groups of subjects, multivariable analysis was used to control for 
remaining differences in baseline comorbidity. After multivariable analyses, AKI remained 
an independent predictor of mid-term mortality risk in the propensity-matched cohort (HR, 
1.52). 
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This is the first study to use a propensity-score matching approach to assess the association 
between post-operative AKI and mid-term mortality. Although propensity score matching is 
usually used to account for treatment selection bias in observational studies, it can also be 
used to compile patient cohorts with and without an exposure who are equivalent in all other 
baseline factors.  Propensity-score matching was performed using AKI as the dependent 
variable without knowledge of mid-term mortality outcomes, just as investigators remain 
blinded during a randomized clinical trial. The propensity-score matching algorithm allowed 
patient and surgical factors associated with the development of AKI to be balanced between 
the AKI and the matched no-AKI control group. The mortality in the propensity score 
matched no AKI control group was higher than that seen in the unmatched population no 
AKI group highlighting the long-term prognostic importance of these AKI related factors 
incorporated into the propensity-score algorithm. Despite the use of these statistical 
techniques, a cause and effect relationship between post-operative AKI and mid-term 
mortality cannot be established with this observational data alone.  
 
When interpreting these results, it is important to note that the 30-day morbidity and 
mortality rates for this surgical cohort appear low. This finding is explained by the choice to 
prospectively exclude patients that died in hospital post-operatively from subsequent 
analysis. A significant proportion of these patients developed AKI. These patients most 
likely represented a group with multi-organ failure rather than a primary renal pathology. 
Inclusion of these patients with multi-organ failure who died early may have confounded any 
subsequent analysis of the effect of AKI upon mid-term mortality.  
 
AKI following cardiac surgery most likely results from a multifactorial renal insult that 
includes ischaemia-reperfusion injury, the systemic inflammatory response to CPB, peri-
operative haemodynamic instability, micro-embolism and/or the peri-operative 
administration of nephrotoxins (such as NSAIDs, ACE inhibitors or iodinated contrast 
media) [172]. Why AKI is associated with long-term mortality is incompletely understood. 
In some patients the surgical procedure may result in irreversible renal injury and the 
development of CKD [96]. Post-operative sCr is a powerful predictor of long term mortality 
following cardiac surgery [173]. The requirement for post-operative dialysis is an extremely 
serious event associated with mortality rates as high as 60% [5]. However, AKI with 
complete resolution of renal function (measured by sCr) is also associated with an increase 
in long-term mortality, although it is suggested that a number of these patients may 
subsequently develop CKD [114]. As previously discussed the development of CKD is 
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strongly associated with the development and progression of cardiovascular disease, and is 
likely to be a driver of adverse cardiac outcomes in these patients. Currently there is little 
specific follow-up of patients that develop post operative AKI.  
 
3.4.1 Study Strengths and Limitations 
The main strength of this study is that it objectively assesses outcomes following CABG in a 
large contemporary cohort of consecutive patients. This means that our results are relevant to 
a broad patient population. Prospectively collected data upon short-term morbidity and 
mortality were collected in addition to the primary end point of all-cause mortality.  
 
There are a number of limitations to this study worthy of note. Firstly, the primary end-point 
is all-cause mortality rather than cardiac death, and it is possible that other disease processes 
could have affected outcome. Second, as with all observational cohort studies, it was open to 
residual bias and unknown confounding factors. The propensity score-matching algorithm 
allowed the generation of comparable study groups, but our c-statistic for the algorithm 
suggests that there may be missing covariates that could affect mid-term mortality after 
CABG. The purpose of multivariable analysis of the propensity-matched cohort was to 
correct for any residual differences in baseline comorbidity. Third, I have no data upon post-
operative urine output. Urine output in addition to sCr form the basis of the RIFLE 
classification system. It is possible that some patients that did not meet RIFLE sCr criteria 
would have been reclassified as having sustained AKI if urine output data was available. 
Fourth, the risk of AKI after cardiac surgery is increased when coronary angiography and 
surgery occur in close succession. I have no data on timing of coronary angiography in 
relation to cardiac surgery. Because all elective patients were discharged from the hospital 
after coronary angiography to wait for admission for cardiac surgery at a later date, it is 
likely that early cardiac surgery after coronary angiography only occurred in patients 
undergoing urgent cardiac surgery. Procedural urgency was incorporated within the 
propensity-matching model and, thus, was evenly balanced between the AKI and propensity-
matched no AKI groups. Finally, patients that sustain AKI following cardiac surgery may be 
less likely to receive beneficial cardiovascular risk modification therapies prior to hospital 
discharge (most notably ACE inhibitors). I have no data upon patient’s medical therapy at 
hospital discharge. If these therapies are not subsequently optimized during outpatient 
follow-up this may affect long-term outcome.  
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3.5 Conclusion 
In this large single centre observational study the development of AKI following CABG 
surgery is independently associated with worse mid-term survival, both in the unmatched 
and propensity-score matched cohorts. The multivariable models and propensity score 
matching approaches suggest that this excess mortality following hospital discharge cannot 
be explained simply by pre-operative comorbidity or surgical complexity. 
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Chapter 4 
 
4. A randomized controlled trial of remote ischaemic 
preconditioning in patients with chronic kidney disease for the 
prevention of myocardial and kidney injury after cardiac 
surgery. 
 
Introduction 
Perioperative complications of cardiac surgery including myocardial infarction (MI) and 
acute kidney injury (AKI) are associated with substantial morbidity and mortality. We 
assessed the impact of remote ischaemic preconditioning (RIPC) upon these complications 
in patients with chronic kidney disease (CKD). 
 
Methods 
86 adult patients with CKD (defined as eGFR < 60mL/min) undergoing coronary surgery 
with or without concomitant aortic valve replacement with cardiopulmonary bypass were 
randomized 1:1 to standard care with (n=43) or without (n=43) RIPC. RIPC consisted of 
three 5 min cycles of forearm ischaemia and reperfusion. The primary end points for this 
trial were two fold; the primary renal end point was development of AKI defined as a 50% 
post operative increase in sCr within 5 days of surgery. The primary cardiac end point was 
myocardial injury defined by 72 h troponin T area under the curve (72 h AUC cTnT). In 
addition, serum (NGAL, IL-18 and cystatin C) and urinary (NGAL, IL-18 and KIM-1) 
biomarkers of renal injury were also measured. 
 
Results 
Clinical and operative characteristics were similar between RIPC and control groups. 16 of 
86 patients developed postoperative AKI. The incidence of AKI was similar in both groups  
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(RIPC 10/43 (23.3%) vs control 6/43 (14.0%); p=0.4065). There was no difference between 
the RIPC and control groups in the primary cardiac endpoint of 72 h AUC cTnT (RIPC 
34686 vs control 31269 ng/L/72h; p=0.3668). Furthermore, there were no differences in any 
of the serum or urinary biomarkers of renal injury measured between the RIPC and control 
groups following surgery.  
 
Conclusions 
RIPC using forearm ischaemia confers no meaningful additional renal or myocardial 
protection in patients with CKD undergoing cardiac surgery. 
 
4.1 Introduction 
In recent years we have seen a change in the profile of preoperative medical comorbidity of 
patients accepted for cardiac surgery [1]. It is now commonplace for patients with conditions 
such as diabetes, peripheral vascular disease or left ventricular dysfunction to be offered 
surgery, when previously they would not have been considered ‘fit’ enough for these major 
operations. Unsurprisingly, these ‘higher-risk’ patients are more susceptible to peri-operative 
complications including MI, congestive cardiac failure, AKI and/or stroke. They are also 
more likely to require high-level post-operative critical care support, and have extended 
post-operative hospital stays.  
 
As I have shown in Chapter 2 patients with advanced CKD represent a group at especially 
elevated risk of adverse events following cardiac surgery. A particular peri-operative 
problem for patients with CKD is the development of AKI. Chapter 3 demonstrates that AKI 
is a harbinger of poor prognosis after cardiac surgery independent of baseline pre-operative 
comorbidity. Currently there are no effective therapies to prevent or treat AKI in patients 
undergoing cardiac surgery. This chapter details a randomized control trial investigating 
whether forearm remote ischaemic preconditioning (RIPC) is effective in reducing the 
incidence of peri-operative AKI and myocardial injury in patients with CKD undergoing 
cardiac surgery. 
 
4.1.1 Ischaemia reperfusion injury  
The most common clinical example of ischaemia reperfusion injury (IRI) is acute MI. 
Interruption of coronary blood flow results in ischaemic myocellular injury. Early 
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reperfusion of ischaemic myocardium can potentially salvage viable myocardium and limit 
infarct size. However, reperfusion can itself paradoxically induce further injury and cell 
death; the so called ‘double edge sword’ of reperfusion [174]. This lethal reperfusion injury 
attenuates the benefit of reperfusion strategies such as PCI or thrombolysis for MI.  
 
Although not yet fully understood the key cellular mechanisms of IRI are thought to include 
intracellular calcium overload and redistribution, overproduction of reactive oxygen species 
(ROS), rapid fluxes in intracellular pH and a local and systemic inflammatory reaction [175]. 
These processes culminate in cell death through the opening of the mitochondrial 
permeability transition pore (mPTP) [175]. Usually the mitochondrial membrane is 
impermeable to ions and metabolites. During IRI a combination of intracellular events result 
in the mPTP becoming permeable to molecules of 1500kDa or smaller. Opening of the 
mPTP collapses the mitochondrial membrane potential and uncouples oxidative 
phosphorylation, resulting in ATP depletion and eventual cell death{Kharbanda, [175, 175-
177].  
 
In cardiac surgery IRI results from aortic cross-clamping. Aortic cross-clamping is a 
fundamental component of modern cardiac surgery that allows a blood-free operative field 
for the surgeon. However clamping and unclamping of the ascending aorta causes episodes 
of IRI that may result in peri-operative myocardial and kidney injury. To mitigate the insult 
of aortic cross clamping, myocardial protection strategies including electrochemical cardiac 
arrest induced by perfusing the heart with cardioplegic solution (either via the aortic root or 
coronary sinus) or hypothermic intermittent cross-clamp fibrillation have evolved. Despite 
these modern myocardial protection techniques ‘high-risk’ cardiac surgical patients still 
sustain significant IRI with subsequent clinical end-organ dysfunction.  
 
Novel strategies to reduce IRI and enhance clinical outcomes in ‘high-risk’ cardiac surgical 
patients are urgently needed. To date clinical research to modulate IRI has been in three 
main areas, 
1. Induction of endogenous protection via local and remote ischaemic conditioning. 
2. Pharmacological induction of endogenous protection. 
3. Pharmacological therapy targeting components of the IRI cascade [178].  
The technique that has shown most promise in modifying IRI to date has been ischaemic 
preconditioning. 
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4.1.2 Ischaemic preconditioning 
The heart possesses endogenous mechanisms capable of protecting against IRI. Ischaemic 
preconditioning is the term given to the finding that brief episodes of non-lethal ischaemia 
and reperfusion applied directly to an organ, can protect the same organ from a subsequent 
episode of sustained lethal IRI. This phenomenon was first described in 1986 using an 
animal model of MI [179]. Four 5 min cycles of myocardial ischaemia and reperfusion 
rendered the myocardium resistant to a subsequent prolonged (40 min) episode of ischaemia 
and reperfusion. The resultant MI in conditioned hearts was reduced to 25% of the size of 
that observed in the non-conditioned control hearts. Many of the ensuing studies into 
ischaemic preconditioning have focused upon the heart, but more recently ischaemic 
preconditioning has been demonstrated in a variety of other organs including the kidney 
[180], liver [181], and brain [182]. However, it remains possible that each organ has a 
‘preconditioning threshold’, such that a preconditioning stimulus sufficient to induce the 
protection from an ischaemic insult in one organ may not prove protective in all organs.  
 
The mechanisms of ischaemic preconditioning are as yet not fully elucidated, although many 
of the signal transduction pathways involved have been deciphered. For example, ischaemic 
precondition activates the cyclic guanosine monophosphate/cGMP-dependent protein kinase 
(cGMP/PKG) pathway [183], reperfusion injury salvage kinase (RISK) pathway [184] and 
the survivor activating factor enhancement (SAFE) pathway [185]. These pathways 
terminate at the mitochondria resulting in the opening of mitochondrial KATP channels and 
the generation of mitochondrial ROS, which may mediate cellular protection by inhibiting 
the opening of the mPTP [186]. 
 
Animal Studies suggest there are two distinct periods of organ protection induced by 
ischaemic preconditioning. The first is early, named acute or classical ischaemic 
preconditioning that is immediate but transient, disappearing approximately 3 h after the 
preconditioning stimulus [175, 179]. The second window of protection is known as delayed 
or late ischaemic preconditioning and appears 12 to 24 h after the conditioning stimulus and 
lasts for up 3 days [187].  
 
Despite promising preclinical work ischaemic preconditioning has not been translated into a 
clinical therapy. Translation has been limited by the need for the conditioning stimulus to be 
applied before a sustained episode of lethal ischemia, and also that the conditioning stimulus 
must be applied directly to an organ. Consequently the settings in which ischaemic 
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preconditioning may be beneficial are limited. In cardiac surgery both of these prerequisites 
can be met. IRI associated with aortic cross-clamping is predictable and direct access to the 
heart is possible. The first human trial of ischaemic preconditioning in cardiac surgery was 
conducted in 1993 [188]. The preconditioning stimulus was two cycles of 3 min of aortic 
cross-clamping with 2 min of reperfusion prior to cardiac arrest induced with intermittent 
cross-clamp fibrillation.  Patients that received preconditioning had higher myocardial ATP 
levels in ventricular biopsies and lower levels of serum troponin T (cTnT) than patients in 
the control group. More than 20 studies of ischaemic preconditioning in cardiac surgery have 
now been completed. A meta-analysis (22 studies collectively involving 933 patients) of 
ischaemic preconditioning published in 2008 concluded that ischaemic preconditioning was 
associated with a reduced frequency of ventricular arrhythmias, reduced post-operative 
inotrope requirement and shorter stay on the intensive care unit [189]. Notwithstanding these 
studies, ischaemic preconditioning has not become commonplace in cardiac surgery. 
Potential reasons for this lack of uptake include,  
1. A reluctance of surgeons to apply an invasive conditioning stimulus that prolongs 
the duration of the surgery.  
2. The finding that volatile anaesthetic agents also confer preconditioning effects. 
3. That the very patients that ischaemic preconditioning may benefit most (the elderly 
or those with significant comorbidity) may be resistant to preconditioning  
4. That aortic cross-clamping predisposes to atheroembolic complications [190].  
 
4.1.3 Remote ischaemic preconditioning 
Remote ischaemic preconditioning (RIPC) circumvents the need to apply a direct 
conditioning stimulus to the heart, which is both inconvenient and potentially harmful. RIPC 
is the term used to describe the finding that the classic ischaemic-preconditioning stimulus of 
brief episodes of non-lethal ischaemia and reperfusion is still effective when applied to a 
remote organ or tissue. RIPC was first demonstrated in a canine model of MI [191].  The 
application of four 5-min cycles of ischaemia and reperfusion to the circumflex coronary 
artery reduced the size of a subsequent myocardial infarction generated by 4.5-h of occlusion 
of the left anterior descending artery by 70% compared with control. Ensuing studies have 
demonstrated that cardiac RIPC can be achieved by applying ischaemia and reperfusion to 
remote organs such as the kidney, liver or intestine [192] but most clinically relevant, it can 
be generated by preconditioning the upper or lower limb [193].  
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The precise mechanism of RIPC is currently unclear although several hypotheses to explain 
this phenomenon exist. For example, it is proposed that local production of an endogenous 
substance generated in the ischaemic organ such as adenosine, bradykinin or calcitonin gene-
related peptide (CGRP) may potentially activate neural pathways that terminate at the heart 
mediating cardioprotection [186]. Supporting this theory, autonomic ganglionic blockade in 
a rat MI model abolished cardioprotection induced by RIPC achieved by mesenteric artery 
occlusion but had no effect on myocardial IPC [192]. An alternative hypothesis is that a 
locally produced humoral factor such as adenosine, bradykinin, opioids, CGRP, 
endocannabinoids, or Angiotensin I in the ischaemic organ enters the blood stream and 
directly activates a cellular receptor in the myocardium [186]. Evidence for the involvement 
of such a factor is supported by the observation that in a rabbit MI model, cardioprotection 
can be transferred by the transfusion of serum from a rabbit that has undergone ischemic 
preconditioning to one which has not [194]. However these cardioprotective signals reach 
the heart, once there, they are thought to activate intracellular signal transduction 
mechanisms similar to those that participate in IPC. 
 
The first demonstration of RIPC in humans was in 2002 [195]. A RIPC protocol consisting 
of 3 cycles of 5 min of forearm ischaemia (generated using a blood pressure cuff inflated to 
200 mmHg on the upper arm) with 5 min of intervening reperfusion was applied to healthy 
volunteers. Subsequently contralateral forearm endothelial IRI was induced (using a blood 
pressure cuff inflated to 200 mmHg on the upper arm for 20 min followed by reperfusion). 
Endothelial IRI was assessed using strain-gauge plethysmography to measure forearm blood 
flow response to the endothelium-dependent vasodilator dilator acetylcholine (ACh). In the 
control group the expected increase in blood flow following ACh was significantly 
attenuated (due to endothelial IRI). Forearm blood flow increased as expected in the RIPC 
group suggesting that RIPC induced with intermittent forearm ischaemia conferred a 
protective effect against endothelial IRI. This less invasive technique has led to a resurgence 
of interest in translating ischaemic preconditioning into a useful clinical therapy. The 
flexibility of using intermittent limb ischaemia as a conditioning stimulus enables RIPC to 
be applied in a wide variety of clinical settings, for example MI, cardiac surgery, cardiac 
arrest, vascular surgery or organ transplantation.   
 
4.1.4 Remote ischaemic preconditioning as cardioprotection during cardiac 
surgery 
Despite modern cardioprotective strategies patients undergoing cardiac surgery may 
experience substantial peri-operative myocardial injury. This is due to IRI induced during 
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the operation by aortic-cross clamping, manual handing of the heart, microembolization of 
atheromatous debris and systemic inflammation due to CPB[196]. Surrogate measures of 
peri-operative myocardial injury, including serum cardiac enzymes (either creatine kinase or 
cTnT) or area of myocardial necrosis measured using late gadolinium enhancement cardiac 
MRI (LGE-CMR), have been associated with worse post-surgical outcomes [196]. 
 
The first study of RIPC induced by transient limb ischaemia in cardiac surgery was a small 
pilot study of only eight patients undergoing CABG[197]. Preconditioning was achieved 
using a tourniquet placed on the upper arm to render the forearm ischaemic. The study was 
negative, with no difference in serum CK-MB 5 min after de-clamping of the aorta. 
Interpretation of this study is difficult as it is severely underpowered with only four patients 
in the control and RIPC arms and the preconditioning stimulus of two cycles of 3 min 
ischaemia with 2 min reperfusion may have been inadequate to trigger endogenous 
myocardial protection. The failure to examine serum cardiac enzymes beyond 5 min post 
aortic de-clamping is also a signification limitation of this study. 
 
The first positive study of RIPC in cardiac surgery was a pilot study conducted in 37 
children undergoing surgery to correct congenital heart defects [198]. The preconditioning 
stimulus was 4 cycles of 5 min leg ischaemia with 5 min reperfusion. Children that received 
RIPC had less perioperative myocardial injury (measured using 24 h AUC troponin I 
(cTnI)), lower inotrope usage and improved lung function when compared with children who 
received the control treatment of a non-inflated blood pressure cuff applied to the thigh pre-
operatively. 
 
In 2007 the first successful trial of RIPC in adult patients undergoing CABG was published 
[199]. In this trial, 57 elective patients undergoing CABG were randomized to receive RIPC 
(induced using 3 cycles of 5-min forearm ischaemia with 5 min reperfusion using a blood 
pressure cuff on the upper arm inflated to 200mmHg) or control (a deflated blood pressure 
cuff placed on the upper arm for 30 minutes) in the anaesthetic room prior to surgery. 
Perioperative myocardial injury (measured using 72 h AUC cTnT) was 43% less patients 
that received RIPC compared with the control group. Following this landmark clinical study 
the interest in RIPC to reduce peri-operative myocardial injury has grown rapidly. There are 
now numerous clinical studies of RIPC in different cardiac surgical settings (Table 10)
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Table 10 Clinical studies of remote ischaemic preconditioning in patients undergoing 
cardiac surgery (adapted from [196]) 
Study RIPC 
protocol  
(min), (site) 
Patients Outcome 
Günaydin et al 
[197]. (2000) 
 
3!3 (leg) 8 adults undergoing CABG 
surgery±valvoplasty 
No change in CK-MB 
5min after aortic 
unclamping 
Cheung et al 
[198]. (2006) 
4x5 (leg) 37 children (aged 1–2 years) 
undergoing corrective cardiac 
surgery for congenital heart disease 
Decreased 24 h AUC 
troponin I, 
Decreased inotrope 
score, Decreased airway 
pressures 
 
Hausenloy et al 
[199] (2007) 
 
3x5 (arm) 57 adults undergoing CABG 
surgery±valvoplasty 
Decreased 72 hour trop 
T AUC (by 43%) 
Venugopal et al 
[200]. (2009) 
 
3x5 (arm) 45 adults undergoing CABG 
surgery±valvoplasty 
Decreased 72 hour trop 
T AUC (by 42%) 
Wenwu et al 
[201]. (2010) 
 
3x5 (arm) 60 children (aged <7 years) 
undergoing corrective cardiac 
surgery for congenital heart disease 
Decreased 2h, 4h, 12h, 
24h CK-MB and 
troponin T 
Thielmann et al 
[202]. (2010) 
 
3x5 (arm) 53 adults undergoing CABG 
surgery 
Decreased 48h AUC 
troponin I (by 35%) 
Rahman et al 
[146]. (2010) 
 
3x5 (arm) 162 adults undergoing elective or 
urgent CABG surgery 
No difference in 48h 
troponin T or LVEF 
Wagner et al 
[203]. (2010) 
 
3x5 (arm) 101 adults undergoing CABG 
surgery±valvoplasty 
Decreased 8h troponin I 
(by 27%) 
Ali et al [204].  
(2010) 
 
3x5 (arm) 100 adults undergoing elective 
CABG surgery 
Decreased 6h, 24h, 48h 
CK-MB and troponin T 
Xie et al [205]. 
(2012) 
 
3x5 (arm) 73 adults undergoing valvular 
surgery 
Decreased 72hr AUC 
troponin T (by 44%) 
Young et al 
[206]. 
(2012) 
3x5 (arm) 96 adults undergoing  “high risk ‘ 
cardiac surgical procedures 
Increased 6hr and 12 hr 
troponin T in RIPC 
group 
 
However, these studies are not uniformly positive. For example the largest study of RIPC in 
cardiac surgery to date (162 patients undergoing either elective or urgent CABG) failed to 
show any effect upon perioperative myocardial injury (measured using 48 h AUC troponin 
release), inotrope requirements, renal or lung injury following CABG[146]. Potential 
explanations for the discrepant study results include: 
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Concomitant medications: Volatile anaesthetic gases such as isoflurane and sevoflurane 
can decrease infarct size in animal models [207]. Furthermore, both propofol and 
intravenous nitrates have been reported to protect the heart against IRI during cardiac 
surgery [208]. Therefore, it is conceivable that specific anaesthetic regimes may either 
augment or ameliorate the effects of RIPC.  
 
Comorbidity: Potential benefits of ischaemic preconditioning may be reduced by a number 
of clinical conditions that coexist in patients with coronary disease [209]. For example, 
diabetes affects potassium ATP channels, thought to be important in the mechanism of 
preconditioning, and so may reduce the protection conferred by preconditioning [210]. 
Studies also suggest that hyperlipidemia, hypertension and age may reduce the effect of 
preconditioning [211]. MI may induce a conditioning stimulus. Thus patients undergoing 
early surgery following MI will gain little additional benefit from another preconditioning 
stimulus immediately before surgery [196]. Ironically this means that patients with the 
highest burden of comorbidity undergoing urgent high-risk surgery are the very group who 
may not respond to this intervention. 
 
Surgical characteristics: whether aortic cross-clamp time or duration of cardiopulmonary 
bypass affects the efficacy of ischaemic preconditioning is unknown. It has also been 
suggested that cardiopulmonary bypass itself may be a preconditioning stimulus [212]. 
 
In order to definitively assess the effect of RIPC upon perioperative myocardial injury and 
clinical outcomes after cardiac surgery two large multicentre clinical trials are currently 
ongoing. 
 
4.1.5 Remote ischaemic preconditioning to protect the kidney during cardiac 
surgery 
IRI is an important component in the mechanism of AKI following cardiac surgery. 
Consequently there is potential for RIPC to reduce its incidence. RIPC has been reported to 
ameliorate renal injury after abdominal aortic aneurysm (AAA) surgery [144], but to date 
there is limited data investigating the reno-protective effect of RIPC in cardiac surgery 
(Table 11). 
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The first report of RIPC as a reno-protective strategy in cardiac surgery was a retrospective 
secondary analysis of renal outcomes drawn from 2 randomized trials of RIPC used for 
myocardial protection [145]. RIPC using three 5 min cycles of ischaemia and reperfusion of 
the forearm was associated with a 14.5% reduction in the incidence of AKI (defined by 
AKIN criteria as a 26.4 "mol/L increase in post-operative sCr). Important criticisms of this 
data are that the intervention and control groups are imbalanced in terms of pre-operative 
comorbidity, and that patients with either diabetes or CKD were excluded from the trial. 
Furthermore, as it is a retrospective secondary analysis drawing any firm conclusions is 
difficult. 
 
Table 11 Clinical studies of remote ischaemic preconditioning as renoprotection 
in patients undergoing cardiac surgery  
Study RIPC 
protocol  
(min) 
Patients Outcome 
Venugopal  et 
al [145]. 
(2010) 
 
3x5 (arm) 78 adults undergoing elective 
CABG 
RIPC decreased the incidence of AKI 
(by 14.5%). 
Rahman et 
al[146].  
(2010) 
3x5 (arm) 162 adults undergoing 
elective or urgent CABG 
surgery 
Day 4 SCr levels and incidence of 
AKI were not different between 
groups. 
 
Choi et al 
[147].  
(2011) 
3x10 (leg) 76 adults undergoing complex 
valvular surgery 
No difference in post-operative 
incidence of AKI or levels of renal 
biomarkers (serum NGAL or cystatin 
C). 
 
Zimmerman et 
al [148]. 
(2011) 
3x5 (leg) 120 adult undergoing cardiac 
surgery with cardiopulmonary 
bypass 
RIPC decreased the incidence of AKI 
(by 27%). 
 
 
Pederson et al 
[213]. (2012) 
4x5 (leg) 115 children undergoing 
corrective cardiac surgery for 
congenital heart disease 
No difference in post-operative 
incidence of AKI or levels of renal 
biomarkers (serum/urine NGAL or 
cystatin C). 
 
Young et al 
[206]. (2012) 
3x5 (arm) 96 adults undergoing  ‘high 
risk ‘ cardiac surgical 
procedures 
No difference in post-operative 
incidence of AKI 
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The first prospective study designed to investigate the effects of RIPC upon renal function 
post cardiac surgery was published in 2011 [147]. This study enrolled patients undergoing 
complex cardiac surgery that predisposed to post-operative AKI. RIPC induced by three 10-
min cycles of leg ischaemia did not affect the incidence of AKI (defined by AKIN criteria) 
or renal biomarker release profiles (serum NGAL and serum cystatin C) post cardiac 
surgery. Although anaesthetic regimes were standardized the nature of cardiac procedures 
were quite different between the RIPC and control groups. Potentially the heterogeneity in 
surgical procedures may have affected the results of this study. Later the same year the first 
positive reno-protective study of RIPC in cardiac surgery was published [148]. This trial 
randomised 120 patients undergoing elective cardiac surgery to receive RIPC (induced using 
3 cycles of 5 min of leg ischaemia with 5 min of reperfusion) or a control group. There was 
an absolute reduction in the incidence of AKI (defined by AKIN criteria) of 27% in the 
patients that received RIPC compared with the control group. The single greatest risk factor 
for developing AKI following cardiac surgery is pre-existing kidney disease. Although 
patients with CKD were not excluded from this study, only 16% of enrolled patients had an 
eGFR < 60 mL/min. Whether patients with CKD respond to renal RIPC remains unknown. 
Animal models suggest that uraemia alone does not reduce the effects of cardiac RIPC [214].  
  
4.1.6 Rationale for current study 
Patients with CKD (defined as eGFR < 60mL/min) make up approximately 30% cardiac 
surgical patients [215]. These patients are at high risk of adverse events post-operatively; 30-
day mortality rates are markedly increased in these patients and CKD is the major risk factor 
for the development of post-operative AKI [3]. RIPC has shown promise as both a 
cardioprotective and reno-protective measure in patients undergoing cardiac surgery. 
Patients with CKD may accrue significant benefit from RIPC given the increased peri-
operative risk they face. Whether RIPC is efficacious in this patient population is unknown. 
We have undertaken a randomized controlled trial to assess the effect of RIPC upon 
perioperative myocardial and renal injury in patients with CKD undergoing cardiac surgery. 
  
4.2 Methods 
4.2.1 Trial overview 
This was a single-center, single-blinded, prospective, randomized, placebo-controlled trial of 
RIPC in patients with CKD undergoing first time CABG with or without concomitant aortic 
valve replacement (AVR) on CPB. The trial was approved by the local research ethics 
committee (MREC No. 10/H0703/92), and was registered with the Barts Health research and 
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development department (R&D No. 007424). Written informed consent was obtained from 
each study subject. 
4.2.2 Study Hypothesis 
The hypothesis was that RIPC would reduce perioperative myocardial injury (assessed using 
72 h AUC serum troponin T level) and the incidence of AKI (defined as a 50% post-
operative increase in sCr within 5 days of cardiac surgery) compared to standard care in 
patients with CKD undergoing cardiac surgery.  
 
4.2.3 Patients and Setting 
We enrolled patients with CKD (eGFR <60 mL/min) undergoing either elective or urgent 
(post acute coronary syndrome) surgery at Barts Health NHS Trust between February 2011 
and April 2012. GFR was estimated using the Modification of Diet in Renal Disease 
equation [7] on two separate occasions pre-operatively; for elective patients this was in a 
pre-admission clinic approximately 1 month before surgery and also on the day before the 
operation. For patients undergoing urgent surgery GFR was estimated at hospital admission 
and again on the day before the operation. All eligible patients meeting trial inclusion 
criteria, with no exclusion criteria (Table 12) were approached for trial enrollment. 
 
Table 12 Study inclusion and exclusion criteria 
Inclusion 
Criteria 
1. Planned to undergo elective or urgent CABG with or without concomitant AVR 
2. CKD defined by an eGFR < 60mL/min on 2 occasions prior to cardiac surgery 
3. Planned use of CPB 
4. Age > 18 and < 85 years 
5. Able to give informed consent 
 
Exclusion 
Criteria 
1. Myocardial infarction within 1 week of surgery 
2. Planned ‘off-pump’ cardiac surgery 
3. Premorbid ESRD or previous renal transplant 
4. Preoperative AKI: defined as an increase in sCr > 50% from either pre-admission or 
admission value to value obtained on the day before surgery  
5. Coronary angiography within 1 week of surgery 
6. Enrolled in a conflicting study 
7. Pregnancy 
8. Unable to give informed consent 
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4.2.4 Sample size 
This was a pilot study: At study conception there was no published data describing the effect 
of RIPC upon the incidence AKI following cardiac surgery. However, published data 
suggested that RIPC may reduce myocardial injury following CABG by 43% (measured by 
72 h AUC cTnT) [199]. Patients with CKD have a high prevalence of co-morbid conditions 
(such as diabetes mellitus and hypertension) and may have a reduced response of RIPC. We 
assumed a less dramatic response to RIPC in our cohort of a 25% reduction in myocardial 
injury. To detect a difference of at least 25% between the two groups, with power of 95% 
and confidence intervals of 95% we needed to recruit at least recruit 41 pairs of patients.   
 
4.2.5 Randomisation 
Patients were stratified by type of surgery (CABG or CABG with AVR) and presence of 
diabetes mellitus and were then randomized within strata using a computer generated 
randomization tool to remote ischaemic preconditioning or control group in a 1:1 ratio in 
randomly sequenced blocks of 4 or 6, which were then concealed using numbered sealed 
envelopes. Patients, anesthetists, surgeons, and critical care teams were all blinded to study 
group allocation, although investigators were not blinded.  
 
4.2.6 Study protocol (Figure 7) 
For patients randomized to receive RIPC a 9cm blood pressure cuff was placed upon the 
upper arm prior to anaesthetic induction. After induction, the cuff was inflated 3 times to a 
pressure of 200mmHg, or a pressure of 50mmHg greater than systolic blood pressure, for 5 
min with an intervening 5 min of reperfusion between cuff inflations. RIPC was conducted 
while patient monitoring, intravascular catheters, and an indwelling bladder catheter were 
being placed in order not to affect the time from anaesthetic induction to CPB. Control 
patients had an identical deflated blood pressure cuff placed on the upper arm (but not 
inflated) for 30 min. All patients otherwise received standard intraoperative and 
perioperative care at the discretion of the cardiac anesthetic teams.  
 
Cardiac surgery was undertaken using standard non-pulsatile CPB with a membrane 
oxygenator and cardiotomy suction. The coronary bypass grafts, either left internal 
mammary artery or saphenous venous grafts were constructed whilst on CPB with each 
anastomosis to the coronary arteries completed with the use of either intermittent cross-
clamp fibrillation or cardioplegia. Once all of the grafts were constructed CPB was 
discontinued.  Post-operative care was at the discretion of the critical care team. 
 86 
 
 
Figure 7 Study protocol 
Patients with CKD 
undergoing cardiac 
surgery
Study inclusion criteria met. No 
exclusion criteria
Consent
Baseline blood samples: CTn, SCr and 
serum samples for biomarker analysis. 
Urine sample: for biomarker analysis.
Randomisation
RIPC: three cycles of 5 
minutes upper arm 
ischaemia and 5 minutes 
reperfusion
Control
Cardiac surgery
6-hours post surgery 
Blood samples: CTn and blood serum 
samples for biomarker analysis. 
Urine sample: for biomarker analysis.
12-hours post surgery 
Blood samples: CTn and blood serum 
samples for biomarker analysis. 
Urine sample: for biomarker analysis.
24-hours post surgery 
Blood samples: CTn, SCr and blood serum 
samples for biomarker analysis. Urine 
sample: for biomarker analysis.
48-hours post surgery 
Blood samples: CTn and SCr.
72-hours post surgery 
Blood samples: CTn and SCr.  
96-hours post surgery 
Blood samples: SCr
120-hours post surgery 
Blood samples: SCr
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4.2.7 Data collection  
Detailed demographic and clinical information was recorded from the hospital clinical 
records at trial enrollment. This information included age, sex, ethnicity, clinical 
presentation (either elective or urgent), BMI, NYHA class, history of previous MI, PCI, 
diabetes mellitus, diabetic treatment status, hypertension, hypercholesterolaemia, PVD, 
stroke, COPD, pre-operative renal status (including sCr, eGFR, and urinary protein 
creatinine ratio), anatomical severity of CAD, pre-operative left ventricular function 
(obtained by either echocardiography, contrast ventriculography or CMR imaging) and 
logistic EuroScore [157].We also recorded the date of any recent MI and cardiac 
catheterization along with a detailed pre-operative drug history.  
 
Procedural information recorded included the method of cardioprotection employed 
(cardioplegia or intermittent cross-clamp fibrillation), cross clamp time, perfusion time, use 
of internal mammary arterial (IMA) grafts, number of coronary bypass grafts constructed 
and types of volatile anesthetic used.   
 
Post operatively urine output was recorded hourly; hemodynamics and inotrope scores 
recorded every 3 h for the first 24 h. The volume of crystalloid, colloid and blood products 
administered over the first 24 h were also recorded. The inotrope score was calculated from 
the dose of the individual inotropes used as follows [198],  
 
Inotrope score = Dosages (in "g/kg/min) of 
1. Dopamine + Dobutamine +  
2. [(Adrenaline + Noradrenaline + Isoproterenol + Isoproterenol) x 100] +  
3. [Enoximone x 15]  
 
Postoperative complications (including MI, arrhythmia requiring treatment and/or congestive 
cardiac failure), length of intensive care stay, hospital stay and 30-day mortality were also 
recorded. Perioperative myocardial infarction was defined by the presence of new left 
bundle-branch block or new Q waves of 2 mm in depth in 2 contiguous leads by 
postoperative day 3. 
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4.2.8 Biochemistry Samples 
Blood samples for measurement of troponin T were taken before surgery and at 6, 12, 24, 48, 
and 72 h after surgery. cTnT concentrations were measured using the commercially available 
Elecsys electrochemiluminescence immunoassay (ECLIA) troponin T high sensitive assay 
kit. The coefficient of variation for intra-assay variation was 4.87% in our laboratory. 
 
Blood samples for sCr were drawn less than 24 h before surgery and then daily for 5 days 
postoperatively unless the patient was discharged within this period. sCr was measured using 
a buffered kinetic Jaffe reaction on an automated clinical chemistry analyser (Roche 
Modular Analytics, Core unit and Control unit). The coefficient of variation for intra-assay 
variation for creatinine concentration was 3.75% in our laboratory.  
 
Blood samples were collected for measurement of serum neutrophil gelatinase–associated 
lipocalin (NGAL), serum cystatin C (CyC), and serum interleukin-18 (IL-18) before surgery 
and at 6, 12 and 24 hours post-operatively. Serum was separated from blood by 
centrifugation at 1300 rpm for 15 minutes and stored at -70 oC until assay. Urine samples 
were collected for measurement of urine NGAL, urine IL-18, urine kidney injury molecule-1 
(KIM-1) and urine creatinine before surgery and at 6, 12 and 24 hours post-operatively.  
Urine samples were also centrifuged and stored at -70 oC until assay. 
 
Serum and urine NGAL levels were detected by using a commercially available enzyme-
linked immunosorbent assay kit (Human Lipocalin-2/NGAL Immunoassay; R&D Systems, 
Europe Ltd., Abingdon, U.K.) according to manufacturer instructions (see appendix 1). The 
coefficient of variation for intra-assay variation for NGAL concentration was 7.2% in our 
laboratory.  
 
Serum and urine IL-18 levels were detected by using a commercially available enzyme-
linked immunosorbent assay kit (Human IL-18 BPa Immunoassay; R&D Systems, Europe 
Ltd., Abingdon, U.K.) according to manufacturer instructions (see appendix 1). The 
coefficient of variation for intra-assay variation for IL-18 concentration was 11.9% in our 
laboratory and corresponds to that reported by manufacturer.  
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Serum CyC level was detected by using a commercially available enzyme-linked 
immunosorbent assay kit (Human Cystatin C Immunoassay; R&D Systems, Europe Ltd., 
Abingdon, U.K.) according to manufacturer instructions (see appendix 1). The coefficient of 
variation for intra-assay variation for Cystatin C concentration was 5.1% in our laboratory.  
 
Urinary KIM-1 level was detected by using a commercially available enzyme-linked 
immunosorbent assay kit (TIM-1/KIM-1/HAVCR Immunoassay; R&D Systems, Europe 
Ltd., Abingdon, U.K.) according to manufacturer instructions (see appendix 1). The 
coefficient of variation for intra-assay variation for KIM-1 concentration was 4.8% in our 
laboratory.  
 
Urinary creatinine was detected by using a commercially available fluorometric assay 
(Creatinine Assay; Abcam, Cambridge, UK) (see appendix 1).  
 
To adjust urinary biomarker concentrations to urinary creatinine concentration we calculated 
a ratio of urinary biomarker/urinary creatinine by dividing urinary biomarker concentration 
(ng/mL) by the urinary creatinine concentration (mg/mL). 
 
4.2.9 End Points 
The primary end points for this trial were two fold; the primary renal end point was AKI 
defined in accordance with RIFLE criteria as any post-operative increase in the sCr of 
greater than 50% from the preoperative value within 5 days of surgery. The primary cardiac 
end point was myocardial injury defined by 72 h AUC cTnT.  
 
Secondary renal end points included, 
• Percentage change in sCr: pre-operative baseline to post-operative peak (# SCr). 
• AKI defined by RIFLE class: post-operative increases in sCr of 50 -100% were 
categorized as RIFLE R, increases in sCr of 100-200% were categorized as RIFLE I 
and increases in sCr > 200% were categorized as RIFLE F. 
• Duration of AKI: patients with AKI were categorized as AKI duration for 1 to 2, 3 
to 4, or > 5 days. For this sCr had to be >50% above the pre-operative value on each 
of the consecutive days. 
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• Renal Biomarker end-points: the effect of RIPC on serum and urine NGAL, serum 
and urine IL-18, serum CyC and urinary KIM-1 levels at 6h, 12 h and 24 h.  
 
Secondary cardiac end points included, 
• 6 hour cTnT. 
• Peak cTnT. 
• Incidence of post-operative MI. 
• Occurrence of post-operative atrial fibrillation. 
 
The effect of RIPC upon the need for dialysis during the index hospitalization, inotrope 
score, duration of mechanical ventilation, length of intensive care unit stay, length of 
hospital stay and 30 day mortality was also assessed   
 
The primary cardiac and renal end points were also assessed in the following pre-specified 
sub-groups, 
1. Non-diabetic patients 
2. Patients undergoing elective surgery 
3. Patients undergoing surgery with cardioplegia 
 
4.2.10 Statistical analysis  
All data were analysed according to the intention-to-treat principle. Normality of distribution 
of continuous data was assessed using the Shapiro-Wilks test. Normally distributed 
continuous data are presented as mean (±SD); whereas skewed continuous data are presented 
as median (interquartile range [IQR]). Normally distributed data were compared with an 
unpaired Student’s t-test and non-normally distributed data were analysed non-
parametrically (Mann-Whitney U test). Categorical data are summarized using absolute 
values (percentage). Categorical data were compared using the Pearson chi-square test or 
Fishers exact test where appropriate. All tests were two-tailed; statistical significance was 
indicated by a p-value <0.05. Univariate analyses and figure preparation was undertaken 
using GraphPad Prism 5 for MacOS (GraphPad Software, San Diego, CA, USA; http:// 
www.graphpad.com).  
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4.3 Results 
One hundred and one patients with CKD underwent CABG with or without AVR within the 
study period. Eighty-six of these patients were recruited to the study (Figure 8).  
 
Participant demographics, clinical characteristics and operative details were similar between 
the randomised groups. The demographic and clinical characteristics are described in Table 
13. The operative characteristics are described in Table 14.  
 
 
 
 
Figure 8. Trial flowchart. Enrolled patients are stratified by scheduled surgery 
and presence of diabetes mellitus then randomized to study groups.
101 Eligible 
patients within 
study period
86 Consented 
for study
Randomisation
43 RIPC 43 Control
11 Refused consent 
1 Underwent off-pump surgery 
1 Not enrolled for logistical reasons 
2 Refused surgery
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Table 13 Baseline demographics and clinical characteristics of the study 
patients stratified by study group 
Variable  RIPC 
(43 patients) 
Control 
(43 patients) 
p value 
Demographics    
Age years±SD  68.7±11.0 72.8±8.4 0.107 
BMI kg/m2±SD  28.2±4.7 27.4±4.7 0.432 
Gender (male:female)  33:10 36:7 0.417 
 
Ethnicity  
    
0.897 
 Caucasian n,% 28 (65.1) 29 (67.4)  
 Afro-Caribbean n,% 3 (7.0) 2 (4.7)  
 South Asian n,% 11 (25.6) 10 (23.3)  
Pre-operative Symptom status    
NYHA class > 3 n,%  18 (41.8) 11 (25.6) 0.110 
     
Clinical characteristics     
Diabetes Mellitus (DM)     0.630 
 Non-insulin treated DM n,% 14 (32.6) 18 (41.9)  
 Insulin treated DM n,% 13 (30.2) 10 (23.3)  
 
Hypertension n,% 
  
34 (79.1) 
 
37 (86.0) 
 
0.394 
Hypercholesterolaemia n,%  37 (86.0) 30 (69.5) 0.069 
Previous MI n,%  25 (58.1) 20 (46.5) 0.280 
Previous stroke or TIA n,%  9 (20.9) 6 (14.0) 0.394 
Peripheral vascular disease n,%  15 (34.9) 14 (32.6) 0.820 
COPD n,%  5 (11.6) 4 (9.3) 0.725 
     
Pre-operative Renal Function    
Median eGFR mL/min (IQR)  51 (42 to 54) 51 (43 to 55) 0.952 
Median sCr "mol/L IQR  121 (111 to 
143) 
121 (113 to 
143) 
0.746 
 
CKD stage 
    
0.923 
 Stage 3a n,% 29 (67.4) 28 (65.1)  
 Stage 3b n,% 11 (25.6) 11 (25.6)  
 Stage 4 n,% 3 (7.0) 4 (9.3)  
Cardiac status    
Mean LVEF % ±SD  52.5±13.4 51.4±12.4 0.684 
 
LVEF category 
    
0.667 
 Good (LVEF > 55%) n,% 21 (48.5) 24 (55.8)  
 Moderate (LVEF 35–55%) 
n,% 
18 (41.9) 14 (32.6)  
 Poor (LVEF < 35%) n,% 4 (9.3) 5 (11.6)  
 
No. diseased coronary arteries 
   
0.331 
 1 n,% 1 (2.3) 2 (4.7)  
 2 n,% 7 (16.3) 12 (27.9)  
 3 n,% 35 (81.4) 29 (67.4)  
Left main stem involvement n,%  7 (16.3) 9 (20.9) 0.579 
     
Pre-operative drug history    
Aspirin n,%  41 (95.3) 42 (97.7) 1.000 
Clopidogrel n,%  13 (30.2) 6 (14.0) 0.118 
$ blockers n,%  31 (72.1) 39 (90.7) 0.116 
Ca2+ channel blockers n,%  16 (37.2) 16 (37.2) 1.000 
Lipid lowering therapy n,%  40 (93.0) 39 (90.7) 1.000 
ACE antagonist n,%  32 (74.4) 36 (83.7) 0.427 
Long acting nitrates n,%  15 (35.0) 19 (44.2) 0.509 
Potassium channel blockers n,%  2 (4.7) 2 (4.7) 1.000 
Antidiabetic drugs  Insulin n,% 14 (32.6) 10 (23.3) 0.471 
 Metformin n,% 12 (28.0) 17 (39.5) 0.362 
 Sulphonylureas n,% 10 (23.3) 8 (18.6) 0.792 
RIPC denotes remote ischaemic preconditioning; BMI body mass index; NYHA New York Heart Classification; 
MI myocardial infarction; TIA transient ischaemic attack; COPD chronic obstructive pulmonary disease; eGFR 
estimated glomerular filtration rate; sCr serum creatinine; CKD chronic kidney disease; LVEF left ventricular 
ejection fraction; ACE angiotensin converting enzyme. 
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Table 14 Operative characteristics of the study patients stratified by study group 
Variable  RIPC 
(43 patients) 
Control 
(43 patients) 
p value 
Surgical procedure    0.645 
 CABG n,% 40 (93.0) 41 (95.3)  
 CABG+AVR 
n,% 
3 (7.0) 2 (4.7)  
Procedural urgency    0.820 
 Elective n,% 29 (67.4) 28 (65.1)  
 Urgent n,% 14 (32.6) 15 (34.9)  
Isoflurane anaesthesia n,%  37 (86.0) 38 (88.4) 0.747 
Intermittent cross clamp fibrillation n,% 6 (14.0) 9 (20.9) 0.394 
Number of grafts    0.762 
 1 n,% 1 (2.3) 2 (4.7)  
 2 n,% 4 (9.3) 6 (14.0)  
 3 n,% 26 (60.5) 26 (60.5)  
 >3 n,% 12 (27.9) 9 (20.9)  
Cross-clamp time min±SD  66 (49 to 90) 58 (45 to 77) 0.092 
Perfusion time min±SD  94 (78 to 119) 94 (74 to 123) 0.613 
Input during operation     
 Crystalloid 
mL±SD 
1993±1129 1826±376 0.875 
 PRBC 
units±SD 
0.302±0.118 0.279±0.096 0.879 
Fluid input (0-24 hours) 
mL±SD 
 2566±946 3160±1583 0.202 
Urine output (0-24 hours) 
mL±SD 
 2600±949 2920±1340 0.274 
PRBC input (0-24 hours) 
mL±SD 
 0.97±0.29 1.32±0.25 0.152 
RIPC denotes remote ischaemic preconditioning; CABG coronary artery bypass graft surgery; AVR 
aortic valve replacement; PRBC packed red blood cells. 
 
4.3.1 Renal Outcomes 
16/86 (18.6%) of patients developed post-operative AKI defined by RIFLE criteria. The 
incidence of AKI was not different between the RIPC and control group (RIPC 10/43 
[23.3%] vs 6/43 [14.0%]; p=0.4065) (Figure 9). There was no significant difference in 
postoperative maximal increase in sCr between patients receiving RIPC and control (RIPC # 
SCr 110.3 [96.8 to 144.1] vs control # SCr 116.0 [108.3 to 127.4]; p=0.3509) (Figure 9).  
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In a post hoc analysis of patients who had AKI, 5 (11.6%) patients in each group had peak 
RIFLE category R; 3 (7.0%) and 1 (2.3%) patients had peak RIFLE category I; and 2 (4.6%) 
and 0 (0%) had peak RIFLE category F in the RIPC and control groups respectively 
(p=0.3577) (Table 15).  
 
There was no difference in the incidence of AKI sustained for greater than 2 days (RIPC 5 
[11.6%] vs control 2 [4.6%]) or 5 days (RIPC 2 [4.6%] vs control 1 [2.3%]) between the 
groups (p=0.7188) (Table 15). Finally, there was no difference in the need for renal 
replacement therapy between the groups; 2 (4.6%) patients in the RIPC group, compared 
with no (0%) patients in the control group (p=0.1524) (Table 15). 
 
 
Figure 9 A) Incidence of AKI defined by a greater than 50% post-operative 
increase in sCr from pre-operative level. There was no statistically significant 
difference in the incidence of AKI between the RIPC and control groups (p=0.4065). 
B) Absolute changes in plasma creatinine concentration after cardiac surgery 
from baseline to peak value at any time within the first five postoperative days. 
Boxes represent 25th to 75th centiles, line median, bars 10th to 90th centiles.  
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Table 15 Post operative renal outcomes of study cohort stratified by study 
group 
Variable RIPC 
(43 patients) 
Control 
(43 patients) 
p value 
Primary renal end-point 
Incidence of AKI n,% 
 
10 (23.3) 
 
6 (14.0) 
 
0.268 
Secondary renal end-points 
# SCr median (IQR) 
 
Stage of AKI: 
RIFLE max R n,% 
RIFLE max I n,% 
RIFLE max F n,% 
 
Duration of AKI: 
1-2 days n,% 
3-4 days n,% 
>5 days n,% 
 
110.3 (96.8 to 
144.1) 
 
5 (11.6) 
3 (7.0) 
2 (4.6) 
 
 
3 (7.0) 
5 (11.6) 
2 (4.6) 
 
116.0 (108.3 to 
127.4) 
 
5 (11.6) 
1 (2.3) 
0 (0) 
 
 
3 (7.0) 
2 (4.6) 
1 (2.3) 
 
0.351 
 
0.358 
 
 
 
 
0.605 
 
 
Incidence of post-operative RRT 
n,% 
 
2 (4.6) 
 
0 (0) 
 
0.154 
RIPC demotes remote ischaemic preconditioning; AKI acute kidney injury; sCr serum 
creatinine; RRT renal replacement therapy; 
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4.3.2 Serum Biomarkers 
There was no difference in baseline, 6 h, 12 h or 24 h serum NGAL concentration (Table 16).  
Similarly, there were no differences in baseline, 6 h, 12 h or 24 h serum cystatin-C 
concentration or baseline, 6 h, 12 h, or 24 h serum IL-18 concentration (Table 16).   
 
Table 16 Serum biomarker concentrations at 6 h, 12 h and 24 h after surgery stratified 
by study group 
RIPC denotes remote ischaemic preconditioning; NGAL neutrophil gelatinase associated lipocalin; 
CABG coronary artery bypass graft surgery; IL-18 interleukin-18. 
 
4.3.3 Urine Biomarkers 
Urinary NGAL/urinary creatinine ratios were not different at baseline, 6 h, 12 h, or 24 h 
(Table 17).  Similarly, no changes in baseline, 6 h, 12 h or 24 h urinary KIM-1/urinary 
creatinine ratio or baseline, 6 h, 12 h or 24 h urinary IL-18/urinary creatinine ratio were 
evident  (Table 17). 
 RIPC 
(n=43) 
Control 
(n=43) 
P value 
 
Serum NGAL concentrations (ng/ml) 
  
Baseline (IQR) 127.5 [74.5 to 179.5] 127.6 [79.5 to 178.0] 0.8830 
6 hours post CABG (IQR) 256.2 [158.0 to 364.8] 207.7 [157.7 to 318.0] 0.5804 
12 hours post CABG (IQR) 237.5 [159.6 to 407.9] 220.7 [174.5 to 314.0 0.5116 
24 hours post CABG (IQR) 297.6 [166.8 to 440.4] 277.7 [191.7 to 351.2] 0.8022 
    
Serum Cystatin-C (ng/ml)   
Baseline (IQR) 1376 [1163 to 1910] 1359 [1187 to 1746] 0.7493 
6 hours post CABG (IQR) 1173 [938.5 to 1531] 1125 [913 to 1523] 0.7493 
12 hours post CABG (IQR) 1330 [874 to 1769] 1326 [1070 to 1654] 0.7297 
24 hours post CABG (IQR) 1486 [1103 to 2268] 1452 [1155 to 1936] 0.8089 
    
Serum IL-18 (ng/ml)   
Baseline (IQR) 18.92 [12.94 to 23.21] 18.75 [13.89 to 23.82] 0.8022 
6 hours post CABG (IQR) 14.26 [11.16 to 17.27] 15.13 [11.5 to 18.12] 0.7955 
12 hours post CABG (IQR) 23.17 [18.65 to 27.32] 24.15 [18.26 to 29.26] 0.3737 
24 hours post CABG (IQR) 30.76 [24.54 to 42.67] 32.2 [26.74 to 42.62] 0.5687 
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Table 17 Urinary biomarker concentrations at 6 h, 12 h and 24 h after surgery stratified 
by study group 
RIPC denotes remote ischaemic preconditioning; NGAL neutrophil gelatinase associated lipocalin; 
CABG coronary artery bypass graft surgery; KIM-1 kidney injury molecule-1; IL-18 interleukin-18. 
 
4.3.4 Cardiac Outcomes 
Of 516 possible cTnT measurements, all were assayed and available for subsequent analysis. 
There was no difference between the groups in terms of the primary cardiac end-point of 72 h 
AUC cTnT release (RIPC, 34686 [23838 to 57768] vs control 31269 [22374 to 41958] 
ng/L/72 h; p=0.3668) (Figure 10). Furthermore, 6 h cTnT (RIPC 851 [532 to 1316] vs control 
758 [560 to 1036] ng/L; p=0.4046) and peak cTnT (RIPC 851 [558 to 1407] vs control 842 
[607 to 1344] ng/L; p=0.7168) were not different between the groups.  Finally, the incidence 
of post-operative myocardial infarction (RIPC 3/43 vs control 2/43; p=1.0) and post-operative 
atrial fibrillation (RIPC 13/43 vs 15/43; p=0.8183) (Table 18) were not different between the 
groups. 
 
 RIPC 
(n=43) 
Control 
(n=43) 
P value 
 
Urinary NGAL/urinary creatinine ratios (ng/mg) 
 
Baseline (IQR) 607.4 [269.5 to 2754] 633.6 [331.7 to 3100] 0.9518 
6 hours post CABG (IQR) 4616 [2917 to 10764] 3550 [1431 to 12333] 0.7297 
12 hours post CABG (IQR) 5673 [3250 to 11795] 5057 [1689 to 9851] 0.3691 
24 hours post CABG (IQR) 2783 [812.5 to 11191] 2760 [867.3 to 8647] 0.8969 
    
Urinary KIM-1/urinary creatinine (pg/mg)  
Baseline (IQR) 988.1 [471.1 to 1530] 908.7 [471 to 1463] 0.9656 
6 hours post CABG (IQR) 586.9 [305.3 to 1119] 744.5 [338.3 to 1284] 0.2615 
12 hours post CABG (IQR) 1389 [767.8 to 2531] 1585 [732.1 to 2956] 0.7889 
24 hours post CABG (IQR) 1470 [931.8 to 2488] 1207 [695.1 to 3032] 0.6409 
    
Urinary IL-18/ urinary creatinine ratio (ng/mg)  
Baseline (IQR) 1280 [522.2 to 2244] 881.7 [330.1 to 2291] 0.4576 
6 hours post CABG (IQR) 403.6 [148.8 to 897.3] 344.9 [96.26 to 969.5] 0.9589 
12 hours post CABG (IQR) 716.9 [197.8 to 3003] 534.1 [126.8 to 1750] 0.2803 
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Figure 10 Cardiac troponin T release over 72 hours. Medians and interquartile 
ranges are presented. No difference in release profiles were identified (p=0.3668). 
 
4.3.5 Other postoperative outcomes  
There was no significant difference between groups in the use inotropes over the first 24 h, or 
the duration of mechanical ventilation. Length of intensive care unit stay and hospital stay 
after surgery were comparable between the groups. Two patient in the control group and 2 
patients in the RIPC group died within 30 days of surgery (Table 18).  
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Table 18 Post operative outcomes of study cohort stratified by study group 
Variable RIPC 
(43 patients) 
Control 
(43 patients) 
p value 
Primary cardiac end-point 
72 hours cTnT AUC ng/L (IQR) 
 
34686 (23838 to 
57768) 
 
31269 (22374 to 
41958) 
 
0.367 
Secondary cardiac end-points 
6-hour cTnT (IQR) 
 
Peak cTnT (IQR) 
 
Incidence of MI n, % 
Incidence of AF n, % 
 
851 (532 to 
1316) 
851 (558 to 
1407) 
3 (7.0) 
13 (30.2) 
 
758 (560 to 
1036) 
842 (607 to 
1344) 
2 (4.6) 
15 (34.9) 
 
0.405 
 
0.717 
 
1.000 
0.818 
 
Other outcomes 
Inotrope use n, % 
 
 
31 (72.1) 
 
 
34 (79.1) 
 
 
0.451 
Inotrope score 0-24 hours (IQR) 64.5 (0 to 201) 63 (3 to 180) 0.882 
Extubation time, min (IQR) 483 (530 to 885) 720 (395 to 930) 0.239 
ICU length of stay, h (IQR) 22.4 (14.4 to 
31.8) 
22.0 (17.3 to 
47.8) 
0.242 
Hospital length of stay days, % 8 (6 to 12) 8 (6 to 12) 0.512 
30-day mortality n, % 2 (4.6) 2 (4.6) 1.000 
RIPC demotes remote ischaemic preconditioning; cTnT AUC cardiac troponin T area 
under the curve; MI myocardial infarction; AF atrial fibrillation; ICU intensive care 
unit. 
 
4.3.6 Sub-group analysis 
When the analysis of primary end-points was repeated in the 31 non-diabetic patients (16 
RIPC and 15 control) who underwent surgery there was no difference in 72 h AUC cTnT 
release (RIPC 30153 [19045 to 52501] vs control 33999 [23397 to 38355] ng/L/72 h; 
p=0.4526), or the incidence of AKI (RIPC 2/16 [12.5%] vs control 2/15 [13.3]; p=1.000) 
between the groups. Similarly, in elective surgical patients (29 RIPC and 28 controls) 72 h 
AUC cTnT release (RIPC 36699 [27072 to 58412] vs control 30981 [22630 to 41447] 
ng/L/72h; p=0.1698) and incidence of AKI (RIPC 3/29 [10.3%] vs 5/28 [17.9%]; p=0.4703) 
was not different between the groups. Finally, in patients undergoing surgery with 
cardioplegia (37 RIPC vs 34 controls) RIPC had no effect upon 72 h AUC cTnT release 
(RIPC 34677 [23391 to 58412] vs control 30645 [21293 to 40426] ng/L/72h; p=0.2844) or 
the incidence of AKI (RIPC 9/37 [24.3%] vs 5/34 [14.7%]; p=0.3789) when compared to 
controls. 
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Importantly, it must be stated that analyzing sub-groups in such a small study is fraught with 
difficulties. Even though these sub-groups were pre-specified they are small and 
underpowered to provide any definitive statistical results.   
 
4.4 Discussion 
The present randomized controlled study investigates whether RIPC induced by intermittent 
forearm ischaemia in the anaesthetic room immediately before cardiac surgery attenuates 
subsequent myocardial or renal injury sustained during CPB in patients with established 
CKD. There was no evidence to suggest that RIPC reduces the incidence of AKI, assessed by 
either RIFLE criteria or changes in biomarker of renal injury. Furthermore RIPC had no 
effect upon myocardial enzyme release or other important clinical end-points including length 
of ITU or hospital admission and 30-day mortality. 
 
AKI is a significant problem following cardiac surgery. Consistent factors implicated in the 
development of AKI following cardiac surgery include advanced age, diabetes mellitus, 
congestive heart failure, need for emergency surgery, surgical complexity and most 
importantly pre-operative CKD [54, 98, 100, 107]. Once AKI has occurred, it is associated 
with an increase in subsequent mortality [6, 99, 100, 106, 113, 171]. Mortality is highest in 
patients with AKI that requiring post-operative dialysis, and may exceed 60% [100], 
however, smaller transient post-operative increases in sCr without obvious immediate clinical 
sequelae are also associated with an increase in both early and late mortality [6, 113]. As 
shown in chapter 3 the relationship between AKI and excess mortality persist even after 
adjusting for patient comorbidity and surgical complexity [6, 113]. 
 
Despite advances in our understanding of the aetiology and the pathophysiological processes 
central to the development of AKI following cardiac surgery, neither the incidence nor the 
mortality associated with this condition have changed [108]. Currently no established 
prophylaxes or therapies for AKI exist [133] and novel methods to prevent and manage this 
complication are now urgently needed to improve outcomes. RIPC describes a phenomenon 
by which the application of brief non-lethal ischaemia and reperfusion injury to an organ 
protects a distant organ from a subsequent episode of prolonged ischaemia and reperfusion. 
RIPC induced using transient limb ischaemia has been reported to reduce perioperative 
myocardial enzyme release in both adults and children undergoing cardiac surgery [198, 199]. 
RIPC has also been reported to afford renal protection in patients undergoing vascular surgery 
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[144], coronary angiography [216], and cardiac surgery [148]. Due to their particularly high 
incidence of post-cardiac surgical AKI, patients with CKD may accrue significant benefit 
from RIPC. Whether RIPC is efficacious in patients with CKD is unknown as it not 
previously been studied selectively in such a cohort. For a variety of reasons patients with 
CKD may be ‘resistant’ to the organ protection generated using RIPC. Our research group 
found that uraemia does not attenuate the affect of RIPC in a rodent model of myocardial 
infarction [214]. This finding stimulated our hypothesis that RIPC may offer important renal 
protection and myocardial protection in patients with CKD undergoing cardiac surgery. 
 
Most previous studies of RIPC have been undertaken in low-risk patients undergoing isolated 
CABG surgery. These patients are least likely to accrue any meaningful benefit from RIPC. 
For RIPC to be translated into a useful clinical adjunct in cardiac surgery it must be proven 
within a ‘high-risk’ surgical cohort such as patients with CKD.  
 
RIPC had no effect upon the incidence of AKI defined by the RIFLE criteria. AKI defined 
using these criteria has been associated with both short and long term complications after 
cardiac surgery [6]. These criteria are largely based upon peri-operative changes in sCr. sCr 
has several limitations as a marker of AKI; firstly sCr can be affected by age, gender, diet, 
muscle mass, and some drugs. Secondly, important changes in glomerular filtration may be 
masked as up to 40% of creatinine clearance is due to the renal secretion of creatinine. 
Finally, sCr levels only become abnormal when greater than 50% of glomerular filtering 
capacity is lost, and it may require up to 24 h following AKI for increases in sCr to become 
evident. For this reason we also assessed AKI using novel biomarkers of renal injury; namely 
serum and urine NGAL, serum and urine IL-18, serum Cy-C and urinary KIM. These 
biomarkers have been reported to be sensitive, specific surrogates of renal injury and 
potentially may be useful to detect small difference in renal outcome in interventional studies 
[217]. We found no effect of RIPC upon the post-operative levels of these biomarkers of renal 
injury during the first 24 h after cardiac surgery.  
 
Perioperative myocardial injury during cardiac surgery was assessed by serial cTnT 
measurements over the first 72 h following surgery. This is a standard end-point in cardiac 
RIPC studies. Early post-operative cTn elevation is associated with an increased early and 
late mortality following cardiac surgery[218]. Conceptually, improved myocardial protection 
reduces cTn release, and may translate into improved post surgical clinical outcomes. We 
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found no effect of RIPC upon cardiac troponin release following cardiac surgery in patients 
with CKD. 
 
A potential criticism of the study methodology is that cTn release and excretion is altered in 
end stage renal disease (ESRF). CTn elevation in the absence of myocardial injury is common 
in patients with ESRD and identifies patients at risk of premature cardiac death [219].  
However, cTn is not cleared by the kidney, and lesser degrees of renal dysfunction are not 
associated with cTn elevation in the absence of cardiac disease [220]. ESRD represented a 
study exclusion, and the majority (>90%) of patients in the study cohort had lesser degrees of 
renal dysfunction (eGFR 30-60 mL/min). Thus it seems cTn is a legitimate surrogate marker 
of myocardial injury in the study cohort. It should be noted that 2 patients in the RIPC group 
required renal replacement therapy. It is possible that cTnT AUC in these patients was altered 
as certain haemodialysis filters can affect the clearance of cTnT. Alternative surrogates of 
perioperative myocardial injury that may have been used include serum CK-MB but this is 
subject to many of the same issues as cTn in patients with CKD[221], and/or LGE-CMR. 
Delayed LGE washout of infarcted myocardium allows CMR to detect area of confluent 
infarcted myocardium as small as 1 gram [222]. We had initially planned to use LGE-CMR as 
a secondary cardiac end-point but the use of LGE-CMR was prevented by concerns of 
administering gadolinium to patients with an eGFR < 30 mls/min or recent AKI.  
 
Following cardiac surgery myocardial IRI may be manifest as cardiac stunning; a transient 
period of reversible myocardial contractile dysfunction. Clinically cardiac stunning is treated 
by optimizing haemodymanics with temporary inotropic support. There was no difference in 
inotrope requirements over the first 24 hours post-operatively suggesting that RIPC did not 
effect cardiac stunning in this cohort.  Finally RIPC did not effect time on intensive care, 
hospital length of stay or 30-day mortality, although obviously the study was underpowered 
to detect any differences in these clinical parameters. 
 
There are a number of potential explanations for the lack of organ protection afforded by 
RIPC in this study. Firstly, comorbidity including hypertension, hyperlipidaemia, and heart 
failure may render organs resistant to RIPC [209, 211]. As these comorbidities are frequently 
present in patients with CKD this cohort may be particularly resistant to RIPC. Furthermore, 
diabetes (also especially prevalent in our study cohort) and antidiabetic medication may 
interfere with the signal transduction pathways believed to mediate RIPC thus reducing 
efficacy of RIPC [210]. Secondly, by recruiting patients undergoing cardiac surgery post MI, 
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we may have reduced any measurable effect of RIPC. Although MI within 1 week of surgery 
represented a study exclusion, it is conceivable that a recent MI may have conferred some 
degree of subsequent organ protection by a mechanism similar to RIPC, making any 
beneficial organ protection afforded by RIPC more difficult to detect. Finally, anaesthetic and 
surgical technique may affect RIPC organ protection. Volatile anaesthetics, propofol and 
intravenous nitrates can independently mediate organ protection [207, 208]. Most negative 
RIPC studies have allowed the use of volatile anaesthetics, and this is often quoted as a 
potential reason for the failure to demonstrate a beneficial effect of RIPC [141]. Also, 
intermittent cross-clamp fibrillation may offer direct preconditioning of the myocardium. A 
single surgeon working at Barts Health NHS Trust still uses this technique. Potentially the use 
of intermittent cross-clamp fibrillation could reduce any additional organ protection conferred 
by RIPC thus confounding our results. We chose not to standardise anaesthetic or surgical 
regimens in order to maintain the clinical relevance of this study. For RIPC to be adopted into 
modern cardiac surgical practice it must offer benefit above and beyond currently used renal 
and cardiac protective therapies.  
 
4.4.1 Limitations  
This was a single blinded study. Patients, anesthetists, surgeons and critical care staff were 
blinded to study group allocation. However for logistical reasons researchers were not 
blinded. As RIPC represents a binary intervention and our cardiac and renal outcomes are 
clearly objective, it is unlikely that researchers could introduce any significant bias into the 
study. 
 
The RIPC stimulus used in this study was 3 cycles of 5 min forearm ischaemia induced in the 
anaesthetic room immediately before surgery. This is a standard preconditioning protocol 
used in many previous studies of RIPC. It is possible that patients with CKD have a higher 
‘conditioning threshold’ and thus the stimulus used here was submaximal. The only 
prospective cardiac surgical study to demonstrate renal protection with RIPC used leg 
ischaemia as the preconditioning stimulus [144, 148]. Using leg ischaemia or, more or longer 
cycles of forearm ischaemia and reperfusion may have been more appropriate in a potentially 
‘RIPC resistant’ cohort. 
 
This was a pragmatic study. No ‘meaningful’ clinical effect of RIPC upon the renal or 
myocardial end-points studied was evident. However, this is different to concluding that 
RIPC has no effect in this setting. The a priori assumption was that RIPC would reduce 
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myocardial enzyme release by 25%. Failure to achieve this degree of cardioprotection means 
that our study is underpowered to provide definitive statistical results. Furthermore, the lack 
of standardized anaesthetic and surgical protocols may have prevented any effect of RIPC 
from becoming evident. But as stressed through out, for anaesthetists and surgeons to adopt 
RIPC into daily practice it must be a useful adjunct to current standard therapies, rather than 
an awkward and time consuming alternative.  
 
4.5 Conclusions 
RIPC conferred no evident additional myocardial or renal protection beyond current standard 
anaesthetic and surgical management of patients with CKD undergoing cardiac surgery. 
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Chapter 5 
 
5. Comparative analysis of biomarkers for the early detection of 
cardiac surgery associated – acute kidney injury in patients 
with CKD 
 
Introduction 
Acute kidney injury (AKI) is a common and serious complication of cardiac surgery. We 
have investigated the accuracy of 3 serum (NGAL, IL-18 and CyC) and 3 urinary 
(NGAL, IL-18 and KIM-1) biomarkers for predicting AKI in patients with CKD 
undergoing cardiac surgery. 
 
Methods 
AKI biomarkers were measured at 6, 12 and 24 hours after cardiac surgery in 86 patients 
with CKD undergoing cardiac surgery. AKI was defined as a %50% increase in serum 
creatinine from preoperative levels. AUC-ROC curves were constructed to assess 
sensitivities and specificities for each biomarker.  
 
Results 
Sixteen patients (18.6%) patients developed AKI. The best predictor of AKI at all time 
points was percentage change in serum CyC level displaying the highest AUC-ROC at 24 
hours after CABG (AUC-ROC 0.94 [0.89-0.99]). Percentage change in serum NGAL was 
also a fair predictor of AKI at all time points with best performance at 24 hours (AUC-
ROC 0.83 [0.74-0.93]). Serum IL-18, and all of the urinary biomarkers studied were poor 
predictors of AKI.  
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Conclusions 
Change in serum CyC and serum NGAL over the first 24 hours after cardiac surgery were 
useful predictors of CSA-AKI in adults with CKD after cardiac surgery. Urinary 
biomarkers of CSA-AKI were less useful as early predictors of CSA-AKI in this cohort.  
 
5.1 Introduction 
As I have detailed throughout this thesis, despite a myriad of research in the area no 
prophylactic intervention has been definitively shown to reduce the incidence of AKI 
following cardiac surgery. Despite the theoretical promise of RIPC, this intervention also 
failed to modify AKI in our surgical cohort.  
 
Rather than relying solely upon prophylaxis, therapeutic modification of confirmed AKI 
may be possible. Preclinical studies have demonstrated that pharmacological treatment of 
AKI is effective, but only if therapies are initiated early after the renal insult [223-226]. 
The current clinical diagnosis of AKI is based upon changes in sCr. SCr is an indicator of 
renal function, and not a marker of renal injury. Concentrations of sCr do not change until 
approximately 50% of renal function is lost, and an increase in sCr diagnostic of AKI 
may lag by as much as 3 days behind the initial renal insult. Attempts to modify AKI at 
this late stage are unlikely to be effective as renal tubular injury is already established. 
This lag time between the renal injury and the resultant loss of function finally reflected 
as an elevation of sCr is a missed therapeutic opportunity. An alternative to sCr that 
allows the early diagnosis of AKI is now urgently needed if novel therapies to treat AKI 
are to be developed.  
 
The American Society of Nephrology has designated identification and development of 
new AKI biomarkers as a key research objective [227]. The ideal AKI biomarker would 
allow early identification of renal injury, stratify the severity of renal injury, 
characterization of the location and/or aetiology of injury, provide prognostic information 
and allow the monitoring of response to therapy. However, due to heterogeneity of AKI it 
unlikely that any single AKI biomarker can achieve all of these properties. Thus it seems 
likely that more than one AKI biomarker will be needed and combination of AKI 
biomarkers in a ‘kidney injury’ panel will be necessary. 
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With the application of functional genomics and proteomics to human and animal AKI 
models several potential AKI biomarkers have been identified. The most promising of 
these include neutrophil gelatinase-associated lipocalin (NGAL), cystatin C (CyC), 
kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18). These biomarkers have 
the potential to revolutionise care for patients with AKI. Below I will review the evidence 
supporting the use of these AKI biomarkers for the prediction of AKI in cardiac surgery. 
 
5.1.1 Neutrophil gelatinase-associated lipocalin:  
In health NGAL is barely detectable in serum or urine. It mediates iron transport to the 
proximal tubular cells, where it exerts a protective bacteriostatic effect, binding to and 
inactivating iron gathering molecules (siderophores) synthesised by bacteria, and an 
antioxidant effect, gathering free iron to prevent production of ROS that may result in 
oxidative stress and renal tubular injury [228]. In response to acute tubular injury NGAL 
is excreted in huge quantities, becoming readily detectable in both serum and urine more 
than 24 hours prior to any rise in sCr [228]. It is this characteristic that enables NGAL to 
serve as a potential biomarker of AKI. 
 
The first clinical study evaluating NGAL as an AKI predictor was in children at risk of 
AKI after cardiac surgery. At between 2 and 6 h post CPB both urine and plasma NGAL 
were excellent predictors of the subsequent development of CSA-AKI, demonstrating 
area under the receiver-operating characteristic curve (AUC- ROC) of >0.9 [229]. NGAL 
has proven a less impressive predictor AKI in adult cardiac surgical cohorts [230]. 
Although NGAL is demonstrated in significant quantities in both urine and plasma within 
3 h of surgery in patients subsequently diagnosed with AKI, the AUC-ROC for AKI 
prediction has varied widely from 0.61 to 0.96 in published studies [203, 217, 231-233]. 
The limited ability of NGAL to predict AKI in adult cardiac surgery may in part be due to 
the increased burden of comorbidity seen in these patients.  For example diabetes [234] 
and CKD [235] may affect the diagnostic performance of NGAL. Moreover, the non-
uniform definitions of AKI, different NGAL sampling times and detection techniques 
used in some of these studies are also likely to have affected the performance of NGAL 
as a predictor of AKI [236]. Despite this a recent meta-analysis of published adult cardiac 
surgical studies (10 studies 1204 patients) reported an overall AUC-ROC of 0.76 (95% 
CI 0.70 to 0.82) for prediction of AKI (defined as a >50% increase in sCr) when either 
urinary or plasma NGAL was measured within 6 h of initiation of CPB [231]. This 
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performance compares favorably with that of cTn for the prediction of MI during its 
clinical implementation period [231]. 
 
5.1.2 Cystatin C:  
CyC is a low molecular weight cysteine protease inhibitor that is produced by all 
nucleated cells. In health CyC is freely filtered at the glomerulus. It is neither secreted nor 
reabsorbed by renal tubules but is taken up by proximal tubule cells where it is 
completely catabolized. Consequently the CyC concentration in urine and serum is 
negligible. As CyC levels are not significantly affected by age, gender, race, or muscle 
mass, and it is not secreted by the renal tubules, CyC is probably a better measure of 
glomerular function than sCr [237]. After renal tubular injury GFR falls leading to an 
increase in serum CyC levels. Also urinary CyC concentration increases due to decreased 
reabsorption of CyC in the proximal tubule [237]. 
 
Serum CyC appears to be an extremely promising AKI biomarker. It reaches peak serum 
concentration approximately 10 h later than NGAL at around 12-24 h post CPB [227]. A 
recent meta-analysis (9 cardiothoracic surgical studies comprising 1330 adult and 
paediatric patients) reported that CyC was a good predictor of AKI with an AUC-ROC 0f 
0.78 – 0.96 if measured within 12 h of CPB [238].  
 
5.1.3 Interleukin 18:  
IL-18 is a proinflammatory cytokine and powerful modulator of ischaemic AKI.  In 
response to renal injury IL-18 is induced and cleaved in the proximal tubule becoming 
detectable in urine [237]. In human studies IL-18 appears a specific marker of AKI not 
detectable in the urine of patients with CKD, or urinary tract infections [237]. 
 
To date urinary IL-18 has proved at best a moderate predictor of CSA-AKI. In 3 studies 
enrolling 258 adults, the AUC-ROC for urinary IL-18 at admission to intensive care for 
the prediction of CSA-AKI ranged from 0.53 to 0.66 [239-241]. Importantly IL-18 levels 
peak approximately 6 - 12 h post CPB, and so early sampling time may potentially 
explain the disappointing results of these studies.  When combined with other AKI 
biomarkers IL-18 has yielded more promising results [240].  
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5.1.4 Kidney injury molecule-1:  
KIM-1 is a transmembrane glycoprotein, not usually expressed in healthy kidneys or 
urine. KIM-1 is important modulator of the immune response and repair processes of the 
injured kidney. Following ischaemic or toxic renal injury, KIM-1 expression is up 
regulated, transforming surviving proximal renal epithelial cells into phagocytes that may 
assist with the clearance of apoptotic and necrotic cells resulting from AKI [237]. After 
renal injury the ectodomain segment of KIM-1 becomes detectable in urine (with levels 
peaking 12 to 24 h after the renal insult), thus stimulating interest in urinary KIM-1 as a 
potential biomarker of proximal renal tubular injury [227].   
 
Although in non-cardiac surgical cohorts several groups have found that KIM-1 is a 
sensitive indicator of AKI, KIM-1 has been less intensively investigated than NGAL or 
CyC in cardiac surgery. A meta-analysis (8 studies between 2002 to 2009) evaluating the 
performance of urinary KIM-1 in cardiac surgery found that within 24 hours of CPB the 
sensitivity of KIM-1 for detecting CSA-AKI ranged from 92% to 100% and the AUC-
ROC from 0.78 to 0.91 [242].  
 
In summary, there are currently a number of promising candidate AKI biomarkers to 
facilitate the early diagnosis of AKI after cardiac surgery. To date the diagnostic 
performance of these biomarkers in a population of cardiac surgical patients with CKD is 
untested. As these patients represent those at the greatest risk of developing AKI, and 
they are accounting form an increasing proportion of patients undergoing cardiac surgery 
each year, the development of biomarkers that can reliably differentiate those patients 
that will develop AKI at an early post-operative time point would constitute a significant 
advance. Potentially novel treatments for AKI could then be instituted within a time 
frame when AKI can be modified.  
 
This chapter describes the secondary analysis of the randomized control trial to assessing 
RIPC in patients with CKD undergoing CABG. The aim of this analysis was to evaluate 
the diagnostic performance of a number of serum and urine AKI biomarkers within 
cohort of cardiac surgical patients with established CKD.  
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5.2 Methods 
This is a secondary analysis of the trial described in chapter 4. In brief, this was a 
randomised, controlled, single centre study of the effect of RIPC upon myocardial and 
renal injury in 86 patients with non-dialysis dependent CKD undergoing CABG with or 
without AVR. No effect of RIPC upon either AKI or myocardial injury was evident. 
 
5.2.1 Study Protocol 
Study enrollment is described in chapter 4. 86 patients with CKD (eGFR < 60 mL/min) 
were enrolled. Detailed demographic, clinical and surgical data were recorded for all 
patients as previously described.  
 
Blood samples for sCr were drawn pre-operatively and then daily for 5 days post-
operatively unless patients were discharged within this period. Blood and urine samples 
for biomarkers of renal injury were obtained pre-operatively and then post–operatively at 
6, 12 and 24 h after separation from CPB. Both blood and urine samples for biomarkers 
were centrifuged at 1300 rpm for 15 minutes. Serum and urinary supernatant were 
removed and stored at -80oC until biomarker assay. 
 
AKI was defined in accordance with RIFLE criteria as any post-operative increase in sCr 
> 50% from the preoperative value within 5 days of cardiac surgery [110].  
 
5.2.2 Biomarker analysis 
Serum NGAL, IL-18 and cystatin C, and urinary NGAL, IL-18 and KIM-1 were 
assessed. All biomarkers were measured using commercially available enzyme-linked 
immunoabsorbant assay (ELISA) kits in accordance with the manufacturers instructions. 
 
NGAL (ELISA): A commercially available ELISA kit (Human Lipocalin-2/NGAL 
Immunoassay; R&D Systems, Europe) was used to measure NGAL concentration in 
serum and urine samples. The protocol for measurement of NGAL concentration is 
detailed in appendix 1. 2.  
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IL-18 (ELISA): IL-18 concentration in serum and urine were measured using a 
commercially available ELISA kit (Human IL-18 BPa Immunoassay; R&D Systems, 
Europe). The detailed protocol for measurement of IL-18 concentration is available in 
appendix 1.3.  
 
CyC ELISA: CyC concentration in serum was measured using a commercial ELISA kit 
(Human Cystatin C Immunoassay; R&D Systems, Europe). The protocol for cystatin C 
measurement is detailed in appendix 1.4.  
 
KIM-1 ELISA: A commercially available ELISA kit (TIM-1/KIM-1/HAVCR 
Immunoassay; R&D Systems, Europe) was used to measure KIM-1 concentration in 
urine samples. The protocol for measurement of KIM-1 concentration is detailed in 
appendix 1.5.  
 
All measurements were performed in duplicate. All urinary biomarker results were 
normalized to urinary creatinine values, by dividing urinary biomarker concentration 
(ng/mL) by the urinary creatinine concentration (mg/mL) and expressed as ng/mg of 
creatinine. 
 
Urinary creatinine assay: Urinary creatinine was detected by using a commercially 
available fluorometric assay (Creatinine Assay; Abcam).  The protocol for urinary 
creatinine measurement is detailed in appendix 1. 5.  
 
5.2.3 Statistical Analysis 
Patients were divided into those that sustained AKI (AKI group) and those that did not 
(no AKI group) for further analysis (Figure 11). Normality of distribution of continuous 
data was assessed using the Shapiro-Wilks test. Normally distributed continuous data are 
presented as mean (±SD); whereas skewed continuous data are presented as median 
(interquartile range [IQR]). Normally distributed data were compared with a Students t-
test and non-normally distributed data were analysed non-parametrically (Mann-Whitney 
U test). Categorical data are summarized using absolute values (percentage). Categorical 
data were compared using the Pearson chi-square test or Fishers exact test where 
appropriate.  
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Individual biomarker performance characteristics for the detection of AKI were evaluated 
with receiver operator characteristic (ROC) curve analysis. There was substantial 
variability between individual patients in absolute biomarker concentrations at baseline 
and subsequent time points. Therefore, we chose to assess the performance of biomarkers 
using percentage change in concentration rather than absolute value. Optimal cut-off 
points for predicting AKI for each biomarker were determined using the Youden index, 
which is calculated by adding sensitivity and specificity and subtracting 1 [243]. This 
identifies the point on the ROC curve that has the maximum vertical distance to the 
chance line. Biomarkers were dichotomized using these cut-offs to allow sensitivity, 
specificity, negative predictive value and positive predictive value for each biomarker to 
be calculated. In addition, serum and urine biomarkers with the best area-under-the-ROC 
curve (AUC-ROC) at 6 and 12 h were combined in order to assess the value of 
combination biomarker panels for the prediction of AKI.  
 
Differences were considered statistically significant at a p < 0.05. Statistical analyses and 
figure preparation were undertaken using SPSS (Version 18.0, IBM SPSS statistics UK) 
and GraphPad Prism 5 for MacOS (GraphPad Software, San Diego, CA, USA).  
 
 
Figure 11 Study flow chart. Patients were divided into those that sustained acute 
kidney injury (AKI group; n=16) and those that did not sustain acute kidney 
injury (no AKI; n=70) for analysis. 
86 patients 
enrolled in 
RIPC study
 AKI group
n=16
No AKI
n=70
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5.3 Results  
5.3.1 Characteristics of the study cohort 
The clinical characteristics of the study cohort stratified by development of AKI are 
displayed in Table19. The surgical characteristics of the study cohort are displayed in 
Table 20.  
 
The incidence of AKI in the study cohort was 18.6% (16/86). There was no significant 
difference in any clinical or surgical characteristic between those that developed AKI and 
those that did not. Post-operatively there was a trend towards increased length of ITU 
(32.2 vs 21.3 h; p=0.058) and total hospital stay (13.0 vs 7.5 day; p=0.053) in patients 
that developed AKI. Also, post-operative dialysis (2/16 vs 0/70; p=0.033) and 30-day 
mortality (2/16 vs 0/70; p=0.033) were significantly higher in those patients that 
developed AKI. 
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Table 19 Baseline demographics and clinical characteristics of the study cohort 
stratified by the presence or absence of AKI 
Variable  AKI 
(16 patients) 
No AKI 
(70 patients) 
p value 
Demographics    
Age(years)  75.5 (57.3 to 81.3) 71.0 (64 to 77.25) 0.534 
BMI (kg/m2)  25.7 (23.2 to 29.4) 27.9 (24.7 to 30.6) 0.267 
Gender (female)  2 (12.5) 15 (21.5) 0.418 
Ethnicity     0.412 
Caucasian 9 (56.3) 48 (56.3)  
Afro-Caribbean 2 (12.5) 3 (4.3)  
South Asian 5 (31.3) 16 (22.9)  
    
Pre-operative Symptom status    
NYHA class > 3   6 (37.5) 23 (32.9) 0.851 
     
Clinical characteristics     
Diabetes Mellitus (DM)     0.469 
Non-insulin treated DM 6 (37.5) 26 (37.1)  
Insulin treated DM 6 (37.5) 17 (24.3)  
Hypertension  15 (93.8) 56 (80.0) 0.191 
Hypercholesterolaemia  15 (93.8) 52 (74.3) 0.090 
Previous MI  11 (68.8) 34 (48.6) 0.145 
Previous stroke   4 (25.0) 11 (15.7) 0.377 
Peripheral vascular disease  4 (25.0) 25 (35.7) 0.413 
COPD  1 (6.3) 8 (11.4) 0.542 
     
Pre-operative Renal Function    
Median eGFR (mL/min)  47.5 (38.5 to 52.8) 51.0 (43.8 to 56.0) 0.161 
Median sCr ("mol/L)  124.0 (114.0 to 155.3) 121.0 (110.5 to 137.8) 0.421 
     
Cardiac status    
Mean LVEF (%)  47.5 (39.3 to 57.5) 56.0 (45.0 to 60.0) 0.113 
LVEF category    0.215 
Good (LVEF > 55%) 6 (37.5) 39 (55.7)  
Moderate (LVEF 35 – 55%) 9 (56.3) 23 (32.9)  
Poor (LVEF < 35%) 1 (6.3) 8 (11.4)  
3 vessel coronary artery disease 15 (93.8) 47 (70.0) 0.142 
Left main stem involvement  1 (6.3) 15 (21.4) 0.159 
BMI denotes body mass index; NYHA New York Heart Association; DM diabetes mellitus; MI 
myocardial infarction; eGFR estimated glomerular filtration rate; sCr serum creatinine; LVEF left 
ventricular ejection fraction. 
 
 115 
Table 20 Surgical characteristics and post-operative outcomes of the study cohort 
stratified by the presence or absence of AKI 
Variable AKI 
(16 patients) 
No AKI 
(70 patients) 
p value 
Surgical procedure   0.271 
CABG 16 (100.0) 65 (92.9)  
CABG + AVR 0 (0) 5 (7.1)  
Procedural urgency   0.127 
Elective 8 (50.0) 49 (70.0)  
Urgent 8 (50.0) 21 (30.0)  
    
Number of grafts   0.161 
1 0 (0) 3 (4.3)  
2 0 (0) 10 (14.3)  
3 14 (87.5) 38 (54.3)  
>3 2 (12.5) 19 (27.1)  
    
Cross-clamp time (min) 97.5 (75.8 to 119.0) 93 (76.0 to 119.3) 0.863 
Perfusion time (min) 63.5 (57.3 to 83.8) 60.0 (46.8 to 89.0) 0.363 
    
Post-operative outcomes    
Post-operative dialysis 2 (2.3) 0 (0) 0.033 
Myocardial infarction 0 (0) 5 (7.1) 0.271 
Atrial fibrillation 7 (43.8) 21 (30.0) 0.290 
Pneumonia 2 (12.5) 1 (1.4) 0.088 
Need to return to theatre 1 (6.3) 2 (2.9) 0.505 
    
Length of ICU stay (h) 32.2 (21.3 to 56.7) 21.3 (16.8 to 32.4) 0.058 
Length of hospital stay (day) 13.0 (6.5 to 17.5) 7.5 (6.0 to 11.0) 0.053 
30-day mortality 3 (18.8) 0 (0) 0.006 
CABG denotes coronary artery bypass graft surgery; AVR aortic valve replacement; ICU 
intensive care unit 
 
5.3.2 Serum creatinine after CABG (Figure 12) 
There was no difference in median pre-operative sCr levels between the AKI and no AKI 
groups (124 "mol/L vs 121 "mol/L; p=0.421). By post-operative day 1 a significant 
separation in sCr levels between the AKI and no AKI groups became evident, and this 
was sustained until post-operative day 5. AKI defined by RIFLE criteria was evident after 
a median of 2 days (2 to 3) in those that sustained AKI. 
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Figure 12 Median % increase in serum creatinine over the first 5 post-
operative days stratified by the presence or absence of AKI. The AKI group is 
displayed in red and the non-AKI group in blue. Error bars represent 25th, and 
75th percentile values. There was no difference in baseline sCr between patients 
with no AKI and patients with AKI (121.0 vs 124.0; p=0.4209). On each post 
operative day the AKI group have a higher % increase in serum creatine than the 
no AKI group; day 1 (no AKI -4.7% vs AKI 10.9%; p=0.0007), day 2 (no AKI -
1.4% vs AKI 57.6%; p<0.0001), day 3 (no AKI 0.5% vs AKI 64.6%; p<0.0001), 
day 4 (no AKI -1.7% vs 75.1%; p<0.0001) and day 5 (no AKI -2.7% vs AKI 
54.5%; p<0.0001).  
 
5.3.3 Serum AKI biomarkers after CABG (Figure 13) 
NGAL: Pre-operative serum NGAL concentration was not different between the groups 
(AKI 130.9 [87.9 to 214.5] vs 108.5 [72.9 vs 172.1] ng/mL; p=0.2507). Percentage 
change in serum NGAL was significantly higher in the AKI group at 6 h (AKI 116.1% vs 
No AKI 69.5%; p=0.0046), 12 h (AKI 150.3% vs No AKI 82.1%; p=0.0002) and 24 h 
(AKI 222.3% vs 92.6%; p<0.0001) post CPB. 
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Figure 13 Median % increase in serum NGAL concentration over the first 24 h 
after cardiac surgery stratified by the presence or absence of AKI. The AKI 
group is displayed in red and the non-AKI group in blue. Error bars 
represent 25th, and 75th percentile values. Percentage change in serum NGAL 
was significantly higher in the AKI group at 6 h (AKI 116.1% vs No AKI 69.5%; 
p=0.0046), 12 h (AKI 150.3% vs No AKI 82.1%; p=0.0002) and 24 h (AKI 
222.3% vs 92.6%; p<0.0001) post CPB. 
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Figure 14 Median % increase in serum IL-18 concentration over the first 24 
h after coronary surgery stratified by the presence or absence of AKI. The 
AKI group is displayed in red and the non-AKI group in blue. Error bars represent 
25th, and 75th percentile values. There was no significant difference in percentage 
change of serum IL-18 between the groups at any time point studied. 
 
IL-18: There was no difference in pre-operative serum IL-18 level (AKI 18.5 [12.9 to 
24.6] vs 20.0 [17.7 vs 21.1] ng/mL; p=0.531), or percentage change of serum IL-18 
between the groups at any time point (Figure 14).  
 
CyC: Median pre-operative serum CyC was not different between the groups (AKI 1372 
[1218 to 1869] vs 1364 [1164 vs 1807] ng/mL; p=0.7518). Percentage change in serum 
CyC level was significantly higher in the patients with AKI at 12h (AKI 12.6% vs No 
AKI -10.9%; p=<0.0001) and 24h post CABG (AKI 42.1% vs No AKI -2.6%; p<0.0001) 
(Figure 15). 
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Figure 15 Median % increase in serum CyC concentration over the first 24 h 
after coronary surgery stratified by the presence or absence of AKI. The AKI 
group is displayed in red and the non-AKI group in blue. Error bars represent 
25th, and 75th percentile values. At 6 h post CABG serum CyC level have fallen 
from baseline in both groups. At 12 h (AKI 12.6% vs No AKI -10.9%; 
p=<0.0001) and 24h (AKI 42.1% vs No AKI -2.6%; p<0.0001) post-surgery 
percentage increase in serum CyC was significantly higher in the patients with 
AKI.  
 
5.3.4 Urinary AKI biomarkers after CABG 
NGAL: There was no significant difference in pre-operative urinary NGAL/urinary 
creatinine ratio between the groups (AKI 940.7 [361.3 - 2502.0] vs 593.5 [249.3 - 
4241.0] ng/mg; p=0.7772). Median percentage increase in urinary NGAL/urinary 
creatinine ratio was higher 6, 12 and 24 h post-CABG in the AKI group. However, 
statistical significance was reached only at the 24 h time point (AKI 515% [162 – 2891] 
vs 149% [42 – 566]; p=0.0195) (Figure 16). 
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Figure 16 Median %increase in urinary NGAL/ urinary creatinine ratio over 
the first 24 h after coronary surgery stratified by the presence or absence of 
AKI. The AKI group is displayed in red and the non-AKI group in blue. Error 
bars represent 25th, and 75th percentile values. Median percentage increase in 
urinary NGAL/urinary creatinine ratio was higher 6, 12 and 24 h post-CABG in 
the AKI group. However, statistical significance was reached only at the 24 h time 
point (AKI 515% [162 – 2891] vs 149% [42 – 566]; p=0.0195). 
 
IL-18: There was no significant difference in pre-operative urinary IL-18/urinary 
creatinine ratio between the groups (AKI 1494.0 [398.7 – 2739.1] vs 942.4 [486.2 – 
2107.0] ng/mg; p=0.6293). Post-operatively urinary IL-18/urinary creatinine ratios appear 
to fall from baseline levels in both groups. Paradoxically at both 12 h and 24 h post-
CABG there was a greater reduction in urinary IL-18/urinary creatinine ratio in the AKI 
group compared with the no AKI group (Figure 17).  
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Figure 17 Median % change in urinary IL-18/ urinary creatinine ratio over 
the first 24 h after coronary surgery stratified by the presence of CSA-AKI. 
The AKI group is displayed in red and the non-AKI group in blue. Error bars 
represent 25th, and 75th percentile values. There was no significant difference in 
percentage change of urinary IL-18/ urinary creatinine ratios between the groups 
at any time point studied 
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Figure 18 Median % change in urinary KIM-1/ urinary creatinine ratio over 
the first 24 h after coronary surgery stratified by the presence of CSA-AKI. 
The AKI group is displayed in red and the non-AKI group in blue. Error bars 
represent 25th, and 75th percentile values. There was no significant difference in 
percentage change of urinary KIM-1/ urinary creatinine ratios between the groups 
at any time point studied 
 
KIM-1: There was no difference between the groups in urinary KIM-1/urinary creatinine 
ratio at baseline (AKI 54.3 [18.4 – 151.9] vs 60.1 [15.6 – 168.6] ng/mg; p=0.8287), or 
any subsequent time point (Figure 18). 
 
5.3.5 Performance of biomarkers as predictors of AKI 
Results of the ROC analysis are displayed in Table 21. The best performing serum 
biomarker for the prediction of AKI at all time points was serum CyC which displayed 
the highest AUC-ROC at 6 h (AUC-ROC 0.73 [0.60 – 0.86]), 12 h (AUC-ROC 0.86 
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[0.75-0.98]) and 24 h (AUC-ROC 0.94 [0.89-0.99]). Using a cut-off value of a 3.2% 
increase in concentration of cystatin C at 12 hours after surgery, cystatin C had a 
sensitivity of 81% and specificity of 59% for the prediction of AKI in our cohort. A cut-
off value of a 17.8% increase in concentration of cystatin C at 24 hours after surgery gave 
a sensitivity of 88% and specificity of 87% for the prediction of AKI. Serum NGAL was 
a fair predictor at all time points with AUC at 6 h (AUC-ROC 0.71 [0.57 – 0.84]), 12 h 
(AUC-ROC 0.80 [0.70-0.90]) and 24 h (AUC-ROC 0.83 [0.74-0.93]). Serum IL-18 was 
poor predictor of AKI at all time points. The combination the two best performing serum 
biomarkers, NGAL and cystatin C, did not improve AUC-ROC for the predicting AKI 
within 12 h of surgery above that obtained with cystatin C alone (Table 22). 
 
At the post-CABG time points studied, all of the urinary biomarkers performed poorly as 
predictors of AKI. The combination of urinary NGAL (the best performing urinary 
biomarker) with either serum NGAL or serum cystatin C or both was not associated with 
a better AUC-ROC for the early prediction of AKI than cystatin C alone.
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Table 21 AKI biomarker test characteristics for the prediction of AKI 
 Cut off  
(% biomarker 
increase)*  
Sensitivity  
(%) 
Specificity  
(%) 
Positive predictive 
value (%) 
Negative predictive 
value (%) 
AUC-ROC  
(95% CI) 
Serum Biomarkers       
NGAL 6 h > 97 75 59 29 91 0.71 (0.57 – 0.84) 
NGAL 12 h > 110 81 76 43 95 0.80 (0.70 – 0.90) 
NGAL 24 h > 113 94 63 37 98 0.83 (0.74 – 0.93) 
IL-18 6 h > 28 81 13 18 75 0.51 (0.37 – 0.66) 
IL-18 12 h > 18 50 34 15 75 0.50 (0.35 – 0.66) 
IL-18 24 h > 97 31 43 11 73 0.52 (0.37 – 0.68) 
CyC 6 h > -16 69 67 32 90 0.74 (0.60 – 0.86) 
CyC 12 h > 3 81 59 59 95 0.86 (0.75 – 0.98) 
CyC 24 h > 18 88 87 61 97 0.94 (0.89 – 0.99) 
Urine Biomarkers       
NGAL 6 h > 111 94 33 24 96 0.56 (0.42 – 0.69) 
NGAL 12 h > 414 75 53 27 90 0.63 (0.49 – 0.77) 
NGAL 24 h > 143 81 50 27 92 0.69 (0.55 – 0.83) 
IL-18 6 h > -82 56 29 15 74 0.54 (0.39 – 0.70) 
IL-18 12 h > -82 38 17 9 55 0.67 (0.50 – 0.84) 
IL-18 24 h > -75 19 36 6 66 0.69 (0.54 – 0.83) 
KIM-1 6 h > -94 100 16 21 100 0.55 (0.41 – 0.70) 
KIM-1 12 h > -51 63 57 25 87 0.53 (0.36 – 0.70) 
KIM-1 24 h > -57 75 36 21 86 0.50 (0.35 – 0.66) 
Optimal cut-off points for each biomarker were determined using the Youden index, which is calculated by adding sensitivity and specificity and subtracting 1 [243]. Biomarkers were dichotomized using the cut-offs 
to allow sensitivity, specificity, negative predictive value and positive predictive value for each biomarker to be calculated  
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Table 22 AKI biomarker panel characteristics for the prediction of AKI 
 Sensitivity (%) Specificity (%) Positive 
predictive value 
(%) 
Negative 
predictive value 
(%) 
AUC-ROC  
(95% CI) 
6 h serum CyC/ serum NGAL 94 37 25 96 0.74 (0.60 – 0.87) 
12 h serum CyC/ serum NGAL 100 39 27 100 0.85 (0.78 – 0.93) 
6 h serum NGAL/ urine NGAL 100 19 22 100 0.59 (0.46 – 0.71) 
12 h serum NGAL/ urine NGAL 100 37 27 100 0.65 (0.52 – 0.78) 
6 h serum CyC / urine NGAL 94 23 22 94 0.56 (0.43 – 0.69) 
12 h serum CyC / urine NGAL 100 41 28 100 0.64 (0.50 – 0.78) 
6 h serum CyC / serum NGAL/ urine NGAL 100 10 20 100 0.58 (0.46 – 0.71) 
12 h serum CyC / serum NGAL/ urine NGAL 100 21 25 100 0.67 (0.54 – 0.80) 
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5.4 Discussion 
This study compared the ability of 3 serum and 3 urinary biomarkers to predict AKI 
after CABG in patients with CKD. Serum CyC was the best performing biomarker at all 
post-operative time points studied. The maximal diagnostic precision of CyC was at the 
24 h post surgery time point when the AUC-ROC was 0.94. Serum NGAL also 
performed relatively well with a maximum AUC-ROC of 0.83 at the 24 h time point. 
Unfortunately serum IL-18 and all of the urinary biomarkers studied performed poorly 
as predictors of AKI in this cohort. 
 
Although generally considered a surrogate marker of GFR, serum CyC has shown 
significant promise as a biomarker for predicting AKI [238]. It has never before been 
tested exclusively in a population of patients with pre-existing CKD. In this cohort by 12 
h post CABG serum CyC levels were significantly higher in the patients that 
subsequently developed AKI when compared with patients that did not. At 24 h post 
CABG serum CyC could predict the subsequent development of AKI with a sensitivity 
of 88% and a specificity of 87%. AKI was not reliably detectable using sCr until 2 days 
after surgery. That serum CyC can accurately predict AKI at least 24 h earlier than the 
current gold-standard sCr clearly represents a significant advance. However diagnosis 
12 – 24 h post CABG may still be too late to alter the course of AKI.  
 
Both SCr and serum CyC are surrogate markers of GFR. They display a similar inverse 
linear relationship with GFR, so as GFR falls both sCr and serum CyC concentrations 
will increase. In this study AKI was defined in accordance with the consensus RIFLE 
criteria that emphasise post-operative change in sCr. As both sCr and serum CyC are 
related (by GFR), the impressive performance of serum CyC as a predictor of AKI in 
this cohort may simply be due the fact AKI is defined using sCr. Importantly elevation 
of serum CyC is apparent at a far earlier time point than sCr. 
 
Serum NGAL also showed promise as a predictor of AKI. At 12 h post CABG the 
AUC-ROC for serum NGAL was 0.80 and this improved to 0.83 by the 24 h time point. 
Previous reports suggest that NGAL peaks in plasma/serum early after cardiac surgery, 
with its predictive accuracy for AKI at its highest within 2 - 6 h after separation from 
CPB [229, 230]. There was no 6 h NGAL peak in this cohort, rather serum NGAL levels 
steadily increased from baseline to 24 h post surgery. It should be noted that no 
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biomarker was sampled until 6 h post surgery. It is possible that serum NGAL levels 
peaked and fell prior to the 6 h sampling time point. Thus the performance of serum 
NGAL as an early predictor of AKI after CABG may have been underestimated. Serum 
NGAL has not been assessed before in cohort of patients with CKD. The release kinetics 
of NGAL in such a population remains undefined. Potentially patients with CKD may 
not be able to rapidly synthesize and secrete NGAL, and the early NGAL peak observed 
in non-CKD populations may simply not occur in patients with already diseased kidneys 
[235].  
 
All of the urinary biomarkers studied performed poorly as predictors of AKI. There is no 
published data upon the predictive accuracy of either urinary IL-18 or KIM-1 in patients 
with CKD. The effect of renal function upon the diagnostic performance of urinary 
NGAL has been previously investigated, and consistent with these results, urinary 
NGAL was found to perform poorly as an AKI predictor in patients with an eGFR <60 
mL/min [235]. Intact renal tubular cell function may be a prerequisite for rapid synthesis 
and secretion of urinary AKI biomarkers. Reduced renal tubular cell function in patients 
with CKD may render them unable to rapidly express these biomarkers in response to 
injury, and thus explain the poor predictive performance of these biomarkers observed in 
this study 
 
Arguably AKI biomarkers in combination may perform better than any single 
biomarker. In this study the best performing serum and urine biomarkers were combined 
in order to evaluate their diagnostic performance within the first 12 h after CABG with 
the goal of accurate early prediction of AKI. Prediction of AKI early within the first 12 
h after surgery is desirable for any potential intervention to be maximally effective. No 
combination biomarker ‘panel’ had a superior AUC-ROC to serum CyC alone for 
predicting AKI within the first 12 h post-CABG. AUC-ROC is essentially a trade off 
between sensitivity and specificity of a diagnostic test. However, relying upon AUC-
ROC as a measure of test performance may lead to the under appreciation of a tests 
clinical utility. For example CyC had a sensitivity of 88% and a specificity of 87% for 
detecting AKI at 24 h. At this time AKI may be already established and refractory to 
intervention, thus the test is of limited utility. Combining serum and urine NGAL at 6 h 
after surgery had a sensitivity of 100% for detecting patients with CSA-AKI, albeit at 
the expense of a high false positive rate. Furthermore, the negative predictive value of 
this biomarker combination was 100%, which is clinically important, as it enables 
  128 
patients that will not develop AKI to be reliably distinguished and spared inappropriate 
therapies at an early time point. Combination biomarker panels with high early 
sensitivity may be useful in clinical research, allowing the compilation of ‘at-risk’ study 
cohorts with a high-expected event rate. Evaluation of new AKI therapies in such high-
risk cohorts is an attractive idea meaning low numbers of patients need to be recruited in 
order to adequately power prospective studies. 
 
5.4.1 Strength and limitations of this study 
To my knowledge this is the first study to evaluate novel candidate AKI biomarkers in a 
cohort of patients with CKD undergoing cardiac surgery. This is the major strength of 
the study. The lack of data upon biomarker performance in patients with CKD is an 
important gap in the current published literature. As patients with CKD now represent a 
significant proportion of patients undergoing cardiac surgery and form the majority of 
those who sustain post-operative AKI, specific research in this patient population was 
overdue. 
 
The most important limitation of this study was the power. As only 86 patients were 
included in this study, and the frequency of AKI was only 19%, the study is 
underpowered to provide definitive conclusions on the performance of these biomarkers 
for predicting AKI in patients with CKD after CABG. Using only 16 examples of AKI 
in order to validate these biomarkers makes the generation of definitive statistical results 
challenging. 
 
A second important limitation of this study is that it was a secondary analysis of the data 
collected in RIPC trial described in Chapter 4, and not a study specifically designed to 
examine the predictive value of AKI biomarkers. In the parent study troponin sampling 
time points were specified at 6, 12 and 24 h post-operatively in order to be comparable 
with similar published studies. For pragmatic reasons in this study biomarker samples 
were collected concurrently with troponin samples. However, the biomarker collection 
times represent an important potential limitation. Previous studies have suggested that 
serum/urine NGAL and urine IL-18 levels may peak early and fall within the first 6 h 
following cardiac surgery. Thus, by not sampling biomarkers until 6 h the predictive 
performance of these biomarkers may have been underestimated. Also it is possible that 
intervention in the parent study (namely RIPC) may have affected biomarker 
concentration. Although biomarkers levels are not different between the RIPC and 
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control groups in the parent study, it was inadequately powered to detect any small 
effect of RIPC upon these AKI biomarkers. 
Finally, serum and urine biomarker concentrations were calculated using commercially 
available research ELISAs. There is inherent variability associated with the ELISA 
technique, which requires multiple complex steps. This may have affected the predictive 
performance of the biomarkers measured. Any variability is likely to be improved by 
increasing patient numbers and the number of sample repeats. Furthermore, there are 
now a number of available commercial platforms to measure each AKI biomarker, all 
with differing test characteristics. Comparison of biomarker performance between 
studies is limited by the lack of a standardized assay for each individual biomarker. The 
assays themselves may effect the results of the study. Notwithstanding these limitation 
both change in serum cystatin-C and serum NGAL performed well as predictors of 
CSA-AKI in this cohort.  
. 
5.4.2 The future for AKI biomarker research 
Combining AKI biomarkers with a clinical risk prediction model in order to more 
accurately define an individual’s likelihood of developing CSA-AKI is an attractive 
proposition. To date a number of observational studies have identified several risk 
factors consistently associated with the development of AKI after cardiac surgery. As a 
result several models for predicting AKI after cardiac surgery have been developed[98, 
100, 104-107]. The addition of AKI biomarkers to these models could further enhance 
the predictive accuracy of such models. Combining AKI biomarkers with a AKI risk 
prediction model was not possible in this cohort. It would have been inappropriate to 
apply any existing risk model to this study cohort, as no model has been validated in a 
CKD cohort, and generally these models predict the need for post-operative dialysis 
rather than RIFLE defined AKI. However, in the future it is likely that AKI biomarkers 
will have an important role in any clinical AKI risk model. 
 
In general larger studies with consistent AKI definition, biomarker collection times, and 
biomarker measurement techniques are needed to develop standardised cut-offs for each 
biomarker. Such studies must include patients with CKD. As AKI is caused by multiple 
pathophysiological mechanisms it seems unlikely that a single biomarker would be 
sufficient for the accurate and consistent diagnosis of AKI. Although further research 
into individual biomarkers is important, the combination of biomarkers in multi-marker 
panels may prove the biggest step towards the accurate early diagnosis of AKI. 
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5.5 Conclusions 
In this study serum CyC and serum NGAL were useful predictors of AKI in adults with 
CKD after CABG.  
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Chapter 6 
 
6. Summary and Conclusions 
6.1 Introduction 
CKD is a major health problem that effects approximately 1 in 10 of the UK’s adult 
population [9, 11]. Many patients with CKD develop accelerated, diffuse CAD that can 
be especially challenging to treat [244]. Myocardial revascularisation may improve 
survival in selected patients with CKD and multivessel CAD, and current international 
guidelines recommend CABG as the revascularisation modality of choice in this patient 
group [244]. Furthermore, patients with CKD and multivessel CAD appear to derive a 
survival advantage from CABG compared with PCI which is not present in patients with 
normal renal function [244]. For these reasons, the proportion of patients undergoing 
CABG who have CKD has increased steadily over the last 10 years, with patients with 
CKD now accounting for approximately one third of patients undergoing CABG [3, 
150, 151, 163]. 
 
A particular problem for patients with CKD that undergo CABG is the development of 
post-operative AKI. Depending upon definition, AKI may complicate as many as one 
third of CABG operations [6, 99]. The development of AKI in this setting is associated 
with increased length of hospital stay, increased utilization of resources but most 
importantly it is associated with an increase in both short- and long-term post-operative 
mortality [5, 6, 106, 115]. Currently there are no prophylaxes or therapies proven to 
reduce the incidence of AKI post-CABG. The purpose of this thesis was to investigate 
strategies to reduce the incidence of AKI in patients with CKD undergoing cardiac 
surgery.  
 
The specific aims of this thesis were: 
1. In our local cardiac surgical cohort to evaluate,  
a. The effects of CKD upon outcome after CABG. 
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b. The importance of AKI after CABG.  
2. To assess the potential for RIPC to reduce AKI and myocardial injury in 
patients with CKD undergoing CABG. 
3. To investigate the diagnostic performance of serum and urine AKI biomarkers 
in a population of patients with CKD undergoing CABG.  
 
6.2 Summary of thesis findings 
Analysis of the Barts Health NHS Trust cardiac surgical dataset revealed some 
important findings. Firstly, patients with CKD (eGFR<60mL/min) are a group at 
particularly high risk of both early and late mortality following CABG. Notably these 
patients represent approximately one third of patients undergoing isolated coronary 
surgery but account for almost two thirds of all early mortality after CABG. Secondly, 
CKD was an important predictor of both short- and long-term post-operative mortality 
even after accounting for comorbidity that is commonly present in these patients. 
Thirdly, the relationship between mortality after CABG and renal dysfunction was non-
linear. The risk of post-operative mortality increased steeply once eGFR fell below 60 
mL/min. Finally, as expected the incidence of post-operative AKI was highest in 
patients with CKD.  
 
My second analysis of the Barts Health NHS Trust cardiac surgical dataset highlighted 
the prognostic importance of AKI after CABG. In our local cardiac surgical population 
AKI was common, affecting 12% of patients after CABG. The development of AKI was 
associated with an increase in long-term mortality. Whether AKI has a causal 
relationship with subsequent mortality or its development simply reflects an increased 
burden of comorbidity and/or procedural complexity within a high-risk patient 
population already destined to do poorly after surgery is often debated. After using 
advanced statistical matching techniques to correct for baseline patient comorbidity and 
surgical factors AKI remained an important independent predictor of subsequent 
mortality in this population. 
 
The pathophysiology of AKI following cardiac surgery is complex and incompletely 
understood. It is thought that renal IRI is an important component of a multifactorial 
renal insult that also includes a systemic inflammatory response to CPB, peri-operative 
haemodynamic instability, and/or peri-operative nephrotoxins. RIPC is a non-invasive 
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therapy that mitigates IRI and may modulate systemic inflammation in cardiac surgery. 
It is potentially a non-pharmacological strategy to reduce the incidence of AKI 
following cardiac surgery. RIPC has shown promise in reducing the incidence of AKI in 
patients undergoing major vascular surgery, coronary angiography and in cardiac 
surgery. RIPC has never before been evaluated specifically in a cohort of patients with 
CKD. Patients with CKD may accrue significant benefit from RIPC given the increased 
peri-operative risk they face. Unfortunately, in the randomized trial described in this 
thesis, RIPC despite its intuitive appeal did not reduce the incidence of AKI after CABG 
in patients with CKD.  
 
Within the randomized RIPC trial serum and urine samples were collected for the 
analysis of a number of candidate AKI biomarkers. These biomarkers offer the potential 
for the early diagnosis of AKI at a time point when renal injury may be potentially 
modified. The performance of these biomarkers at predicting AKI in a population of 
patients with CKD undergoing CABG has never before been investigated. Serum CyC 
and serum NGAL performed impressively as predictors of AKI in patients with CKD. 
These biomarkers facilitated the diagnosis of AKI more than 24 hours before sCr.  
 
6.3 Implications of this thesis  
This thesis has helped to clarify the impact of pre-operative CKD upon outcomes after 
CABG. Understanding that patients with an eGFR<60mL/min are at such high risk of 
adverse outcomes following cardiac surgery is extremely important for cardiologists and 
cardiac surgeons when balancing the risks and benefits of CABG in different patient 
groups and when discussing the expected outcomes after surgery with their patients. 
This information applies to a significant proportion of patients undergoing CABG. In the 
unselected study population presented in this thesis, for example, approximately one 
third of the patients had CKD.  
 
AKI is also a common problem following cardiac surgery. The development of this 
complication may identify patients with an increased risk of subsequent mortality 
following hospital discharge. Currently, there are no established prophylaxes or 
therapies proven to reduce the incidence nor the mortality associated with this condition. 
Hopefully this thesis and the publications arising from it will stimulate the closer post-
discharge monitoring of patients that sustain AKI after cardiac surgery. In clinical 
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practice there is little specific follow-up of these patients. AKI at the time of cardiac 
surgery may result in ongoing progressive renal damage beyond the acute renal insult 
despite the normalization of sCr [114]. This is an important message for cardiologists, 
cardiac surgeons and renal physician responsible for the care of these patients following 
cardiac surgery. Although, future studies are needed to determine the optimal post-
discharge follow-up and management of patients that sustain perioperative AKI, 
aggressive therapy to optimize control of cardiovascular risk factors should form the 
mainstay of the current management for these high-risk patients. 
 
Unfortunately RIPC did not reduce the incidence of AKI in patients with CKD 
undergoing CABG. As with so much of the research into cardiac surgery associated AKI 
the randomized trial described in this thesis was small and underpowered. However, that 
RIPC failed to offer any meaningful cardiac or renal protection beyond conventional 
standard surgical and anaesthetic technique means that RIPC is unlikely to be readily 
adopted into clinical practice. Importantly, the AKI biomarkers measured in this study 
allowed the accurate early prediction of AKI in patients with CKD. These biomarkers 
will be central to our future understanding and management of CSA-AKI. 
 
6.4 The future of cardiac surgery associated AKI 
The acceptance of a consensus RIFLE definition of AKI following cardiac surgery 
represents an important advance within AKI research. It has allowed the comparison of 
clinical trials using a standardized end-point. However, the RIFLE criteria that 
emphasize percentage change in sCr and urine output for the diagnosis of AKI may in 
part be to blame for the lack of progress in developing new strategies to prevent or 
modify AKI. Both sCr and urine output are relatively insensitive and late markers of 
AKI, thus reliance upon the RIFLE criteria to define AKI will inevitably delay the 
recognition, and the institution of therapeutic interventions for AKI. Potentially AKI 
may be prevented if pharmacological interventions are initiated early. This is not 
possible relying upon the RIFLE definition of AKI. 
 
Novel AKI biomarkers offer the promise of early accurate diagnosis of AKI following 
cardiac surgery. They will undoubtedly become central to any future definitions of AKI. 
Biomarker research is likely to lead to an evolution in our understanding of AKI. 
Combinations of biomarkers in multimarker panels, each with their own release 
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characteristics, will hopefully allow early identification of renal injury, stratification of 
the severity of injury, characterization of the location and/or aetiology of injury, provide 
prognostic information and allow the monitoring of response to therapy. Most 
importantly, early diagnosis of AKI will hopefully allow the institution of therapies that 
may modify renal injury at a time when the interventions may be effective. However, 
until novel therapeutic interventions that may modify the incidence or course of AKI 
become widely available, the early diagnosis of AKI is purely academic, as currently 
once established AKI cannot be modified. 
 
The pre-operative estimation of risk of developing AKI after cardiac surgery is vital to 
individualize and optimize peri-operative care. Currently no model for predicting RIFLE 
defined AKI exists. The development of such a risk prediction model would be a major 
advance in this arena. Such a risk model that predicts lesser forms of AKI in patients 
with and without CKD would not only be of benefit to patients undergoing cardiac 
surgery, but would also be a powerful research tool for selecting patients for trials of 
renoprotective therapies. Any future risk model is likely to incorporate AKI biomarkers.  
 
6.5 Conclusions 
Firstly I must conclude that CKD is a particularly important risk factor for predicting 
adverse events following coronary revascularization. Secondly the development of an 
AKI at the time of revascularization portends an adverse long-term prognosis. 
Unfortunately, despite the intuitive appeal of RIPC it affords no meaningful cardiac or 
renal protection in patients with CKD undergoing cardiac surgery. 
 
In the future better risk stratification will likely allow the prediction of patients that will 
develop AKI after cardiac surgery, and tailored care will likely contribute to 
improvements in renal outcomes. More importantly, updated definitions of AKI that 
emphasis novel AKI biomarkers will hopefully facilitate prompt AKI diagnosis, and will 
likely herald the development of new therapies to combat this important condition. 
Hopefully these changes, combined with larger randomized controlled trials, will lead to 
the improved outcomes for patents undergoing cardiac surgery. 
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7. Appendix 1 
7.1 Materials and Methods for Biomarker ELISA Assays 
7.1.1 Standard solutions for all ELISA assays  
1. Phosphate Buffered Saline (PBS) 
Made by adding 1 sachets of Sigma PBS 7.4 (Cat P3813) to 1 L of H20 
Contains 137 mM Na Cl, 2.7 mm K Cl, 8.1 mM Na2 HPO4, 1.5 mm KH2PO4, pH 7.2-
7.4, 0.2!m filtered. 
 
2. Reagent Buffer  
Made by adding 5g of Fraction V Bovine Serum Albumin to 500 mL PBS  
Contains 1% BSA in PBS, pH 7.2-7.4, 0.2 !m filtered. 
 
3. Wash Buffer  
Made by adding 1 mL of neat Tween 20 to 2 L PBS  
Contains 0.05% Tween 20 in PBS, pH 7.2-7.4 
 
4. Substrate Solution (R and D Systems Catalogue # DY 999) 
1:1 mixture of Colour Reagent A (H2O2) and Colour Reagent B (Tetramethylbenzidine) 
 
5. Stop Solution (R and D Systems Catalogue # DY 994) 
2N H2SO4 
 
6. Streptavidin-HRP 
Working solution made by diluting supplied Streptavidin-HRP solution (1 mL of 
streptavidin conjugated to horseradish-peroxidase) 1 in 200 in Reagent Diluent.  
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7.2 NGAL ELISA  
Serum and urine NGAL levels were detected by using a commercially available 
enzyme-linked immunosorbent assay kit (Human Lipocalin-2/NGAL Immunoassay; 
R&D Systems, Europe (Catalogue Number DY1757) 
 
The kit contained: 
Capture Antibody (rat anti-human Lipocalin-2) 
Reconstituted by adding 1 mL of PBS to dry capture antibody to create diluted capture 
antibody with a concentration of 360 !g/mL. This diluted capture antibody solution was 
further diluted by adding 55 !L into 10 mL PBS to give working solution of 2 !g/mL. 
 
Standards (recombinant human Lipocalin-2) 
Reconstituted by adding 0.5 mL of reagent diluent to dry standard to create diluted 
NGAL standard with a concentration of 90 ng/mL. This standard solution was diluted 18 
fold (50 !L added to 850 !L of reagent buffer to create working standard solution of 
5000 pg/mL. The working standard solution was serially diluted to give standards with 
concentrations of: 5000, 2500, 1250, 625, 312.5, 156.25, 78.125 and 0 pg/mL 
 
Detection Antibody (biotinylated goat anti-human Lipocalin-2) 
Reconstituted by adding 1 mL of reagent dilutent to vial.  This diluted detection 
antibody was further diluted by adding 55 !L into 10 mL reagent dilutent to give 
working solution of 100 ng/mL final concentration. 
 
Serum and urine sample dilutions for NGAL ELISA  
We identified that a dilution of serum samples of 1 in 200 with reagent buffer and of 
urine of 1 in 50 with reagent buffers as the most appropriate for our study population.  
 
All samples from an individual patient were measured in a single assay. The co-efficient 
of variation for intra-assay reproducibility for NGAL concentration was 7.2% in our 
laboratory and this corresponds to that reported by the kit manufacturer.  
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Sample assays were repeated across several different plates on different days to ensure 
reproducibility of results although formal inter-assay variation was not calculated. 
 
7.2.1 Assay Protocol 
Plate Preparation 
1. The working concentration of capture antibody is used to coat a 96-well 
microplate with 100 !L capture antibody solution/well. Plate then sealed and 
incubated overnight at room temperature. 
2. Wash plate by aspirating each well with wash buffer, repeating the process 
twotimes for a total of three washes.  
3. Block the plate by adding 300 !L of reagent diluent to each well. Incubate 
plates at room temperature for 1 h. 
4. Repeat wash as in step 2.  
 
Assay Procedure 
1. Add 100 !L of standards to first 16 wells of plate to create ‘standard curve’ for 
plate analysis. 
2. Add 100 !L diluted serum or urine sample to remaining 80 wells of 96-well 
plate. Cover with an adhesive strip and incubate at room temperature for 2 h. 
3. Repeat wash as in step 2 of plate preparation. 
4. Add 100 !L of the working solution of detection antibody to each well. Cover 
with a new adhesive strip and incubate for 2 h at room temperature. 
5. Repeat wash as in step 2 of plate preparation. 
6. Add 100 !L of the working dilution of Streptavidin-HRP to each well. Cover 
the plate and incubate for 20 min at room temperature. Avoid placing the plate 
in direct light. 
7. Repeat wash as in step 2 of plate preparation. 
8. Add 100 !L of substrate solution to each well. Incubate for 20 min at room 
temperature. Avoid placing the plate in direct light. 
9. Add 50 !L of stop solution to each well.  
10. Determine the optical density of each well immediately using a microplate 
reader set to 450nm. 
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Calculation of results 
All standards and samples were analysed in duplicate and the average taken as the final 
value.  
 
A standard curve (Figure 17) was generated using Revelation microplate reading 
computer software (Dynex Technologies, Worthing, U.K), and allowed the derivation of 
sample NGAL concentration. 
 
Figure 17 Standard curve for NGAL assay 
 
 
  
  141 
7.3 IL-18 ELISA  
Serum and urine IL-18 levels were detected by using a commercially available enzyme-
linked immunosorbent assay kit (Human IL-18 BPa Immunoassay; R&D Systems, 
Europe (Catalogue Number DY119) 
 
The kit contained: 
Capture Antibody (mouse anti-human CyC) 
Reconstituted by adding 1 mL of PBS to dry capture antibody to create diluted capture 
antibody with a concentration of 720 !g/mL. This diluted capture antibody solution was 
further diluted by adding 55 !L into 10 mL PBS to give working solution of 4 !g/mL. 
 
Standards (recombinant human IL-18) 
Reconstituted by adding 0.5 mL of reagent diluent to dry standard to create diluted 
NGAL standard with a concentration of 250 ng/mL. This standard solution was diluted 
with reagent buffer to create working standard solution of 6000 pg/mL (21 !L standard 
diluted with 979 !L of reagent buffer). The working standard solution was serially 
diluted to give standards with concentrations of: 6000, 3000, 1500, 750, 375, 187.5, 
93.75 and 0 pg/mL 
 
Detection Antibody (biotinylated goat anti-human IL-18) 
Reconstituted by adding 1 mL of reagent dilutent to vial.  This diluted detection 
antibody was further diluted by adding 55 !L into 10 mL reagent dilutent to give 
working solution of 100 ng/mL final concentration. 
 
Serum and urine sample dilutions for IL-18 ELISA  
We identified that a dilution of serum samples of 1 in 40 in reagent buffer for both 
serum and urine as the most appropriate dilution for our study population.  
 
All samples from an individual patient were measured in a single assay. The co-efficient 
of variation for intra-assay reproducibility for IL-18 concentration was 11.9% in our 
laboratory and this corresponds to that reported by the kit manufacturer.  
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Sample assays were repeated across several different plates on different days to ensure 
reproducibility of results although formal inter-assay variation was not calculated. 
 
7.3.1 Assay Protocol 
Plate Preparation 
1. The working concentration of capture antibody is used to coat a 96-well 
microplate with 100 !L capture antibody solution/well. Plate then sealed and 
incubated overnight at room temperature. 
2. Wash plate by aspirating each well with wash buffer, repeating the process 
twotimes for a total of three washes.  
3. Block the plate by adding 300 !L of reagent diluent to each well. Incubate 
plates at room temperature for 1 h. 
4. Repeat wash as in step 2.  
 
Assay Procedure 
1. Add 100 !L of standards to first 16 wells of plate to create ‘standard curve’ for 
plate analysis. 
2. Add 100 !L diluted serum or urine sample to remaining 80 wells of 96-well 
plate. Cover with an adhesive strip and incubate at room temperature for 2 h. 
3. Repeat wash as in step 2 of plate preparation. 
4. Add 100 !L of the working solution of detection antibody to each well. Cover 
with a new adhesive strip and incubate for 2 h at room temperature. 
5. Repeat wash as in step 2 of plate preparation. 
6. Add 100 !L of the working dilution of Streptavidin-HRP to each well. Cover 
the plate and incubate for 20 min at room temperature. Avoid placing the plate 
in direct light. 
7. Repeat wash as in step 2 of plate preparation. 
8. Add 100 !L of substrate solution to each well. Incubate for 20 min at room 
temperature. Avoid placing the plate in direct light. 
9. Add 50 !L of stop solution to each well.  
10. Determine the optical density of each well immediately using a microplate 
reader set to 450nm. 
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Calculation of results 
All standards and samples were analysed in duplicate and the average taken as the final 
value.  
 
A standard curve (Figure 18) was generated using Revelation microplate reading 
computer software (Dynex Technologies, Worthing, U.K), and allowed the derivation of 
sample IL-18 concentration. 
 
Figure 18 Standard curve for IL-18 assay 
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7.4 CYC ELISA  
Serum CyC levels were detected by using a commercially available enzyme-linked 
immunosorbent assay kit (Human CyC Immunoassay; R&D Systems, Europe 
(Catalogue Number DY1196) 
 
The kit contained: 
Capture Antibody (mouse anti-human CyC) 
Reconstituted by adding 1 mL of PBS to dry capture antibody to create diluted capture 
antibody with a concentration of 720 !g/mL. This diluted capture antibody solution was 
further diluted by adding 55 !L into 10 mL PBS to give working solution of 4 !g/mL. 
 
Standards (recombinant human CyC) 
Reconstituted by adding 0.5 mL of reagent diluent to dry standard to create diluted CyC 
standard with a concentration of 95 ng/mL. This standard solution was diluted 47.5 fold 
(21 !L added to 979 !L of reagent buffer to create working standard solution of 2000 
pg/mL. The working standard solution was serially diluted to give standards with 
concentrations of: 2000, 1000, 500, 250, 125, and 0 pg/mL 
 
Detection Antibody (biotinylated mouse anti-human CyC) 
Reconstituted by adding 1 mL of reagent dilutent to vial.  This diluted detection 
antibody was further diluted by adding 55 !L into 11 mL reagent dilutent to give 
working solution of 250 ng/mL final concentration. 
 
Serum sample dilution for CyC ELISA  
We identified that a dilution of serum samples of 1 in 1250 in reagent buffer as the most 
appropriate dilution for our study population.  
 
All samples from an individual patient were measured in a single assay. The co-efficient 
of variation for intra-assay reproducibility for CyC concentration was 5.1% in our 
laboratory and this corresponds to that reported by the kit manufacturer.  
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Sample assays were repeated across several different plates on different days to ensure 
reproducibility of results although formal inter-assay variation was not calculated. 
 
7.4.1 Assay Protocol 
Plate Preparation 
1. The working concentration of capture antibody is used to coat a 96-well 
microplate with 100 !L capture antibody solution/well. Plate then sealed and 
incubated overnight at room temperature. 
2. Wash plate by aspirating each well with wash buffer, repeating the process 
twotimes for a total of three washes.  
3. Block the plate by adding 300 !L of reagent diluent to each well. Incubate 
plates at room temperature for 1 h. 
4. Repeat wash as in step 2.  
 
Assay Procedure 
1. Add 100 !L of standards to first 16 wells of plate to create ‘standard curve’ for 
plate analysis. 
2. Add 100 !L diluted serum or urine sample to remaining 80 wells of 96-well 
plate. Cover with an adhesive strip and incubate at room temperature for 2 h. 
3. Repeat wash as in step 2 of plate preparation. 
4. Add 100 !L of the working solution of detection antibody to each well. Cover 
with a new adhesive strip and incubate for 2 h at room temperature. 
5. Repeat wash as in step 2 of plate preparation. 
6. Add 100 !L of the working dilution of Streptavidin-HRP to each well. Cover 
the plate and incubate for 20 min at room temperature. Avoid placing the plate 
in direct light. 
7. Repeat wash as in step 2 of plate preparation. 
8. Add 100 !L of substrate solution to each well. Incubate for 20 min at room 
temperature. Avoid placing the plate in direct light. 
9. Add 50 !L of stop solution to each well.  
10. Determine the optical density of each well immediately using a microplate 
reader set to 450nm. 
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Calculation of results 
All standards and samples were analysed in duplicate and the average taken as the final 
value.  
 
A standard curve (Figure 19) was generated using Revelation microplate reading 
computer software (Dynex Technologies, Worthing, U.K), and allowed the derivation of 
sample CyC concentration. 
 
Figure 19 Standard curve for CyC assay 
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7.5 KIM-1 ELISA  
Urinary KIM-1 levels were detected by using a commercially available enzyme-linked 
immunosorbent assay kit (TIM-1/KIM-1/HAVCR Immunoassay; R&D Systems, Europe 
(Catalogue Number DY1750) 
 
The kit contained: 
Capture Antibody (goat anti-human TIM-1) 
Reconstituted by adding 1 mL of PBS to dry capture antibody to create diluted capture 
antibody with a concentration of 72 !g/mL. This diluted capture antibody solution was 
further diluted by adding 55 !L into 10 mL PBS to give working solution of 0.4 !g/mL. 
 
Standards (recombinant human TIM-1) 
Reconstituted by adding 0.5 mL of reagent diluent to dry standard to create diluted TIM-
1 standard with a concentration of 105 ng/mL. This standard solution was diluted 52.5 
fold (19 !L added to 981 !L of reagent buffer to create working standard solution of 
2000 pg/mL. The working standard solution was serially diluted to give standards with 
concentrations of: 2000, 1000, 500, 250, 125, 62.5, 31.25 and 0 pg/mL 
 
Detection Antibody (biotinylated goat anti-human TIM-1) 
Reconstituted by adding 1 mL of reagent dilutent to vial.  This diluted detection 
antibody was further diluted by adding 55 !L into 11 mL reagent dilutent to give 
working solution of 400 ng/mL final concentration. 
 
Serum sample dilution for KIM-1 ELISA  
We identified that a dilution of urine samples of 1 in 2.5 in reagent buffer as the most 
appropriate dilution for our study population.  
 
All samples from an individual patient were measured in a single assay. The co-efficient 
of variation for intra-assay reproducibility for KIM-1 concentration was 4.8% in our 
laboratory and this corresponds to that reported by the kit manufacturer.  
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Sample assays were repeated across several different plates on different days to ensure 
reproducibility of results although formal inter-assay variation was not calculated. 
 
7.5.1 Assay Protocol 
Plate Preparation 
1. The working concentration of capture antibody is used to coat a 96-well microplate 
with 100 !L capture antibody solution/well. Plate then sealed and incubated 
overnight at room temperature. 
2. Wash plate by aspirating each well with wash buffer, repeating the process twotimes 
for a total of three washes.  
3. Block the plate by adding 300 !L of reagent diluent to each well. Incubate plates at 
room temperature for 1 h. 
4. Repeat wash as in step 2.  
 
Assay Procedure 
1. Add 100 !L of standards to first 16 wells of plate to create ‘standard curve’ for plate 
analysis. 
2. Add 100 !L diluted serum or urine sample to remaining 80 wells of 96-well plate. 
Cover with an adhesive strip and incubate at room temperature for 2 h. 
3. Repeat wash as in step 2 of plate preparation. 
4. Add 100 !L of the working solution of detection antibody to each well. Cover with 
a new adhesive strip and incubate for 2 h at room temperature. 
5. Repeat wash as in step 2 of plate preparation. 
6. Add 100 !L of the working dilution of Streptavidin-HRP to each well. Cover the 
plate and incubate for 20 min at room temperature. Avoid placing the plate in direct 
light. 
7. Repeat wash as in step 2 of plate preparation. 
8. Add 100 !L of substrate solution to each well. Incubate for 20 min at room 
temperature. Avoid placing the plate in direct light. 
9. Add 50 !L of stop solution to each well.  
10. Determine the optical density of each well immediately using a microplate reader set 
to 450nm. 
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Calculation of results 
All standards and samples were analysed in duplicate and the average taken as the final 
value.  
 
A standard curve (Figure 20) was generated using Revelation microplate reading 
computer software (Dynex Technologies, Worthing, U.K), and allowed the derivation of 
sample KIM-1 concentration. 
 
Figure 20 Standard curve for CyC assay 
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7.6 Urinary creatinine assay  
Creatinine Assay Kit; Abcam, Cambridge, UK 
Catalogue No.  ab65340 
 
Kit Components 
Creatinine assay buffer 25mLs 
Creatinine Probe (in DMSO) 200!L 
Creatinase   1 vial Reconstitute with 220 !L assay buffer 
Creatininase   1 vial  Reconstitute with 220 !L assay buffer 
Creatinine enzyme mix 1 vial  Reconstitute with 220 !L assay buffer 
10 !mol Creatinine  1 vial  Reconstitute with 100 !L H20 
 
7.6.1 Assay Protocol 
Standard Preparation 
1. Mix 10 !L of creatinine standard with 990 !L of creatinine assay buffer to 
generate 1 nmol/L standard working solution.  
2. Dilute this standard working solution 10 fold (100 !L standard with 900 !L assay 
buffer).  
3. Add 0, 2, 4, 6, 8, 10 !L of diluted standard working solution to 6 consecutive 
wells of a 96-well microplate. Then add 50, 48, 44, 42, 40 !L of assay buffer to 
the wells to bring the volume of each well to 50 !L. 
 
Sample preparation: add 50 !L of samples to each well. 
 
Prepare reaction mix: Each well should contain 42 !L assay buffer, 2 !L creatinase, 2 
!L creatininase, 2 !L creatinine enzyme mix and 0.4 !L creatinine probe. Therefore for 
the 96 well plate mix 4032 !L assay buffer, 196 !L creatinase, 196 !L creatininase, 196 
!L creatinine enzyme mix and 38.4 !L creatinine probe and add 48.4 !L of this reaction 
mix to each standard and sample well. Incubate at 37oC for 1 h. 
 
Read the plate in a fluorescence reader with Ex/Em=538/587 nm. Sample creatinine 
concentrations are determined from a standard curve calculated from standard assays. 
  151 
5 Reference 
1. Bridgewater B Society of Cardiothoracic Surgeons of Great Britain and Ireland Sixth 
National Adult Cardiac Surgical Database Report. 2008 
2. Shroyer A, Coombs L, Peterson E, Eiken M, Delong E, Chen A, Ferguson TJ, Grover 
F, Edwards F. The Society of Thoracic Surgeons: 30-day operative mortality and 
morbidity risk models. Ann Thorac Surg 2003; 75:1856-64.  
3. Cooper W, O'Brien SM, Thourani V, Guyton R, Bridges C, Szczech L, Petersen R, 
Peterson E. Impact of renal dysfunction on outcomes of coronary artery bypass surgery: 
results from the Society of Thoracic Surgeons National Adult Cardiac Database. 
Circulation 2006; 113:1063-1070.  
4. Chertow G, Levy E, Hammermeister K, Grover F, Daley J. Independent association 
between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 
104:343-348.  
5. Chertow G, Burdick E, Honour M, Bonventre J, Bates D. Acute kidney injury, 
mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 
16:3365-3370.  
6. Hobson C, Yavas S, Segal M, Schold J, Tribble C, Layon A, Bihorac A. Acute kidney 
injury is associated with increased long-term mortality after cardiothoracic surgery. 
Circulation 2009; 119:2444-2453.  
7. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, 
classification, and stratification. Am J Kidney Dis 2002; 39:S1-266.  
8. Kirsztajn G, Suassuna J, Bastos M. Dividing stage 3 of chronic kidney disease (CKD): 
3A and 3B. Kidney Int 2009; 76:462-3.  
9. Levey A, Coresh J. Chronic kidney disease. Lancet 2012; 379:165-180.  
10. Levey A, Stevens L, Schmid C, Zhang Y, Castro AR, Feldman H, Kusek J, Eggers P, 
Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. 
Ann Intern Med 2009; 150:604-612.  
11. Stevens P, O'Donoghue DJ, De Lusignan S, Van Vlymen J, Klebe B, Middleton R, 
Hague N, New J, Farmer C. Chronic kidney disease management in the United Kingdom: 
NEOERICA project results. Kidney Int 2007; 72:92-99.  
12. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of 
premature cardiovascular disease. J Intern Med 2010; 268:456-467.  
  152 
13. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, Mcalister F, Garg A. 
Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 
17:2034-2047.  
14. Go A, Chertow G, Fan D, Mcculloch C, Hsu C. Chronic kidney disease and the risks 
of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.  
15. Ruilope L, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. 
Renal function and intensive lowering of blood pressure in hypertensive participants of 
the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12:218-225.  
16. Mann J, Gerstein H, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of 
cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann 
Intern Med 2001; 134:629-636.  
17. Mafham M, Emberson J, Landray M, Wen C, Baigent C. Estimated glomerular 
filtration rate and the risk of major vascular events and all-cause mortality: a meta-
analysis. PLoS One 2011; 6:e25920.  
18. Brenner B, Cooper M, De Zeeuw D, Keane W, Mitch W, Parving H, Remuzzi G, 
Snapinn S, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular 
outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-
869.  
19. Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J, Ritz E, Atkins R, Rohde 
R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in 
patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.  
20. Mattock M, Barnes D, Viberti G, Keen H, Burt D, Hughes J, Fitzgerald A, Sandhu B, 
Jackson P. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. 
Diabetes 1998; 47:1786-1792.  
21. Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B, Halle J, Young J, 
Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, 
death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-
426.  
22. London G, Drueke T. Atherosclerosis and arteriosclerosis in chronic renal failure. 
Kidney Int 1997; 51:1678-1695.  
23. Amann K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of 
uremic patients. J Am Soc Nephrol 1998; 9:1018-1022.  
  153 
24. Cheung A, Sarnak M, Yan G, Dwyer J, Heyka R, Rocco M, Teehan B, Levey A. 
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 
2000; 58:353-362.  
25. Guyton A, Coleman T. Quantitative analysis of the pathophysiology of hypertension. 
1969. J Am Soc Nephrol 1999; 10:2248-2258.  
26. Xu J, Li G, Wang P, Velazquez H, Yao X, Li Y, Wu Y, Peixoto A, Crowley S, Desir 
G. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and 
blood pressure. J Clin Invest 2005; 115:1275-1280.  
27. Yerkey MW. Renal dysfunction and acceleration of coronary disease. Heart 2004; 
90:961-966.  
28. Docci D, Manzoni G, Bilancioni R, Delvecchio C, Capponcini C, Baldrati L, Neri L, 
Feletti C. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic 
hemodialysis. Int J Artif Organs 1994; 17:41-45.  
29. Schiffrin EL, Lipman ML, Mann JFE. Chronic Kidney Disease: Effects on the 
Cardiovascular System. Circulation 2007; 116:85-97.  
30. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340:115-126.  
31. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage 
renal disease. J Am Soc Nephrol 2004; 15 Suppl 1:S77-80.  
32. Ignarro L, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the 
vascular system: an overview. J Cardiovasc Pharmacol 1999; 34:879-886.  
33. Touyz R, Yao G, Quinn M, Pagano P, Schiffrin E. p47phox associates with the 
cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H 
oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 2005; 25:512-518.  
34. Vaziri N, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and 
protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 
39:135-141.  
35. Vaziri N, Dicus M, Ho N, Boroujerdi-Rad L, Sindhu R. Oxidative stress and 
dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. 
Kidney Int 2003; 63:179-185.  
36. Yilmaz M, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten 
T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C. The 
determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric 
dimethylarginine. Am J Kidney Dis 2006; 47:42-50.  
  154 
37. Drueke T, Massy Z. Atherosclerosis in CKD: differences from the general population. 
Nat Rev Nephrol 2010; 6:723-735.  
38. Russo D, Palmiero G, De Blasio AP, Balletta M, Andreucci V. Coronary artery 
calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 
44:1024-1030.  
39. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke S, Chertow G. 
Cardiac calcification in adult hemodialysis patients. A link between end-stage renal 
disease and cardiovascular disease? J Am Coll Cardiol 2002; 39:695-701.  
40. Astor B, Muntner P, Levin A, Eustace J, Coresh J. Association of kidney function 
with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). 
Arch Intern Med 2002; 162:1401-1408.  
41. Walker A, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D. Anemia as a 
predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc 
Nephrol 2006; 17:2293-2298.  
42. Santoro A. Anemia in renal insufficiency. Rev Clin Exp Hematol 2002; Suppl 1:12-
20.  
43. Lipsic E, Schoemaker R, Van Der Meer P, Voors A, Van Veldhuisen DJ, Van Gilst 
WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J 
Am Coll Cardiol 2006; 48:2161-2167.  
44. Hage FG, Venkataraman R, Zoghbi GJ, Perry GJ, Demattos AM, Iskandrian AE. The 
Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease. JAC 2009; 
53:2129-2140.  
45. Shishehbor M, Oliveira L, Lauer M, Sprecher D, Wolski K, Cho L, Hoogwerf B, 
Hazen S. Emerging cardiovascular risk factors that account for a significant portion of 
attributable mortality risk in chronic kidney disease. Am J Cardiol 2008; 101:1741-1746.  
46.International Diabetes Federation. The Diabetes Atlas. 2011; 5th Edition 
47. US Renal Data System Annual Data Report: Atlas of Chronic Kidney Disease and 
End-Stage Renal Disease in the United States. National Institutes of Health, National 
Institute of Diabetes and Digestive and Kidney Diseases 2009;  
48. Shaw J, Sicree R, Zimmet P. Global estimates of the prevalence of diabetes for 2010 
and 2030. Diabetes research and clinical practice 2010; 87:4-14.  
49. US Renal Data System Annual Data Report: Morbidity and mortality in CKD 
patients: 2008;  
  155 
50. Patel T, Charytan DM. Cardiovascular complications in diabetic kidney disease. 
Seminars in dialysis 2010; 23:169-177.  
51. Feener E, King G. Vascular dysfunction in diabetes mellitus. Lancet 1997; 350 Suppl 
1:SI9-13.  
52. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications 
for vascular endothelial function. Biochem Biophys Res Commun 1999; 263:681-684.  
53. Beckman J, Creager M, Libby P. Diabetes and atherosclerosis: epidemiology, 
pathophysiology, and management. JAMA 2002; 287:2570-2581.  
54. Aronson D, Rayfield E. How hyperglycemia promotes atherosclerosis: molecular 
mechanisms. Cardiovasc Diabetol 2002; 1:1.  
55. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Current 
Molecular Medicine 2008; 8:533-543.  
56. Rahman S, Rahman T, Ismail A, Rashid A. Diabetes-associated macrovasculopathy: 
pathophysiology and pathogenesis. Diabetes Obes Metab 2007; 9:767-780.  
57. Johnston N, Dargie H, Jardine A. Diagnosis and treatment of coronary artery disease 
in patients with chronic kidney disease. Heart (British Cardiac Society) 2008; 94:1080-
1088.  
58. Jaber W, Difilippo F, Cerqueira M. Left ventricular hypertrophy and SPECT 
myocardial perfusion imaging: finding the diamonds in the rough. J Nucl Cardiol 2007; 
14:398-407.  
59. Mccullough P, Maynard R. Treatment disparities in acute coronary syndromes, heart 
failure, and kidney disease. Contrib Nephrol 2011; 171:68-73.  
60. Wheeler D, Becker G. Summary of KDIGO guideline. What do we really know about 
management of blood pressure in patients with chronic kidney disease? Kidney Int 2013; 
83:377-383.  
61. Fox C, Muntner P, Chen A, Alexander K, Roe M, Cannon C, Saucedo J, Kontos M, 
Wiviott S. Use of evidence-based therapies in short-term outcomes of ST-segment 
elevation myocardial infarction and non-ST-segment elevation myocardial infarction in 
patients with chronic kidney disease: a report from the National Cardiovascular Data 
Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 
2010; 121:357-365.  
62. Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A, Cairns H, Collins 
R, Foley R, Frighi V, Kourellias K, Ratcliffe P, Rogerson M, Scoble J, Tomson C, 
  156 
Warwick G, Wheeler D. First United Kingdom Heart and Renal Protection (UK-HARP-I) 
study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in 
chronic kidney disease. Am J Kidney Dis 2005; 45:473-484.  
63. Keltai M, Tonelli M, Mann J, Sitkei E, Lewis B, Hawken S, Mehta S, Yusuf S. Renal 
function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J 
Cardiovasc Prev Rehabil 2007; 14:312-318.  
64. Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K. Effects of clopidogrel 
in addition to aspirin in patients with acute coronary syndromes without ST-segment 
elevation. N Engl J Med 2001; 345:494-502.  
65. Baigent C, Landray M, Reith C, Emberson J, Wheeler D, Tomson C, Wanner C, 
Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi L, Levin A, Agodoa L, Gaziano M, 
Kasiske B, Walker R, Massy Z, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, 
Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, De Zeeuw D, Gronhagen-Riska 
C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm 
R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott 
C, Parish S, Simpson D, Sleight P, Young A, Collins R. The effects of lowering LDL 
cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study 
of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 
377:2181-2192.  
66. Seliger S, Weiss N, Gillen D, Kestenbaum B, Ball A, Sherrard D, Stehman-Breen 
CO. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD 
patients. Kidney Int 2002; 61:297-304.  
67. Tonelli M, Moye L, Sacks F, Kiberd B, Curhan G. Pravastatin for secondary 
prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann 
Intern Med 2003; 138:98-104.  
68. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo P, Golino 
P, Calabro R. Carvedilol increases two-year survivalin dialysis patients with dilated 
cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 
41:1438-1444.  
69. Gottlieb S, Mccarter R, Vogel R. Effect of beta-blockade on mortality among high-
risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339:489-497.  
70. Drueke T, Locatelli F, Clyne N, Eckardt K, Macdougall I, Tsakiris D, Burger H, 
Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease 
and anemia. N Engl J Med 2006; 355:2071-2084.  
  157 
71. Singh A, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction 
of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085-
2098.  
72. Pfeffer M, Burdmann E, Chen C, Cooper M, De Zeeuw D, Eckardt K, Feyzi J, 
Ivanovich P, Kewalramani R, Levey A, Lewis E, Mcgill J, Mcmurray J, Parfrey P, 
Parving H, Remuzzi G, Singh A, Solomon S, Toto R. A trial of darbepoetin alfa in type 2 
diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019-2032.  
73. Drueke T, Parfrey P. Summary of the KDIGO guideline on anemia and comment: 
reading between the (guide)line(s). Kidney Int 2012; 82:952-960.  
74. Bhuriya R, Li S, Chen S, Mccullough P, Bakris G. Plasma parathyroid hormone level 
and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney 
Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53:S3-10.  
75. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and 
treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney 
Int Suppl 2009; S1-130.  
76. Fioretto P, Bruseghin M, Berto I, Gallina P, Manzato E, Mussap M. Renal protection 
in diabetes: role of glycemic control. J Am Soc Nephrol 2006; 17:S86-9.  
77. Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T, Raskin P, Zinman B. 
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N 
Engl J Med 2005; 353:2643-2653.  
78. Patel A, Macmahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper 
M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen C, 
Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, De Galan BE, Joshi R, Travert F. 
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N 
Engl J Med 2008; 358:2560-2572.  
79. Gerstein H, Miller M, Byington R, Goff DJ, Bigger J, Buse J, Cushman W, Genuth S, 
Ismail-Beigi F, Grimm RJ, Probstfield J, Simons-Morton DG, Friedewald W. Effects of 
intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559.  
80. Boden W, O'Rourke RA, Teo K, Hartigan P, Maron D, Kostuk W, Knudtson M, Dada 
M, Casperson P, Harris C, Chaitman B, Shaw L, Gosselin G, Nawaz S, Title L, Gau G, 
Blaustein A, Booth D, Bates E, Spertus J, Berman D, Mancini G, Weintraub W. Optimal 
medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 
356:1503-1516.  
  158 
81. De Bruyne B, Pijls N, Kalesan B, Barbato E, Tonino P, Piroth Z, Jagic N, Mobius-
Winkler S, Rioufol G, Witt N, Kala P, Maccarthy P, Engstrom T, Oldroyd K, Mavromatis 
K, Manoharan G, Verlee P, Frobert O, Curzen N, Johnson J, Juni P, Fearon W. Fractional 
flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 
2012; 367:991-1001.  
82. Shaw L, Berman D, Maron D, Mancini G, Hayes S, Hartigan P, Weintraub W, 
O'Rourke RA, Dada M, Spertus J, Chaitman B, Friedman J, Slomka P, Heller G, 
Germano G, Gosselin G, Berger P, Kostuk W, Schwartz R, Knudtson M, Veledar E, 
Bates E, Mccallister B, Teo K, Boden W. Optimal medical therapy with or without 
percutaneous coronary intervention to reduce ischemic burden: results from the Clinical 
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) 
trial nuclear substudy. Circulation 2008; 117:1283-1291.  
83. Caracciolo E, Davis K, Sopko G, Kaiser G, Corley S, Schaff H, Taylor H, Chaitman 
B. Comparison of surgical and medical group survival in patients with left main 
equivalent coronary artery disease. Long-term CASS experience. Circulation 1995; 
91:2335-2344.  
84. Passamani E, Davis K, Gillespie M, Killip T. A randomized trial of coronary artery 
bypass surgery. Survival of patients with a low ejection fraction. N Engl J Med 1985; 
312:1665-1671.  
85. Marso S, Gimple L, Philbrick J, Dimarco J. Effectiveness of percutaneous coronary 
interventions to prevent recurrent coronary events in patients on chronic hemodialysis. 
Am J Cardiol 1998; 82:378-380.  
86. Stone G, Ellis S, Cox D, Hermiller J, O'Shaughnessy C, Mann J, Turco M, Caputo R, 
Bergin P, Greenberg J, Popma J, Russell M. One-year clinical results with the slow-
release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 
2004; 109:1942-1947.  
87. Best P, Lennon R, Ting H, Bell M, Rihal C, Holmes D, Berger P. The impact of renal 
insufficiency on clinical outcomes in patients undergoing percutaneous coronary 
interventions. J Am Coll Cardiol 2002; 39:1113-1119.  
88. Best P, Berger P, Davis B, Grines C, Sadeghi H, Williams B, Willerson J, Granett J, 
Holmes DJ. Impact of mild or moderate chronic kidney disease on the frequency of 
restenosis: results from the PRESTO trial. J Am Coll Cardiol 2004; 44:1786-1791.  
  159 
89. Blackman D, Pinto R, Ross J, Seidelin P, Ing D, Jackevicius C, Mackie K, Chan C, 
Dzavik V. Impact of renal insufficiency on outcome after contemporary percutaneous 
coronary intervention. Am Heart J 2006; 151:146-152.  
90. Papafaklis M, Naka K, Papamichael N, Kolios G, Sioros L, Sclerou V, Katsouras C, 
Michalis L. The impact of renal function on the long-term clinical course of patients who 
underwent percutaneous coronary intervention. Catheter Cardiovasc Interv 2007; 69:189-
197.  
91. Mishkel G, Varghese J, Moore A, Aguirre F, Markwell S, Shelton M. Short- and 
long-term clinical outcomes of coronary drug-eluting stent recipients presenting with 
chronic renal disease. J Invasive Cardiol 2007; 19:331-337.  
92. Halkin A, Mehran R, Casey C, Gordon P, Matthews R, Wilson B, Leon M, Russell 
M, Ellis S, Stone G. Impact of moderate renal insufficiency on restenosis and adverse 
clinical events after paclitaxel-eluting and bare metal stent implantation: results from the 
TAXUS-IV Trial. Am Heart J 2005; 150:1163-1170.  
93. Zhang R, Ni J, Zhang J, Hu J, Yang Z, Zhang Q, Lu A, Shen W. Long term clinical 
outcomes in patients with moderate renal insufficiency undergoing stent based 
percutaneous coronary intervention. Chin Med J (Engl) 2006; 119:1176-1181.  
94. Nakazawa G, Tanabe K, Aoki J, Yamamoto H, Higashikuni Y, Onuma Y, Yachi S, 
Nakajima H, Hara K. Impact of renal insufficiency on clinical and angiographic outcomes 
following percutaneous coronary intervention with sirolimus-eluting stents. Catheter 
Cardiovasc Interv 2007; 69:808-814.  
95. Latif F, Kleiman N, Cohen D, Pencina M, Yen C, Cutlip D, Moliterno D, Nassif D, 
Lopez J, Saucedo J. In-hospital and 1-year outcomes among percutaneous coronary 
intervention patients with chronic kidney disease in the era of drug-eluting stents: a report 
from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. 
JACC Cardiovasc Interv 2009; 2:37-45.  
96. Hillis G, Zehr K, Williams A, Schaff H, Orzulak T, Daly R, Mullany C, Rodeheffer 
R, Oh J. Outcome of patients with low ejection fraction undergoing coronary artery 
bypass grafting: renal function and mortality after 3.8 years. Circulation 2006; 114:I414-
9.  
97. Hemmelgarn B, Southern D, Culleton B, Mitchell L, Knudtson M, Ghali W. Survival 
after coronary revascularization among patients with kidney disease. Circulation 2004; 
110:1890-1895.  
  160 
98. Brown J, Cochran R, Leavitt B, Dacey L, Ross C, Mackenzie T, Kunzelman K, 
Kramer R, Hernandez FJ, Helm R, Westbrook B, Dunton R, Malenka D, O'Connor GT. 
Multivariable prediction of renal insufficiency developing after cardiac surgery. 
Circulation 2007; 116:I139-43.  
99. Brown J, Kramer R, Coca S, Parikh C. Duration of acute kidney injury impacts long-
term survival after cardiac surgery. Ann Thorac Surg 2010; 90:1142-1148.  
100. Chertow G, Lazarus J, Christiansen C, Cook E, Hammermeister K, Grover F, Daley 
J. Preoperative renal risk stratification. Circulation 1997; 95:878-884.  
101. Coca S, Yusuf B, Shlipak M, Garg A, Parikh C. Long-term risk of mortality and 
other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. 
Am J Kidney Dis 2009; 53:961-973.  
102. Karkouti K, Wijeysundera D, Yau T, Callum J, Cheng D, Crowther M, Dupuis J, 
Fremes S, Kent B, Laflamme C, Lamy A, Legare J, Mazer C, Mccluskey S, Rubens F, 
Sawchuk C, Beattie W. Acute kidney injury after cardiac surgery: focus on modifiable 
risk factors. Circulation 2009; 119:495-502.  
103. Mangano C, Diamondstone L, Ramsay J, Aggarwal A, Herskowitz A, Mangano D. 
Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and 
hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research 
Group. Ann Intern Med 1998; 128:194-203.  
104. Mehta R, Grab J, O'Brien SM, Bridges C, Gammie J, Haan C, Ferguson T, Peterson 
E. Bedside tool for predicting the risk of postoperative dialysis in patients undergoing 
cardiac surgery. Circulation 2006; 114:2208-16; quiz 2208.  
105. Palomba H, De Castro I, Neto A, Lage S, Yu L. Acute kidney injury prediction 
following elective cardiac surgery: AKICS Score. Kidney Int 2007; 72:624-631.  
106. Thakar C, Arrigain S, Worley S, Yared J, Paganini E. A clinical score to predict 
acute renal failure after cardiac surgery. J Am Soc Nephrol 2005; 16:162-168.  
107. Wijeysundera D, Karkouti K, Dupuis J, Rao V, Chan C, Granton J, Beattie W. 
Derivation and validation of a simplified predictive index for renal replacement therapy 
after cardiac surgery. JAMA 2007; 297:1801-1809.  
108. Hudson C, Hudson J, Swaminathan M, Shaw A, Stafford-Smith M, Patel UD. 
Emerging Concepts in Acute Kidney Injury Following Cardiac Surgery. Seminars in 
Cardiothoracic and Vascular Anesthesia 2008; 12:320-330.  
  161 
109. Kumar AB, Suneja M. Cardiopulmonary bypass-associated acute kidney injury. 
Anesthesiology 2011; 114:964-970.  
110. Bellomo R, Ronco C, Kellum J, Mehta R, Palevsky P. Acute renal failure - 
definition, outcome measures, animal models, fluid therapy and information technology 
needs: the Second International Consensus Conference of the Acute Dialysis Quality 
Initiative (ADQI) Group. Crit Care 2004; 8:R204-12.  
111. Mehta R, Kellum J, Shah S, Molitoris B, Ronco C, Warnock D, Levin A. Acute 
Kidney Injury Network: report of an initiative to improve outcomes in acute kidney 
injury. Crit Care 2007; 11:R31.  
112. Mehta R, Chertow G. Acute renal failure definitions and classification: time for 
change? J Am Soc Nephrol 2003; 14:2178-2187.  
113. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann L, Druml W, Bauer P, 
Hiesmayr M. Minimal changes of serum creatinine predict prognosis in patients after 
cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol 2004; 15:1597-
1605.  
114. Mehta RH, Honeycutt E, Patel UD, Lopes RD, Shaw LK, Glower DD, Harrington 
RA, Califf RM, Sketch MH. Impact of Recovery of Renal Function on Long-Term 
Mortality After Coronary Artery Bypass Grafting. AJC 2010; 106:1728-1734.  
115. Dasta J, Kane-Gill SL, Durtschi A, Pathak D, Kellum J. Costs and outcomes of acute 
kidney injury (AKI) following cardiac surgery. Nephrol Dial Transplant 2008; 23:1970-
1974.  
116. Okusa M. The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 
90:133-138.  
117. Sutton T, Fisher C, Molitoris B. Microvascular endothelial injury and dysfunction 
during ischemic acute renal failure. Kidney Int 2002; 62:1539-1549.  
118. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute Kidney Injury: A 
Relevant Complication After Cardiac Surgery. ATS 2011; 92:1539-1547.  
119. Harris E, Seelye E, Barratt-Boyes BG. On the availability of oxygen to the body 
during cardiopulmonary bypass in man. Br J Anaesth 1974; 46:425-431.  
120. Rosner M, Portilla D, Okusa M. Cardiac surgery as a cause of acute kidney injury: 
pathogenesis and potential therapies. J Intensive Care Med 2008; 23:3-18.  
121. Palmer B. Renal dysfunction complicating the treatment of hypertension. N Engl J 
Med 2002; 347:1256-1261.  
  162 
122. Kelleher S, Robinette J, Conger J. Sympathetic nervous system in the loss of 
autoregulation in acute renal failure. Am J Physiol 1984; 246:F379-86.  
123. Pathi V, Morrison J, Macphaden A, Martin W, Mcquiston A, Wheatley D. 
Alterations in renal microcirculation during cardiopulmonary bypass. Ann Thorac Surg 
1998; 65:993-998.  
124. Cremer J, Martin M, Redl H, Bahrami S, Abraham C, Graeter T, Haverich A, Schlag 
G, Borst H. Systemic inflammatory response syndrome after cardiac operations. Ann 
Thorac Surg 1996; 61:1714-1720.  
125. Burne-Taney MJ, Rabb H. The role of adhesion molecules and T cells in ischemic 
renal injury. Curr Opin Nephrol Hypertens 2003; 12:85-90.  
126. Sheridan A, Bonventre J. Cell biology and molecular mechanisms of injury in 
ischemic acute renal failure. Curr Opin Nephrol Hypertens 2000; 9:427-434.  
127. Sreeram G, Grocott H, White W, Newman M, Stafford-Smith M. Transcranial 
Doppler emboli count predicts rise in creatinine after coronary artery bypass graft 
surgery. J Cardiothorac Vasc Anesth 2004; 18:548-551.  
128. Salis S, Mazzanti V, Merli G, Salvi L, Tedesco C, Veglia F, Sisillo E. 
Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality 
after cardiac surgery. J Cardiothorac Vasc Anesth 2008; 22:814-822.  
129. Ferraris V, Ferraris S, Saha S, Hessel EN, Haan C, Royston B, Bridges C, Higgins 
R, Despotis G, Brown J, Spiess B, Shore-Lesserson L, Stafford-Smith M, Mazer C, 
Bennett-Guerrero E, Hill S, Body S. Perioperative blood transfusion and blood 
conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of 
Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 
83:S27-86.  
130. Magee M, Edgerton J. Beating heart coronary artery bypass: operative strategy and 
technique. Semin Thorac Cardiovasc Surg 2003; 15:83-91.  
131. Nigwekar S, Kandula P, Hix J, Thakar C. Off-pump coronary artery bypass surgery 
and acute kidney injury: a meta-analysis of randomized and observational studies. Am J 
Kidney Dis 2009; 54:413-423.  
132. Hix J, Thakar C, Katz E, Yared J, Sabik J, Paganini E. Effect of off-pump coronary 
artery bypass graft surgery on postoperative acute kidney injury and mortality. Crit Care 
Med 2006; 34:2979-2983.  
  163 
133. Patel NN, Rogers CA, Angelini GD, Murphy GJ. Pharmacological therapies for the 
prevention of acute kidney injury following cardiac surgery: a systematic review. Heart 
Failure Reviews 2011; 16:553-567.  
134. Bove T, Landoni G, Calabro M, Aletti G, Marino G, Cerchierini E, Crescenzi G, 
Zangrillo A. Renoprotective action of fenoldopam in high-risk patients undergoing 
cardiac surgery: a prospective, double-blind, randomized clinical trial. Circulation 2005; 
111:3230-3235.  
135. Caimmi P, Pagani L, Micalizzi E, Fiume C, Guani S, Bernardi M, Parodi F, Cordero 
G, Fregonara M, Kapetanakis E, Panella M, Degasperis C. Fenoldopam for renal 
protection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth 
2003; 17:491-494.  
136. Halpenny M, Lakshmi S, O'Donnell A, O'Callaghan-Enright S, Shorten G. 
Fenoldopam: renal and splanchnic effects in patients undergoing coronary artery bypass 
grafting. Anaesthesia 2001; 56:953-960.  
137. Mahesh B, Yim B, Robson D, Pillai R, Ratnatunga C, Pigott D. Does furosemide 
prevent renal dysfunction in high-risk cardiac surgical patients? Results of a double-
blinded prospective randomised trial. Eur J Cardiothorac Surg 2008; 33:370-376.  
138. Yallop K, Sheppard S, Smith D. The effect of mannitol on renal function following 
cardio-pulmonary bypass in patients with normal pre-operative creatinine. Anaesthesia 
2008; 63:576-582.  
139. Boerrigter G, Burnett JJ. Natriuretic peptides renal protective after all? J Am Coll 
Cardiol 2011; 58:904-906.  
140. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, Kimura H, Shiono M, 
Takayama T, Hirayama A. Results of low-dose human atrial natriuretic peptide infusion 
in nondialysis patients with chronic kidney disease undergoing coronary artery bypass 
grafting: the NU-HIT (Nihon University working group study of low-dose HANP 
Infusion Therapy during cardiac surgery) trial for CKD. J Am Coll Cardiol 2011; 58:897-
903.  
141. Prowle J, Calzavacca P, Licari E, Ligabo E, Echeverri J, Haase M, Haase-Fielitz A, 
Bagshaw S, Devarajan P, Bellomo R. Pilot double-blind, randomized controlled trial of 
short-term atorvastatin for prevention of acute kidney injury after cardiac surgery. 
Nephrology (Carlton) 2012; 17:215-224.  
  164 
142. Zacharias M, Gilmore I, Herbison G, Sivalingam P, Walker R. Interventions for 
protecting renal function in the perioperative period. Cochrane Database Syst Rev 2005; 
CD003590.  
143. Haase M, Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Reade 
M, Bagshaw S, Seevanayagam N, Seevanayagam S, Doolan L, Buxton B, Dragun D. 
Sodium bicarbonate to prevent increases in serum creatinine after cardiac surgery: a pilot 
double-blind, randomized controlled trial. Crit Care Med 2009; 37:39-47.  
144. Ali ZA, Callaghan CJ, Lim E, Ali AA, Reza Nouraei SA, Akthar AM, Boyle JR, 
Varty K, Kharbanda RK, Dutka DP, Gaunt ME. Remote Ischemic Preconditioning 
Reduces Myocardial and Renal Injury After Elective Abdominal Aortic Aneurysm 
Repair: A Randomized Controlled Trial. Circulation 2007; 116:I-98-I-105.  
145. Venugopal V, Laing CM, Ludman A, Yellon DM, Hausenloy D. Effect of Remote 
Ischemic Preconditioning on Acute Kidney Injury in Nondiabetic Patients Undergoing 
Coronary Artery Bypass Graft Surgery: A Secondary Analysis of 2 Small Randomized 
Trials. American Journal of Kidney Diseases 2010; 56:1043-1049.  
146. Rahman I, Mascaro J, Steeds R, Frenneaux M, Nightingale P, Gosling P, Townsend 
P, Townend J, Green D, Bonser R. Remote ischemic preconditioning in human coronary 
artery bypass surgery: from promise to disappointment? Circulation 2010; 122:S53-9.  
147. Choi Y, Shim J, Kim J, Kang K, Seo Y, Ahn K, Yl K. Effect of remote ischemic 
preconditioning on renal dysfunction after complex valvular heart surgery: A randomized 
controlled trial. The Journal of Thoracic and Cardiovascular Surgery 2011; 1-8.  
148. Zimmerman RF, Ezeanuna PU, Kane JC, Cleland CD, Kempananjappa TJ, Lucas 
FL, Kramer RS. Ischemic preconditioning at a remote site prevents acute kidney injury in 
patients following cardiac surgery. Kidney International 2011; 1-7.  
149. Durmaz I, Yagdi T, Calkavur T, Mahmudov R, Apaydin A, Posacioglu H, Atay Y, 
Engin C. Prophylactic dialysis in patients with renal dysfunction undergoing on-pump 
coronary artery bypass surgery. Ann Thorac Surg 2003; 75:859-864.  
150. Hillis G, Croal B, Buchan K, El-Shafei H, Gibson G, Jeffrey R, Millar C, Prescott G, 
Cuthbertson B. Renal function and outcome from coronary artery bypass grafting: impact 
on mortality after a 2.3-year follow-up. Circulation 2006; 113:1056-1062.  
151. Holzmann M, Hammar N, Ahnve S, Nordqvist T, Pehrsson K, Ivert T. Renal 
insufficiency and long-term mortality and incidence of myocardial infarction in patients 
undergoing coronary artery bypass grafting. Eur Heart J 2007; 28:865-871.  
  165 
152. Howell N, Keogh B, Bonser R, Graham T, Mascaro J, Rooney S, Wilson I, Pagano 
D. Mild renal dysfunction predicts in-hospital mortality and post-discharge survival 
following cardiac surgery. Eur J Cardiothorac Surg 2008; 34:390-5; discussion 395.  
153. Durmaz I, Buket S, Atay Y, Yagdi T, Ozbaran M, Boga M, Alat I, Guzelant A, 
Basarir S. Cardiac surgery with cardiopulmonary bypass in patients with chronic renal 
failure. J Thorac Cardiovasc Surg 1999; 118:306-315.  
154. Jyrala A, Weiss R, Jeffries R, Kay G. Effect of mild renal dysfunction (s-crea 1.2-
2.2 mg/dl) on presentation characteristics and short- and long-term outcomes of on-pump 
cardiac surgery patients. Interact Cardiovasc Thorac Surg 2010; 10:777-782.  
155. Rao V, Weisel R, Buth K, Cohen G, Borger M, Shiono N, Bhatnagar G, Fremes S, 
Goldman B, Christakis G. Coronary artery bypass grafting in patients with non-dialysis-
dependent renal insufficiency. Circulation 1997; 96:II-38-43; discussion II-44-5.  
156. Weerasinghe A, Hornick P, Smith P, Taylor K, Ratnatunga C. Coronary artery 
bypass grafting in non-dialysis-dependent mild-to-moderate renal dysfunction. J Thorac 
Cardiovasc Surg 2001; 121:1083-1089.  
157. Roques F, Nashef S, Michel P, Gauducheau E, De Vincentiis C, Baudet E, Cortina J, 
David M, Faichney A, Gabrielle F, Gams E, Harjula A, Jones M, Pintor P, Salamon R, 
Thulin L. Risk factors and outcome in European cardiac surgery: analysis of the 
EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 
15:816-22; discussion 822-3.  
158. Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D. A more accurate method to 
estimate glomerular filtration rate from serum creatinine: a new prediction equation. 
Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-470.  
159. Choi J, Kim C, Bae E, Ma S, Ahn Y, Jeong M, Kim Y, Cho M, Kim C, Kim S. 
Predicting outcomes after myocardial infarction by using the Chronic Kidney Disease 
Epidemiology Collaboration equation in comparison with the Modification of Diet in 
Renal Disease study equation: results from the Korea Acute Myocardial Infarction 
Registry. Nephrol Dial Transplant 2012;  
160. Zhang R, Zhu Z, Zhang Q, Yang Z, Hu J, Lv A, Zhang J, Shen W. Impact of 
moderate or severe renal insufficiency on long-term outcomes in patients undergoing 
drug-eluting stent based coronary intervention. Int J Cardiol 2009; 136:72-79.  
161. Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney 
disease. Nat Rev Nephrol 2009; 5:287-296.  
  166 
162. Mccullough P. Cardiorenal risk: an important clinical intersection. Rev Cardiovasc 
Med 2002; 3:71-76.  
163. Hillis G, Cuthbertson B, Croal B. Renal function, revascularization and risk. Eur 
Heart J 2007; 28:782-784.  
164. Giachelli C. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15:2959-
2964.  
165. Berry J, Keebler M, Mcguire D. Diabetes mellitus and cardiovascular disease. 
Pandora's box has been opened. Herz 2004; 29:456-462.  
166. Sarnak M, Levey A, Schoolwerth A, Coresh J, Culleton B, Hamm L, Mccullough P, 
Kasiske B, Kelepouris E, Klag M, Parfrey P, Pfeffer M, Raij L, Spinosa D, Wilson P. 
Kidney disease as a risk factor for development of cardiovascular disease: a statement 
from the American Heart Association Councils on Kidney in Cardiovascular Disease, 
High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. 
Circulation 2003; 108:2154-2169.  
167. Leavitt BJ. Effect of Diabetes and Associated Conditions on Long-Term Survival 
After Coronary Artery Bypass Graft Surgery. Circulation 2004; 110:II-41-II-44.  
168. Marso S, Ellis S, Gurm H, Lytle B, Topol E. Proteinuria is a key determinant of 
death in patients with diabetes after isolated coronary artery bypass grafting. Am Heart J 
2000; 139:939-944.  
169. Ryckwaert F, Boccara G, Frappier J, Colson P. Incidence, risk factors, and prognosis 
of a moderate increase in plasma creatinine early after cardiac surgery. Crit Care Med 
2002; 30:1495-1498.  
170. Bihorac A, Yavas S, Subbiah S, Hobson C, Schold J, Gabrielli A, Layon A, Segal 
M. Long-term risk of mortality and acute kidney injury during hospitalization after major 
surgery. Ann Surg 2009; 249:851-858.  
171. Thakar C, Worley S, Arrigain S, Yared J, Paganini E. Improved survival in acute 
kidney injury after cardiac surgery. Am J Kidney Dis 2007; 50:703-711.  
172. Rosner M, Okusa M. Acute kidney injury associated with cardiac surgery. Clin J Am 
Soc Nephrol 2006; 1:19-32.  
173. Brown J, Cochran R, Mackenzie T, Furnary A, Kunzelman K, Ross C, Langner C, 
Charlesworth D, Leavitt B, Dacey L, Helm R, Braxton J, Clough R, Dunton R, O'Connor 
GT. Long-term survival after cardiac surgery is predicted by estimated glomerular 
filtration rate. Ann Thorac Surg 2008; 86:4-11.  
  167 
174. Braunwald E, Kloner R. Myocardial reperfusion: a double-edged sword? J Clin 
Invest 1985; 76:1713-1719.  
175. Yellon D, Hausenloy D. Myocardial reperfusion injury. N Engl J Med 2007; 
357:1121-1135.  
176. Halestrap A, Clarke S, Javadov S. Mitochondrial permeability transition pore 
opening during myocardial reperfusion--a target for cardioprotection. Cardiovasc Res 
2004; 61:372-385.  
177. Turer A, Hill J. Pathogenesis of myocardial ischemia-reperfusion injury and 
rationale for therapy. Am J Cardiol 2010; 106:360-368.  
178. Kharbanda R. Cardiac conditioning: a review of evolving strategies to reduce 
ischaemia-reperfusion injury. Heart 2010; 96:1179-1186.  
179. Murry C, Jennings R, Reimer K. Preconditioning with ischemia: a delay of lethal 
cell injury in ischemic myocardium. Circulation 1986; 74:1124-1136.  
180. Cao C, Wang S, Fan L, Wan X, Liu X, Chen X. Renal protection by ischemic 
preconditioning is associated with p50/p50 homodimers. Am J Nephrol 2010; 31:1-8.  
181. Selzner M, Rudiger H, Selzner N, Thomas D, Sindram D, Clavien P. Transgenic 
mice overexpressing human Bcl-2 are resistant to hepatic ischemia and reperfusion. J 
Hepatol 2002; 36:218-225.  
182. Lusardi T, Farr C, Faulkner C, Pignataro G, Yang T, Lan J, Simon R, Saugstad J. 
Ischemic preconditioning regulates expression of microRNAs and a predicted target, 
MeCP2, in mouse cortex. J Cereb Blood Flow Metab 2010; 30:744-756.  
183. Burley D, Ferdinandy P, Baxter G. Cyclic GMP and protein kinase-G in myocardial 
ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 
2007; 152:855-869.  
184. Hausenloy D, Yellon D. New directions for protecting the heart against ischaemia-
reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. 
Cardiovasc Res 2004; 61:448-460.  
185. Lecour S. Activation of the protective Survivor Activating Factor Enhancement 
(SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J Mol 
Cell Cardiol 2009; 47:32-40.  
186. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: Underlying 
mechanisms and clinical application. Atherosclerosis 2009; 204:334-341.  
  168 
187. Marber M, Latchman D, Walker J, Yellon D. Cardiac stress protein elevation 24 
hours after brief ischemia or heat stress is associated with resistance to myocardial 
infarction. Circulation 1993; 88:1264-1272.  
188. Yellon D, Alkhulaifi A, Pugsley W. Preconditioning the human myocardium. Lancet 
1993; 342:276-277.  
189. Walsh S, Tang T, Kullar P, Jenkins D, Dutka D, Gaunt M. Ischaemic 
preconditioning during cardiac surgery: systematic review and meta-analysis of 
perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg 2008; 
34:985-994.  
190. Vaage J, Valen G. Preconditioning and cardiac surgery. Ann Thorac Surg 2003; 
75:S709-14.  
191. Przyklenk K, Bauer B, Ovize M, Kloner R, Whittaker P. Regional ischemic 
'preconditioning' protects remote virgin myocardium from subsequent sustained coronary 
occlusion. Circulation 1993; 87:893-899.  
192. Gho B, Schoemaker R, Van Den Doel MA, Duncker D, Verdouw P. Myocardial 
protection by brief ischemia in noncardiac tissue. Circulation 1996; 94:2193-2200.  
193. Birnbaum Y, Hale S, Kloner R. Ischemic preconditioning at a distance: reduction of 
myocardial infarct size by partial reduction of blood supply combined with rapid 
stimulation of the gastrocnemius muscle in the rabbit. Circulation 1997; 96:1641-1646.  
194. Dickson E, Lorbar M, Porcaro W, Fenton R, Reinhardt C, Gysembergh A, 
Przyklenk K. Rabbit heart can be "preconditioned" via transfer of coronary effluent. Am J 
Physiol 1999; 277:H2451-7.  
195. Kharbanda R, Mortensen U, White P, Kristiansen S, Schmidt M, Hoschtitzky J, 
Vogel M, Sorensen K, Redington A, Macallister R. Transient limb ischemia induces 
remote ischemic preconditioning in vivo. Circulation 2002; 106:2881-2883.  
196. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an 
update. Nature Publishing Group 2011; 8:619-629.  
197. Gunaydin B, Cakici I, Soncul H, Kalaycioglu S, Cevik C, Sancak B, Kanzik I, 
Karadenizli Y. Does remote organ ischaemia trigger cardiac preconditioning during 
coronary artery surgery? Pharmacol Res 2000; 41:493-496.  
198. Cheung M, Kharbanda R, Konstantinov I, Shimizu M, Frndova H, Li J, Holtby H, 
Cox P, Smallhorn J, Van Arsdell GS, Redington A. Randomized controlled trial of the 
  169 
effects of remote ischemic preconditioning on children undergoing cardiac surgery: first 
clinical application in humans. J Am Coll Cardiol 2006; 47:2277-2282.  
199. Hausenloy D, Mwamure P, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, 
Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, Macallister R, Yellon D. 
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing 
coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007; 
370:575-579.  
200. Venugopal V, Hausenloy D, Ludman A, Di Salvo C, Kolvekar S, Yap J, Lawrence 
D, Bognolo J, Yellon D. Remote ischaemic preconditioning reduces myocardial injury in 
patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised 
controlled trial. Heart 2009; 95:1567-1571.  
201. Zhou W, Zeng D, Chen R, Liu J, Yang G, Liu P, Zhou X. Limb ischemic 
preconditioning reduces heart and lung injury after an open heart operation in infants. 
Pediatr Cardiol 2010; 31:22-29.  
202. Thielmann M, Kottenberg E, Boengler K, Raffelsieper C, Neuhaeuser M, Peters J, 
Jakob H, Heusch G. Remote ischemic preconditioning reduces myocardial injury after 
coronary artery bypass surgery with crystalloid cardioplegic arrest. Basic Res Cardiol 
2010; 105:657-664.  
203. Wagner R, Piler P, Bedanova H, Adamek P, Grodecka L, Freiberger T. Myocardial 
injury is decreased by late remote ischaemic preconditioning and aggravated by tramadol 
in patients undergoing cardiac surgery: a randomised controlled trial. Interact Cardiovasc 
Thorac Surg 2010; 11:758-762.  
204. Ali N, Rizwi F, Iqbal A, Rashid A. Induced remote ischemic pre-conditioning on 
ischemia-reperfusion injury in patients undergoing coronary artery bypass. J Coll 
Physicians Surg Pak 2010; 20:427-431.  
205. Xie J, Liao X, Chen W, Huang D, Chang F, Chen W, Luo Z, Wang Z, Ou J. Remote 
ischaemic preconditioning reduces myocardial injury in patients undergoing heart valve 
surgery: randomised controlled trial. Heart 2012; 98:384-388.  
206. Young P, Dalley P, Garden A, Horrocks C, La Flamme A, Mahon B, Miller J, 
Pilcher J, Weatherall M, Williams J, Young W, Beasley R. A pilot study investigating the 
effects of remote ischemic preconditioning in high-risk cardiac surgery using a 
randomised controlled double-blind protocol. Basic Res Cardiol 2012; 107:256.  
207. Peters J. Remote ischaemic preconditioning of the heart: remote questions, remote 
importance, or remote preconditions? Basic Res Cardiol 2011; 106:507-509.  
  170 
208. Kokita N, Hara A, Abiko Y, Arakawa J, Hashizume H, Namiki A. Propofol 
improves functional and metabolic recovery in ischemic reperfused isolated rat hearts. 
Anesth Analg 1998; 86:252-258.  
209. Ferdinandy P, Schulz R, Baxter GF. Interaction of Cardiovascular Risk Factors with 
Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning. 
Pharmacological Reviews 2007; 59:418-458.  
210. Whittington H, Babu G, Mocanu M, Yellon D, Hausenloy D. The diabetic heart: too 
sweet for its own good? Cardiol Res Pract 2012; 2012:845698.  
211. Lavi S, Lavi R. Conditioning of the heart: from pharmacological interventions to 
local and remote protection: possible implications for clinical practice. Int J Cardiol 2011; 
146:311-318.  
212. Ghosh S, Galinanes M. Protection of the human heart with ischemic preconditioning 
during cardiac surgery: role of cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003; 
126:133-142.  
213. Pedersen K, Ravn H, Povlsen J, Schmidt M, Erlandsen E, Hjortdal V. Failure of 
remote ischemic preconditioning to reduce the risk of postoperative acute kidney injury in 
children undergoing operation for complex congenital heart disease: a randomized single-
center study. J Thorac Cardiovasc Surg 2012; 143:576-583.  
214. Byrne C, Mccafferty K, Kieswich J, Harwood S, Andrikopoulos P, Raftery M, 
Thiemermann C, Yaqoob M. Ischemic conditioning protects the uremic heart in a rodent 
model of myocardial infarction. Circulation 2012; 125:1256-1265.  
215. Bridgewater B Society of Cardiothoracic Surgeons of Great Britain and Ireland:  
Effect of Diabetes and Chronic Kidney Disease on Long-Term Survival After Coronary 
Artery Bypass Grafting. 2012. 
216. Er F, Nia A, Dopp H, Hellmich M, Dahlem K, Caglayan E, Kubacki T, Benzing T, 
Erdmann E, Burst V, Gassanov N. Ischemic preconditioning for prevention of contrast 
medium-induced nephropathy: randomized pilot RenPro Trial (Renal Protection Trial). 
Circulation 2012; 126:296-303.  
217. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like 
biomarker for human acute kidney injury. Nephrology (Carlton, Vic) 2010; 15:419-428.  
218. Domanski M, Mahaffey K, Hasselblad V, Brener S, Smith P, Hillis G, Engoren M, 
Alexander J, Levy J, Chaitman B, Broderick S, Mack M, Pieper K, Farkouh M. 
  171 
Association of myocardial enzyme elevation and survival following coronary artery 
bypass graft surgery. JAMA 2011; 305:585-591.  
219. Apple F, Murakami M, Pearce L, Herzog C. Predictive value of cardiac troponin I 
and T for subsequent death in end-stage renal disease. Circulation 2002; 106:2941-2945.  
220. Jaffe AS. The 10 commandments of troponin, with special reference to high 
sensitivity assays. Heart (British Cardiac Society) 2011; 97:940-946.  
221. George S, Singh A. Current markers of myocardial ischemia and their validity in 
end-stage renal disease. Curr Opin Nephrol Hypertens 1999; 8:719-722.  
222. Ricciardi M, Wu E, Davidson C, Choi K, Klocke F, Bonow R, Judd R, Kim R. 
Visualization of discrete microinfarction after percutaneous coronary intervention 
associated with mild creatine kinase-MB elevation. Circulation 2001; 103:2780-2783.  
223. Chiao H, Kohda Y, Mcleroy P, Craig L, Housini I, Star R. Alpha-melanocyte-
stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin 
Invest 1997; 99:1165-1172.  
224. Conger J, Falk S, Hammond W. Atrial natriuretic peptide and dopamine in 
established acute renal failure in the rat. Kidney Int 1991; 40:21-28.  
225. Kelly K, Tolkoff-Rubin NE, Rubin R, Williams WJ, Meehan S, Meschter C, 
Christenson J, Bonventre J. An oral platelet-activating factor antagonist, Ro-24-4736, 
protects the rat kidney from ischemic injury. Am J Physiol 1996; 271:F1061-7.  
226. Star R. Treatment of acute renal failure. Kidney Int 1998; 54:1817-1831.  
227. Sharma RK. Biomarkers of acute kidney injury. Clinical Queries Nephrology 2011; 
1:13-17.  
228. Schmidt-Ott KM, Mori K, Kalandadze A, Li J, Paragas N, Nicholas T, Devarajan P, 
Barasch J. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney 
epithelia. Curr Opin Nephrol Hypertens 2006; 15:442-449.  
229. Mishra J, Dent C, Tarabishi R, Mitsnefes M, Ma Q, Kelly C, Ruff S, Zahedi K, Shao 
M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin 
(NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 
365:1231-1238.  
230. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. Association 
between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal 
dysfunction after adult cardiac surgery. Anesthesiology 2006; 105:485-491.  
  172 
231. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A, Group NM-AI. 
Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and 
Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis. YAJKD 
2009; 54:1012-1024.  
232. Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, Kasza 
KE, Connor MFO, Konczal DJ, Trevino S, Devarajan P, Murray PT. Urinary cystatin C 
as an early biomarker of acute kidney injury following adult cardiothoracic surgery. 
Kidney International 2008; 74:1059-1069.  
233. Tuladhar SM, Püntmann VO, Soni M, Punjabi PP, Bogle RG. Rapid detection of 
acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after 
cardiopulmonary bypass. Journal of cardiovascular pharmacology 2009; 53:261-266.  
234. Nauta F, Boertien W, Bakker S, Van Goor H, Van Oeveren W, De Jong PE, Bilo H, 
Gansevoort R. Glomerular and tubular damage markers are elevated in patients with 
diabetes. Diabetes Care 2011; 34:975-981.  
235. Mcilroy DR, Wagener G, Lee HT. Neutrophil Gelatinase-Associated Lipocalin and 
Acute Kidney Injury after Cardiac Surgery: The Effect of Baseline Renal Function on 
Diagnostic Performance. Clinical Journal of the American Society of Nephrology 2010; 
5:211-219.  
236. Devarajan P. NGAL in acute kidney injury: from serendipity to utility. Am J Kidney 
Dis 2008; 52:395-399.  
237. Moore E, Bellomo R, Nichol A. Biomarkers of acute kidney injury in anesthesia, 
intensive care and major surgery: from the bench to clinical research to clinical practice. 
Minerva anestesiologica 2010; 76:425-440.  
238. Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a 
systemic review and meta-analysis. Am J Kidney Dis 2011; 58:356-365.  
239. Haase M, Bellomo R, Story D, Davenport P, Haase-Fielitz A. Urinary interleukin-18 
does not predict acute kidney injury after adult cardiac surgery: a prospective 
observational cohort study. Crit Care 2008; 12:R96.  
240. Liangos O, Tighiouart H, Perianayagam MC, Kolyada A, Han WK, Wald R, 
Bonventre JV, Jaber BL. Comparative analysis of urinary biomarkers for early detection 
of acute kidney injury following cardiopulmonary bypass. Biomarkers 2009; 14:423-431.  
  173 
241. Parikh C, Mishra J, Thiessen-Philbrook H, Dursun B, Ma Q, Kelly C, Dent C, 
Devarajan P, Edelstein C. Urinary IL-18 is an early predictive biomarker of acute kidney 
injury after cardiac surgery. Kidney Int 2006; 70:199-203.  
242. Huang Y, Don-Wauchope AC. The clinical utility of kidney injury molecule 1 in the 
prediction, diagnosis and prognosis of acute kidney injury: a systematic review. Inflamm 
Allergy Drug Targets 2011; 10:260-271.  
243. Youden W. Index for rating diagnostic tests. Cancer 1950; 3:32-35.  
244. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, 
James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli M, Pirlet 
C, Pomar J, Reifart N, Ribichini F, Schalij M, Sergeant P, Serruys P, Silber S, Sousa Uva 
M, Taggart D. Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501-
2555.  
 
